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Abstract 
 
                This thesis aims to investigate human antibody responses to dengue virus. Dengue 
virus is a mosquito-borne flavivirus that circulates as 4 distinct serotypes in tropical and sub-
tropical regions of the world. It is known that immunity to one serotype of the virus can be 
life-long but upon infection with a different serotype there is a much higher incidence of 
severe disease. Antibodies play an important role in this immunopathogenesis. Serotype 
cross-reactive antibodies have been shown to enhance the uptake of virus by Fc receptor-
bearing host cells, thereby increasing the number of cells infected and the viral load. The 
work presented will address this concept of antibody-dependent enhancement as part of a 
study of the antibody repertoire in patients with primary and secondary infections.  
                 The antibody response to dengue virus was investigated by producing monoclonal 
antibodies from patients. Antibody variable region sequences were cloned from B cells and 
expressed as whole human IgG; allowing the specificity, neutralisation and enhancement 
features to be identified. By generating a range of antibodies it was possible to investigate 
the breadth of the B cell response. The B cell response was highly diverse, with a range of 
clones stimulated. The antibody variable region sequences were analysed to identify 
features within the repertoire of antibodies stimulated. 
                Additionally, this work describes production of an antigen display tool for 
characterisation of antibody target epitopes. Dengue virus envelope protein was expressed 
on the surface of yeast cells and a mutant library was created to map epitopes of 
monoclonal antibody binding. 
                This work dissects the humoral immune response to dengue virus and contributes 
to the understanding of the immunopathology. This information could be used in creation of 
therapeutic antibodies or to assist in vaccine design and evaluation. 
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Chapter 1 
 
Introduction 
 
 
1.1. Dengue 
 
1.1.1. Dengue virus 
Dengue virus belongs to the Flaviviridae family and flavivirus genus. Many 
flaviviruses are arboviruses transmitted by mosquito or tick (Gould & Solomon, 2008). Those 
of particular medical significance include yellow fever virus, West Nile virus, Japanese 
encephalitis and tick-borne encephalitis. Dengue virus is transmitted to humans by 
mosquito and there are around 50-100 million suspected cases of dengue infection per year 
(WHO, 2009a). Infection is frequently asymptomatic or the outcome can be mild febrile 
illness known as dengue fever  (DF) (WHO, 2009b). In some cases, infection can lead to a 
more severe pathology causing haemorrhage and can be fatal. This is known as dengue 
haemorrhagic fever (DHF). 
 
 
1.1.2. Dengue virus transmission 
Dengue virus has 4 antigenically distinct serotypes (DENV1-4), which exhibit 65-70% 
sequence homology (Green & Rothman, 2006). All 4 serotypes circulate in tropical and 
subtropical regions where the Aedes aegypti species of mosquito is the principle vector. The 
species Aedes albopictus also plays a role in transmission.  Humans and mosquitoes are the 
only hosts in the urban cycle of transmission although a separate sylvatic cycle also exists 
(Wang et al., 2000). Aedes aegypti breeds amongst domestic water containers and often 
bites the human host within 100 metres of its breeding site (WHO, 2009b). It is therefore 
common in urban environments, leading to high rates of human infection. These rates can 
increase following rainy season but occur throughout the year (Halstead, 1966). When the 
female mosquito ingests a blood meal from a DENV-infected individual, virus enters the gut 
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and replicates. Virus dissemination into the blood and saliva of the mosquito takes 8-10 
days, after which it can be transmitted to the next host (Monath, 1994). Vertical 
transmission to mosquito progeny also occurs and allows further virus spread (Gunther et 
al., 2007). Control of vector is recognised to be an important factor for limiting the spread of 
DENV. Recent efforts have aimed to reduce breeding sites or to reduce mosquito 
populations (WHO, 2009b). It is recommended that breeding sites such as disused tyres, 
roof gutters and water storage containers are emptied or mesh used as a barrier. Mosquito 
population control is deployed through use of larvicides and insecticides (WHO, 2009b). 
Techniques to reduce mosquito lifespan have also been investigated (McMeniman et al., 
2009) but these methods in the long term could lead to selective evolution of the virus or 
mosquito. Vector control as a means of preventing DENV transmission requires wide 
participation and support in endemic regions (Kyle & Harris, 2008). Limiting the spread of 
DENV in this way can reduce the burden of disease and of other mosquito-borne viruses. 
Although virus transmission is unlikely to be eliminated, the aim is to maintain low levels 
(WHO, 2009b). 
 
 
1.1.3. Epidemiology 
Dengue virus transmission favours countries with warm and humid climates because 
the vector mosquito survives and breeds best at these conditions (WHO, 2009b). This means 
DENV transmission is currently limited to the tropical and sub-tropical parts of the world 
and it continues to spread. Historically, DENV has been diagnosed for over 200 years and 
had slow transmission prior to World War II (Monath, 1994). With increased travel and 
export, the virus established itself in new countries. In South-East Asia rapid urbanisation 
following the war led to inadequate housing, water storage and waste management and 
provided breeding grounds for mosquitoes (Gubler, 1997). All four serotypes of DENV 
circulated and epidemics of severe disease emerged: dengue haemorrhagic fever (DHF). In 
the Pacific islands DENV transmission was absent between the 1940’s and 1960’s until large 
epidemics of DENV2 occurred followed by the other serotypes a few years later. Efforts to 
reduce mosquito populations in the Americas (to prevent yellow fever virus transmission) 
led to low levels of DENV infections in this region prior to the 1970’s. DENV2 and DENV3 
serotypes were originally circulating but DENV1 and DENV4 were then introduced. The 
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inadvertent introduction of an Asian strain of DENV2 into Cuba subsequently led to the 
emergence of a huge epidemic of DHF in 1981. This genotype caused further epidemics in 
surrounding areas throughout the 1990’s and all serotypes continue to infect across many 
Central and South American countries. In Africa, DENV is endemic and also causes 
epidemics, although may present less of a public health burden than malaria and HIV in 
these countries. Countries with colder climates or winters cannot support growth of 
mosquito larvae and therefore transmission is unlikely. However, introduction of the Aedes 
albopictus mosquito into Northern America and Europe may allow DENV transmission to 
expand further (Gould & Solomon, 2008; Kyle & Harris, 2008). DENV transmission via this 
mosquito has been recently noted in France (Gould et al., 2010) and therefore the virus 
continues its global expansion. 
 The clinical samples used in this thesis originate primarily from Vietnam and some 
from Thailand. Both countries have endemic DENV circulation and annual peaks in cases 
correlating with rainy seasons. The Vietnamese patients form a large part of this work and 
were recruited during November 2009 from Ho Chi Minh City. DENV4 was the predominant 
serotype in 2001-2002 and DENV1 and DENV2 were most prevalent between 2003 and 2006 
(Thai et al., 2010). DENV1 was proposed to occupy 80% of infections during 2009 when the 
samples were taken yet other serotypes were identified in this study. 
 
 
1.1.4. Virus life cycle 
 DENV is an enveloped virus containing a single-stranded positive-sense genome 
(Lindenbach & Rice, 2001). It enters the host cell by receptor-mediated endocytosis. Within 
the endosome, the virus fuses with the cell membrane. The RNA genome is then released 
into the host cell cytoplasm and translated into a single polyprotein (figure 1.1). The amino 
terminus encodes the capsid (C), pre-membrane (prM) and envelope (E). The rest encodes 
non-structural proteins (Lindenbach & Rice, 2001). The 7 non-structural proteins are 
involved in co- and post-translational processing of the polyprotein. NS1 is thought to be 
involved in RNA replication (Mackenzie et al., 1996), NS3 is a serine-protease that cleaves 
the polyprotein and NS2B is a cofactor. NS5 is an RNA polymerase that creates templates for 
synthesis of new positive-sense strands. The remaining proteins NS2A and NS4A and NS4B 
play roles in assembly or replication (Fernandez-Garcia et al., 2009).  
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Figure 1.1. DENV polyprotein 
RNA genome is translated into a single polyprotein that is then cleaved into its structural and non-
structural components: capsid (C), pre-membrane (prM), envelope (E) and non-structural proteins 1-
5 (NS1-5). 
 
The virus is assembled on the endoplasmic reticulum (ER) and immature virions are 
transported through the trans-Golgi network (TGN). The virus matures and is then released. 
These processes are summarised in figure 1.2 (Mukhopadhyay et al., 2005). 
  
 
Figure 1.2. Life cycle of DENV 
From (Mukhopadhyay et al., 2005). See section 1.1.4. 
ER: endoplasmic reticulum. TGN: trans-Golgi network. 
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1.1.5. Structure of E protein 
The DENV envelope protein (E) is a structural antigen that exists as homodimers on 
the surface of the mature virion. Cryo-electron microscopy revealed there are 90 
homodimers arranged in icosahedral order (Kuhn et al., 2002). The arrangement of the 
surface proteins is dependent on the maturation stage of the virion. Each E protein is 495 
amino acids and is anchored into the virus membrane by a C-terminal transmembrane 
domain (Lindenbach & Rice, 2001). The ectodomain is then made up of domains I, II and III. 
The homodimeric arrangement of these domains is shown in figure 1.3. Domain III has an 
immunoglobulin-like structure and protrudes from the surface. It is thought to be the cell 
receptor-binding domain (Crill & Roehrig, 2001) and has been shown to use different 
regions for binding to mammalian and mosquito cells (Hung et al., 2004). Upon receptor-
mediated endocytosis, the mature virion enters the low pH environment of the endosome. 
This triggers a step-wise conformational change (Liao et al., 2010). First, domain III (EDIII) 
dissociates from EDI, which causes a hinge action. EDII becomes exposed and it contains a 
fusion loop required for fusion with the host cell membrane. EDII inserts into the membrane 
and this allows a trimeric arrangement of the E proteins. This irreversible stage involves the 
ectodomain folding back to bring the C terminus of the protein nearer to the fusion loop 
(Modis et al., 2004; Nayak et al., 2009). This brings viral membrane into close proximity with 
host cell membrane for entry.  
 
 
 
Figure 1.3. Structure of DENV E dimer and domains at neutral pH 
From (Modis et al., 2004). EDI is shown in red, EDII in yellow and EDIII in blue. Glycans in EDI and EDII 
are shown as red/yellow ball and stick structures. The fusion loop is highlighted in orange. 
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1.1.6. Structure of prM protein 
Newly assembled immature virions contain 60 spikes with trimers of heterodimeric 
prM-E (Zhang et al., 2003). The prM protein is arranged over the fusion loop of E to prevent 
trimeric arrangement and fusion with the host cell membrane (Heinz et al., 1994; Li et al., 
2008; Lorenz et al., 2002). Cleavage of the prM protein is carried out in the TGN, where the 
low pH allows conformational change in the prM-E (Li et al., 2008). The protease that 
performs this cleavage is furin, a transmembrane endopeptidase that is localised to the TGN 
(Shapiro et al., 1997). Following cleavage, the pr remains associated with the virion (figure 
1.4). The rise in pH upon export then allows the pr to dissociate (Li et al., 2008). The pr does 
not remain in contact with the virion or the host cell after the virion is released (Murray et 
al., 1993).  
 
 
Figure 1.4. Maturation of DENV and conformation of prM-E on the surface (Yu et al., 
2008a) 
(A) Maturation of immature virus through the endoplasmic reticulum (ER), Golgi and trans-Golgi 
network (TGN). The pH of these compartments is indicated. (B) The structure of the E and prM 
proteins on the surface of the virion during maturation. 
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The recognition site for furin is the junction between pr and M. Experimentally-
induced mutation of this sequence in TBEV prevents cleavage and the cell yields immature 
virus (Allison et al., 2001). Therefore the cleavage of this protein is essential for production 
of structurally mature flaviviruses. However, immature virus has been shown to be released 
in vitro from DENV-infected cells (Dejnirattisai et al., 2010; Murray et al., 1993; Zybert et al., 
2008). It is thought that cleavage is not efficient and this may be due to the DENV furin 
recognition sequence (Junjhon et al., 2008; Keelapang et al., 2004). A similar evolution of 
cleavage site has been seen for Ebola virus, whereby natural differences in furin recognition 
sequence lead to secretion of non-infectious virus (Molloy et al., 1999). 
 
 
1.1.7. NS1 protein 
 The non-structural protein NS1 is a 46kDa glycoprotein (Lindenbach & Rice, 2001). 
During infection this protein is localised to the ER, where it becomes a homodimer that can 
translocate through the secretory pathway and associate with host cell plasma membranes 
(Winkler et al., 1989). Its association with the site of RNA replication suggested its role as 
part of the replication complex (Mackenzie et al., 1996). NS1 is also excreted from the cell in 
soluble form (Flamand et al., 1999). The secreted NS1 is not associated with the released 
virion but can be detected as circulating antigen in the sera of DENV-infected patients 
(Young et al., 2000).  
 
 
1.1.8. Host cell receptors 
 Upon inoculation of virus into the human host, Langerhans cells have been shown to 
be the early target cells (Wu et al., 2000). This subset of dendritic cell (DC) is found in skin 
tissues and is therefore available for infection following mosquito bite. The cellular receptor 
that binds to the virus is dendritic cell-specific intracellular adhesion molecule 3 grabbing 
nonintegrin (DC-SIGN) (Tassaneetrithep et al., 2003). This receptor interacts with glycans on 
the virus surface. Once inside the immature DCs the virus is able to replicate and release 
progeny unlike the dermal macrophages, which allowed entry but not virus growth (Kwan et 
al., 2008). The reason for lack of growth in these cells was poorly acidified endosomes in this 
macrophage subset, which are required for pH-dependent virus fusion.  
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Macrophages express DC-SIGN alongside other receptors known to interact with 
DENV. The mannose receptor binds glycans on the virus and potentially facilities 
internalisation via an endocytic or phagocytic pathway (Miller et al., 2008). CLEC5A is 
another receptor that binds DENV and is found on macrophages and monocytes (Chen et 
al., 2008). Binding does not lead to virus entry but to phosphorylation of DAP12, signalling 
proinflammatory cytokine release. This has an impact upon the severity of disease and is 
discussed further in section 1.2.6. Dendritic cells and macrophages can also be infected 
through their Fc receptors (FcR) (Boonnak et al., 2008; Huang et al., 2006). Infection is 
dependent on the presence of antibody that binds to DENV. The Fc portion of the antibody 
binds to FcγRI/II and thereby enables entry of the virus-antibody complex (Halstead & 
O'Rourke, 1977). This mechanism is described as antibody-dependent enhancement (ADE) 
of infection and is discussed in section 1.2.2. A more widely distributed receptor that binds 
to DENV is heparan sulphate (Chen et al., 1997) but its role in infection has not been 
elucidated. 
Permissiveness of other host cells has been debated and there are reports of DENV 
binding or infecting a range of types of cell. Replication of virus within B cells was proven in 
vitro by presence of the replicating strand of DENV genome and increasing quantities of 
virus in culture (Lin et al., 2002). This was proposed to be Fc receptor mediated. Yet the role 
of B cells in infection in vivo is undetermined and monocytes are described as a more 
important viral target (Durbin et al., 2008; Kou et al., 2008). Primary endothelial cells have 
been shown to support viral replication in vitro (Arevalo et al., 2009) and hepatocytes have 
also been shown to be a target cell in the liver (Alcon-LePoder et al., 2005). Therefore DENV 
appears to have several options for viral entry, which can lead to a complex pathogenesis. 
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1.1.9. Symptoms and clinical management of dengue infection 
 Dengue infection manifests with a range of clinical outcomes. Infection is often 
asymptomatic or many patients present with mild undifferentiated fever. Symptomatic 
infection is categorised by severity; from dengue fever (DF) to dengue haemorrhagic fever 
(DHF) and dengue septic shock (DSS). Dengue fever is classified by the World Health 
Organisation (WHO) as fever plus two symptoms from headache, rash, myalgia/arthralgia, 
mild haemorrhagic manifestations and retro-orbital pain. Leukopenia and 
thrombocytopenia may also be present. DHF is divided into grades of severity and is based 
on the presence of further symptoms in combination with those listed for DF. DHF definition 
usually stipulates thrombocytopenia below 100,000 platelets and a 20% rise in haematocrit 
(WHO, 2009b). 
Grade I DHF is described as a positive tourniquet test, grade II includes spontaneous 
bleeding, grade III shows signs of circulatory failure and grade IV (DSS) involves profound 
shock (WHO, 1999). Recently, the World Health Organisation reviewed the clinical 
classification of disease and recommended simplifying classification into dengue (± warning 
signs) or severe dengue (WHO, 2009b) but the grading system is still widely used.  
The progress of disease pathology has been divided into febrile, critical and recovery 
phases (WHO, 2009b). During the febrile phase, a patient develops symptoms of DF perhaps 
with mild haemorrhagic tendencies. This phase lasts for 2-7 days. The critical phase is 
between day 3 and 7, when fever drops (defervescence). At this point the platelet count 
drops and in patients with increased vascular permeability the plasma leakage can cause 
severe symptoms such as pleural effusion, ascites and shock. Recovery phase can occur 
around day 6-7 but depends on the severity of disease and its complications. There is no 
clinical antiviral treatment of dengue infection and so treatment relies on rehydration of 
fluids and management of symptoms. 
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1.1.10. Diagnosis of DENV infection 
 Identification of DENV infection can be initially challenging when distinguishing it 
from other viral fevers. Pathogens inducing similar symptoms are frequently in circulation in 
DENV endemic countries, such as chikungunya, Japanese encephalitis, yellow fever and 
influenza. A probable DENV diagnosis would be based on symptoms and a positive 
laboratory test but a confirmed diagnosis requires detection by more than one test (WHO, 
2009b). During the early phase of infection, virus can be detected in blood (figure 1.5). Virus 
can be isolated from blood by culture in mosquito cell lines, or detected in serum by antigen 
tests such as enzyme-linked immunosorbent assay (ELISA) or lateral flow. This indicates an 
acute infection but can be limited by low sensitivity (Shu & Huang, 2004). Viral RNA can be 
identified through molecular techniques such as reverse-transcriptase polymerase chain 
reaction (RT-PCR) and allows discrimination of serotype. These methods are only valuable 
during the viraemic phase of infection and serology is required in addition (figure 1.5). 
Detection of DENV-specific IgM by ELISA around day 5 can suggest an acute infection but a 
4-fold increase in IgG in paired sera confirms this (WHO, 2009b). DENV-specific antibodies 
can also be detected by haemagglutinin inhibition, indirect immunofluorescent tests and 
virus neutralisation tests (Shu & Huang, 2004).   
 
 
Figure 1.5. Course of DENV infection and timing of diagnostic tests (Halstead, 2007) 
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1.2. Factors involved in the pathogenesis of severe DENV infection 
 
1.2.1. Secondary infection 
It has been shown that the risk of DHF is far higher in a secondary DENV infection 
than in a primary infection (Burke et al., 1988; Sangkawibha et al., 1984). Approximately 
95% DHF cases arise in a secondary infection where the infecting serotype is different to the 
primary serotype (Halstead, 2009). In Cuba, DHF epidemics occurred in 1981, 1997 and 2001 
and 97% DHF cases were in secondary infections (Guzman, 2005). Children born in a period 
free of dengue transmission only had a primary infection and consequently had no DHF/DSS. 
This highlights the acquired immune system as an important risk factor for DHF and this is 
supported by the observation that severe symptoms develop only as viraemia falls 
(Halstead, 2007). The role of humoral and cellular immunity in primary and secondary 
encounters has therefore been a focus of investigation and is discussed in more detail 
below. 
 
 
1.2.2. Antibodies and pathogenesis 
 Antibodies play a well-documented role in the pathogenesis of DHF. In vitro it has 
been shown that antibodies can bind to DENV and allow uptake into Fc receptor-bearing 
cells (Halstead & O'Rourke, 1977). This antibody-dependent enhancement (ADE) can result 
in productive infection by the virus if the antibody cannot prevent viral fusion with the cell 
from within the endosome. Mononuclear phagocytes, particularly immature cells, were first 
identified to be targets for this type of infection (Halstead et al., 1977). Other cell types are 
also now known to be infected via ADE, such as mature dendritic cells (Boonnak et al., 2008) 
and possibly B cells (Lin et al., 2002).  Binding of the virus-antibody complex to the Fc 
receptor signals endocytosis by the host cell. Alternatively, the complex may simply bring 
the virus into close proximity with other cellular receptors facilitating entry (Stephenson, 
2005). The high level of infection is thought to lead to increased viral load, which has effects 
on multiple immune pathways and leads to the symptoms of severe disease. Additionally, 
ADE infection of monocytes leads to release of vasoactive mediators that increase vascular 
permeability (Anderson et al., 1997). 
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 Primary infection induces serotype-specific antibodies thought to confer life-long 
protection and cross-reactive antibodies that are thought to be protective for the first few 
months following infection (Guzman & Kouri, 2002). Following this, the titre is believed to 
fall to subneutralising levels. Upon infection with a heterologous serotype these antibodies 
may cause ADE of infection. This could explain the increased risk for DHF in secondary 
infections and key evidence supporting this is described below. 
ADE has been demonstrated in vitro and in vivo. Passive transfer of DENV-immune 
sera into monkeys proved that it could enhance viral load during infection (Halstead, 1979). 
Epidemiological evidence for ADE has come from the observation that young children born 
to dengue-immune mothers are at high risk of developing DHF (Kliks et al., 1988; Simmons 
et al., 2007). This is because the neutralising antibodies acquired from the mother begin to 
wane to sub-neutralising levels between 4-12 months (Chau et al., 2009). Evidence for ADE 
in vitro stems from studies with sera and monoclonal antibodies. FcR-bearing cells show 
increased titre of infectious virions upon addition of particular antibodies. This is not 
thought to be increased virus production per cell but an increase in viral entry, leading to 
higher output. Polyclonal DENV sera has been used to demonstrate this (Morens & 
Halstead, 1990). On a more specific level, monoclonal antibodies have been shown to 
enhance infection. A non-human primate cross-reactive E-specific antibody enhances 
infection of FcR cell lines and primary monocytes (Goncalvez et al., 2007). Recently human 
monoclonal antibodies have been produced and the cross-reactive E-specific antibodies 
again enhance infection of FcR-bearing cell lines (Beltramello et al., 2010; Schieffelin et al., 
2010). ADE of infection has also been demonstrated with antibodies specific for prM, 
described in the subsequent section. 
 
1.2.2.1 Antibodies specific for prM 
Human antibodies specific for prM have been shown to cause enhancement of 
infection (Beltramello et al., 2010; Dejnirattisai et al., 2010). Only immature or partially 
mature virions contain prM protein and these have been shown to be non-infectious (Zybert 
et al., 2008). Immature DENV is non-infectious due to its conformation. The prM prevents 
trimerisation of E and exposure of the fusion loop for membrane fusion. This lack of fusion 
activity has been demonstrated by creating immature virions in vitro. Guirakhoo et al 
prevented furin-mediated cleavage by raising the pH of the TGN and hence produced 
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immature, fusion-deficient virus (Guirakhoo et al., 1991). Another method for producing 
immature virus is by culture in a furin-deficient cell line, shown to yield non-infectious DENV 
(Zybert et al., 2008).  
Anti-prM antibodies are enhancing because they can bind to these immature virions 
and allow infection of host cells through the Fc receptor (Rodenhuis-Zybert et al., 2010). It 
was shown that upon internalisation of the anti-prM-virus complex, the endogenous furin in 
the endosome can cleave the prM to allow virus maturation. It was speculated that the virus 
was capable of fusion because the pr remained in complex with the antibody instead of 
masking the fusion loop. Therefore anti-prM antibodies render non-infectious virus particles 
infectious and increase viral load (Rodenhuis-Zybert et al., 2010).  
 
1.2.2.2. Antibodies specific for NS1 and their role in pathogenesis 
Antibodies specific for NS1 have not yet shown enhancement characteristics, yet 
they can cause pathology. It has been found that severe infections (DHF) had higher serum 
levels of NS1 antigen than those of DF (Libraty et al., 2002). Antibodies specific for 
circulating NS1 antigen have also been identified in sera. Of concern, these antibodies were 
shown to be self-reactive and bound to endothelial cells (Lin et al., 2003). Binding causes 
complement activation which has been linked to lysis of the cells, thereby resulting in 
vascular leakage (Avirutnan et al., 2006). NS1-specific antibodies that cross-react with 
platelets can also be implicated in pathogenesis through dysregulation of clotting (Falconar, 
1997). Therefore, although not a structural antigen, NS1 plays a role in 
immunopathogenesis of infection and characterisation of antibodies will contribute to the 
understanding of this role. 
 
1.2.2.3. Antibody isotypes in severe DENV infection 
 The titre of particular isotypes of antibodies differs between DF and DHF patients. In 
primary patients, IgM peaks in the first days of defervescence, followed by IgG (WHO, 
2009b). In secondary patients, the IgG levels often peak before IgM. This is to be expected 
of a secondary antigen exposure and is not necessarily linked to severity of disease (Janeway 
et al., 2008). Levels of serum DENV-specific IgA have been shown to be higher in DSS than 
DF/DHF (Koraka et al., 2001) and levels of DENV-specific IgE are higher in DHF/DSS than DF 
(Koraka et al., 2003). It is implied that these antibodies contribute to the severity of 
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infection, particularly IgE-mediated histamine release. However elevated levels could be a 
consequence of the more severe pathology rather than a cause. The role of such antibodies 
has not been widely evaluated. IgG is the focus of ADE because this isotype is secreted by 
memory B cells, is passively transferred through the placenta and has a long half-life in 
serum (Janeway et al., 2008). 
 
 
1.2.3. Complement 
 The complement system pathways (lectin, classical and alternative) have been 
shown to play a role in dengue infection clearance and enhancement. In the lectin pathway, 
mannose-binding lectin binds to carbohydrate ligands on the surface of DENV. This signals 
the complement-mediated lysis of the virus and is therefore a mechanism of viral 
neutralisation (Fuchs et al., 2010). In the classical pathway, anti-DENV antibody binds to the 
virus and the Fc portion of the antibody is recognised by the complement protein C1q. Upon 
binding of C1q, it activates C3 convertase, promoting opsonisation of the virus and 
formation of the membrane attack complex. This not only serves to eliminate virus but the 
C1q binding to antibody Fc regions can prevent ADE (Mehlhop et al., 2007). However, 
activation of complement has also been shown to contribute to the pathology of severe 
disease. There is accumulation of anaphylatoxin C3a in severe disease (Avirutnan et al., 
1998), which causes inflammation and vascular disruption. In DHF/DSS patients there are 
higher levels of terminal complement complex sC5b-9, also shown to increase vascular 
permeability (Avirutnan et al., 2006). These patients have high levels of soluble NS1, which 
is thought to be the cause for the complement activation. The soluble protein activates the 
alternative pathway, but also antibodies to NS1 direct the attack towards infected 
endothelial cells (Avirutnan et al., 2008; Avirutnan et al., 2006). 
 Therefore the increased NS1 production by infected cells in severe DENV disease 
leads to a detrimental complement-mediated response. 
 
 
1.2.4. Dendritic cells and pathogenesis 
 DENV enters immature dendritic cells (DCs) via the cell receptor DC-SIGN but mature 
DCs have low DC-SIGN expression (Tassaneetrithep et al., 2003). In mature DCs, the virus 
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infects via the antibody-dependent enhancement through the Fc receptor (Boonnak et al., 
2008). The FcγRII allows uptake of virus in complex with antibody. This results in high viral 
loads, which have also been associated with DHF via downstream immune processes 
(Boonnak et al., 2008) 
Infection of immature DCs has been linked to vascular leakage in mice (Luplertlop et 
al., 2006). The virus was shown to induce over-production of matrix metalloproteases, 
which normally regulate DC trans-endothelial migration. This caused disruption to 
endothelial cells and increased vascular permeability.  
A role of DCs in infection is to present antigen to T cells and therefore to prime the 
immune response. DENV infection of immature DCs halts their maturation and this limits 
the activation and expansion of antigen specific T cells (Palmer et al., 2005). However, 
bystander DCs are activated by TNFα and type1 IFN and can then stimulate the T cell 
response (Dejnirattisai et al., 2008). In secondary infection, the lower threshold of memory 
T cell activation means a stronger T cell response. Yet this has an impact on disease 
pathology as described in section 1.2.5.  
 
 
1.2.5. The role of T cells in severe disease 
In primary infection, DENV peptide and MHC complex are displayed on antigen-
presenting cells. Circulation of these cells through lymph nodes exposes them to naive T 
cells. T cell receptor engagement and costimulation activates T cells to undergo clonal 
expansion and differentiation (Janeway et al., 2008). This creates populations of DENV 
serotype-specific and cross-reactive effector and memory T cells (Friberg et al., 2010). Upon 
secondary infection with the same DENV serotype, common viral epitopes (often in NS3 and 
NS5) will stimulate the memory T cells for control of infection. However, secondary infection 
with a heterologous serotype has been shown to cause severe disease. The theory of 
original antigenic sin has been applied to explain this and is based on the observation that 
cross-reactive memory T cells can be stimulated by a heterologous infection but have a low 
affinity for the infecting serotype (Mongkolsapaya et al., 2003; Mongkolsapaya et al., 2006).  
 Memory T cells have a lower threshold for activation and can be stimulated rapidly. 
Preference towards memory T cell clone selection over naive T cells would severely limit the 
diversity of the response to current infection. A rapid burst of these cross-reactive cells has 
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been observed and numbers can be correlated with severe disease (Mongkolsapaya et al., 
2003; Rothman, 2009). High numbers of T cells leads to increased cytokine production such 
as pro-inflammatory TNFα and IFNγ. Elevated levels of these factors have been noted in DHF 
patients (Chakravarti & Kumaria, 2006). Together, this data is strong evidence for pre-
existing immunity causing immunopathogenesis.  
 
 
1.2.6. Cytokines and chemokines 
 Many cytokines have been shown to be elevated in DHF patients compared to DF, 
for example IFNγ, TNFα and interleukins (IL) IL-1, IL-2, IL-6, IL-8 and IL-10 (Kurane et al., 
1991; Webster et al., 2009). IFNγ, TNFα and IL-10 have been linked more specifically to 
secondary heterologous infections (Rothman, 2009). Extensive proliferation of T cells during 
infection leads to IFNγ and TNFα production, which can directly affect endothelial cells to 
create vascular permeability. TNFα activates endothelial cells and causes them to express 
adhesion molecules such as intracellular adhesion molecule 1 (ICAM-1) to increase 
lymphocyte migration and recruitment to infected sites (Green et al., 1999). TNFα and IFNγ 
can also cause maturation of DENV-infected immature DC in secondary infection 
(Dejnirattisai et al., 2008). This increases chemokine secretion and the high levels of CXCL9, 
10, 11 interact with CXCR3 on the T cells to bring them to site of infection. 
 Therefore, the elevated levels of particular cytokines in severe DENV infection may 
allude to the mechanisms of vascular leakage and inflammation seen in DHF and DSS.  
 
 
1.2.7. DENV virulence as a factor in severe disease 
Another explanation for the variation in disease outcome is a difference in virulence 
between virus serotypes and genotypes. The 4 serotypes of DENV differ by 30-35% in amino 
acid sequences (Green & Rothman, 2006; Gubler, 1997). DHF is not restricted to particular 
serotypes but DENV1, 2 and 3 have been more strongly linked to DHF incidence (reviewed in 
Kyle & Harris, 2008). DENV1 and 3 were also shown to be more frequently associated with 
DHF in primary infection. However, all serotypes can cause DHF and sequential infection 
with heterologous serotypes is a more widely accepted risk factor for increased severity 
(Green & Rothman, 2006).  
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Within serotypes there is approximately 4% amino acid sequence variation (Monath, 
1994), and 7% described for DENV3 (Wahala et al., 2010). Some of these genotypes have 
been linked with disease outcome. For example, a strain of DENV2 was circulating in the 
Americas with low incidence of DHF/DSS (Gubler, 1997). Following this, a more virulent 
DENV2 genotype with South Asian origin was introduced and led to high rates of DHF/DSS. 
This Asian genotype had amino acid differences in several viral proteins and the 
untranslated region when compared to the American genotype (Rico-Hesse et al., 1997). 
The Asian strain also replicated more rapidly in mosquitoes and human macrophages. A 
DENV3 strain has also been described with increased incidence of DHF/DSS (Dash et al., 
2006; Messer et al., 2003). Sequence variation within dengue viruses has been linked to the 
risk of developing severe disease but the hypothesis is insufficient as it cannot explain all 
cases. DHF develops as viraemia drops, implicating the immune system in pathology and not 
the virus alone. 
 
 
 
 
1.3. Human B cell responses to pathogens and production of antibodies 
 
1.3.1. Early B cell development and somatic recombination 
 The B cell repertoire is extremely diverse and the spectrum of antigen-specific clones 
exists prior to antigen stimulation. This fundamental theory is the clonal selection 
hypothesis (Burnet, 1976; Jerne, 1955) and highlights the importance of an expansive 
variety of B cell receptors. 
The early maturation stages of a B cell occur in the bone marrow. Stem cells receive 
signals from growth factors as they commit to the lymphocyte lineage and IL-7 stimulates 
high mitotic activity (Abbas & Lichtman, 2003). These pro-B cells contain unrecombined 
germline DNA that will encode the B cell receptor (BCR). The BCR, or antibody molecule, 
contains 2 identical heavy chain proteins and 2 identical light chain proteins. Heavy chains 
are attached to each other and light chains are attached to the heavy chains via disulphide 
bonds. The amino termini of the proteins make up a variable region for antigen binding and 
the carboxyl terminal region is the conserved constant region. The gene segments that 
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encode the variable region are the V (variable) and J (joining) segments. The heavy chain 
also has a diversity (D) segment. The constant regions are encoded by constant region genes 
(C). In the heavy chain these genes determine antibody isotype and subclass. For example 
the mu constant region gene (Cμ) encodes IgM and gamma genes 1-4 (Cγ) encode IgG 
subclasses. 
For the heavy chain, the genes are arranged on chromosome 14, separated by 
introns. There are many families of germline gene segments, which have been determined 
by chromosome mapping and sequencing of antibody repertoires (Boyd et al., 2010; Collins 
et al., 2008; Corbett et al., 1997; Hieter et al., 1982; Ignatovich et al., 1997; Ravetch et al., 
1981; Tomlinson et al., 1992; Williams et al., 1996). According to these sources, there are 
approximately 50 different functional V segments (VH), 25 different D segments (DH) and 6 J 
segments (JH) and downstream of these are the constant region genes that determine 
antibody class. The light chain genes are on chromosome 2 for the kappa light chain and 
chromosome 22 for the lambda light chain. There are approximately 40 V (Vκ) and 5 J (Jκ) 
gene segments for the kappa chain and for the lambda chain there are approximately 30 Vλ 
and 4 Jλ (figure 1.6). The V and D gene segments can be categorised into families. There are  
7 VH families, 6 DH, 10 Vλ and 6 Vκ families. 
 
 
 
 
 
Figure 1.6. Germline arrangement of antibody gene segments (Janeway et al., 2008). 
Genetic loci for lambda, kappa and heavy chains are made up of multiple variable (V), diversity (D) 
and joining (J) gene segments. Pseudogenes are excluded and constant region genes (C) are shown 
as single exons for simplicity. Leader region genes (L) are located proximal to V genes. 
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The V segment encodes 3 framework regions (FWRs or FRs) that maintain antibody 
structure and 2 complementarity-determining regions (CDRs). The CDRs are variable loops 
that provide the antigen-binding surface. A third CDR (HCDR3) is encoded by the D segment 
and random nucleotides and is the most variable loop. The J segment makes up the FWR4 
(figure 1.7). 
 
 
 
Figure 1.7. Variability plots of antibody heavy and light chain variable regions (Janeway et 
al., 2008). 
Plots represent the degree of variability at each amino acid position in the variable region from 
several antibody sequences. Here CDRs are called hypervariable regions (HV1...) and are highlighted 
in red. Framework regions are called FR1, 2, 3 and 4 in blue for heavy chain and yellow for light 
chain. 
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Pro-B cells begin to express recombination-activating gene (RAG) proteins, which 
execute the recombination of germline genes into functional transcripts (McBlane et al., 
1995). It is this random recombination that creates the enormous diversity of antibody 
sequences. The heavy chain genes recombine first. The D and J segments of the heavy chain 
recombine first and then a V segment with leader region is recruited. Recombination signal 
sequences (RSS) are located 3’ of the V segments, 5’ of the J segments and flank the D 
segments. The sequence is composed of a conserved heptamer, a spacer of 12 or 23 non-
conserved nucleotides and a conserved nonamer (Abbas & Lichtman, 2003). The spacer 
serves to bring the conserved sequences together in the DNA helix in order to provide a 
recognition site for the RAG complex. RAG1 introduces double-stranded breaks between 
nonamers when flanked by both a 12 and 23 spacer (12/23 rule) and a hairpin loop forms to 
connect them before further cleavage removes all of the intervening sequence between the 
gene segments (Janeway et al., 2008).  
The double-stranded breaks created by RAG leave over-hanging nucleotides at the 
end of the gene segments. DNA polymerase extends these by adding palindromic (P) 
nucleotides to the junctions between V, D and J and this random insertion creates this extra 
diversity in the CDR3 of the antibody sequence. Terminal deoxyribonucleotidyl transferase 
(TdT) then contributes further to this diversity by adding up to 20 nucleotides (N 
insertions/additions) in the junctions before the segments ligate together (Desiderio et al., 
1984). Some rearrangements are non-functional if addition of nucleotides causes a 
frameshift and these pro-B cells die (Jung et al., 2006).  
The next stage of B cell development is the pre-B cell stage. They contain 
recombined VDJ genes and during this stage the μ constant region gene (Cμ) joins the VDJ. 
Poly-A tails are added to the 3’ end of the Cμ and it is brought to the 3’ end of the VDJ 
sequence through splicing (Abbas & Lichtman, 2003). This produces mRNA ready for 
translation into a μ heavy chain. To test the functionality of the translated rearrangement a 
surrogate light chain complexes with the heavy chain and expresses a pre-BCR. This provides 
a signal for proliferation and maturation and prevents further rearrangement of VDJ on the 
second chromosome. This is known as allelic exclusion and permits only one variable region 
sequence to be expressed in a B cell clone (Janeway et al., 2008). 
In the immature B cell, the kappa light chain Vκ and Jκ genes recombine in a similar 
way to heavy chain rearrangement. The Cκ gene joins the VJ for production of mRNA. If this 
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kappa chain recombination is non-functional then the lambda genes subsequently rearrange 
and express. If neither is functional then the cell is destroyed. Expression of a kappa or 
lambda chain alongside the μ heavy chain occurs on the cell surface. It is at this first 
checkpoint that self-reactivity by the BCR will signal the B cell for apoptosis or receptor 
editing. Receptor editing involves more RAG-mediated DNA cleavage and recombination, 
predominantly in the kappa chain, aiming to eliminate the self binding (Gay et al., 1993; 
Tiegs et al., 1993; Wang et al., 2009). Pre-B cell and immature B cell populations are 
frequently self-reactive (Wardemann et al., 2003). Later stages of B cell maturation remove 
many but some persist in the mature B cell repertoire. 
 
 
1.3.2. B cell maturation and antigenic stimulation 
Immature B cells leave the bone marrow and migrate to lymphoid organs for further 
development. The mature naive B cell expresses IgM and IgD. The differential splicing of VDJ 
Cμ-Cδ mRNA leads to translation of both heavy chains. The IgM+ IgD+ cells in the lymphoid 
organs are then ready for antigen stimulation. 
Antigen binds to specific IgM and IgD on the surface of the B cell. Neighbouring Igα 
and Igβ molecules are subsequently phosphorylated in their cytosolic ITAM 
(immunoreceptor tyrosine-based activation motif). This starts a signalling pathway that 
results in activation (Janeway et al., 2008). Virus is endocytosed by the B cell and peptides 
are expressed on its surface in complex with the MHCII. Activated B cells increase 
expression of MHC II and costimulators for cognate helper T cell interaction. They migrate to 
the T cell zone where they form a synapse with the CD4+ T cell (McHeyzer-Williams & 
McHeyzer-Williams, 2005). Binding of the costimulator B7 molecules on the B cell to the 
CD28 of the T cell leads to recognition of the peptide-MHC complex. Then CD40 ligand 
expression is induced on the T cell and it binds to CD40 on the B cell. The subsequent 
signalling pathway and cytokine production drives B cell differentiation and proliferation. 
Differentiation can lead to the VDJ-Cμ transcript splicing its transmembrane domain 
to allow secretion of IgM in polymeric form. For production of other isotypes, the B cell 
undergoes class switch recombination. Different cytokines exert their influence on the 
isotype, for example IL-4 promotes switching to IgG1 (McHeyzer-Williams & McHeyzer-
Williams, 2005). The IgG1 isotype frequently dominates anti-viral responses, including DENV 
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(Koraka et al., 2001). Class switching of genes is initiated by activation-induced deaminase 
(AID), which introduces double-stranded breaks at switch regions (Wang et al., 2009). Then 
C regions are brought into proximity of the VDJ by non-homologous end joining (NHEJ), a 
multi-factorial process that ligates the Cγ/Cα/Cε to the end of the VDJ (Kotnis et al., 2009).  
Some of the activated B cells migrate to extrafollicular areas where they proliferate 
and differentiate into short-lived plasma cells. These will secrete IgM antibody for 3-5 days 
and form part of the early response before they die through apoptosis (McHeyzer-Williams 
& McHeyzer-Williams, 2005). 
Some of the remaining activated B cells migrate to the germinal centres (GC) of the 
lymphoid follicle. Here they proliferate rapidly in clonal pools as centroblasts. Progeny 
migrate to the dark zone of the GC where they express surface BCR and they come into 
contact with follicular dendritic cells (FDCs). These cells present antigen to the B cells and 
allow selection of the higher affinity BCR through the process of affinity maturation (Allen et 
al., 2007). 
The process of modifying BCR affinity is somatic hypermutation (SHM). Mutations in 
the sequence can alter the binding kinetics of the resulting antibody so the GC processes 
ensure the optimal BCR’s are selected for expansion. Mutation occurs at a rate of 1 in 1000 
nucleotides per cell division and is focused 150bp downstream of the transcription site with 
decreasing frequency further away from the site (Odegard & Schatz, 2006). Mutations are 
targeted to particular regions of the sequence to prevent disruption of the basic antibody 
structure. They occur at higher rates in the CDRs of the variable region rather than the FWRs 
(Zheng et al., 2005). The sequence of the variable region influences which nucleotides are 
targeted and it has been shown that there are nucleotide hotspot sequences (Shapiro et al., 
1999). The sequences RGYW and WA and their reverse complements are such hotspots (W = 
A/T; R= A/G; Y= C/T).  
The AID enzyme is responsible for initiating SHM (Muramatsu et al., 2000). Its 
mechanism is debated yet it is thought that the enzyme interacts with the DNA (Liu & 
Schatz, 2009; Neuberger et al., 2003). During transcription, loops of single stranded DNA are 
exposed. AID deaminates cytosine residues in the variable region of the antibody sequence 
and this creates uracil (U) residues in the sequence (Liu & Schatz, 2009). The uracil can be 
removed by uracil DNA glycosylase (UNG), creating a space (an abasic site). Repair of this 
can be error prone and mutations introduced. When these mutations occur in other genes, 
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error repair is of high fidelity and it appears the outcome of AID-induced mutation depends 
on the location and process (Liu & Schatz, 2009; Shivarov et al., 2009). Repair of the abasic 
site occurs through base excision repair, where replication through the site introduces a 
random base (Odegard & Schatz, 2006). Alternatively, if the U is not removed by UNG then 
error-prone repair of U pairing in the DNA occurs through mismatch repair. This involves a 
heterodimer Msh2/Msh6 that triggers excision and resynthesis of a short DNA strand. Here, 
DNA polymerase polη can also mutate A and T residues near the original mismatch (Liu & 
Schatz, 2009; Neuberger et al., 2003).  
Mutated BCR are displayed and come into contact with the antigen on FDCs in the 
light zone of the GC. They take up antigen and present peptides as part of their MHCII 
complexes. Higher affinity BCR will pick up more antigen than those with lower affinity 
(Allen et al., 2007). The cells with lower affinity may die through apoptosis or get recycled 
back through the GC but high affinity cells can also be recycled for further rounds of 
selection. Iterative rounds of mutation and selection lead to BCR with higher and higher 
affinity. If cells are not recycled, they migrate out of the GC as long-lived plasma cells or 
memory cells (McHeyzer-Williams & McHeyzer-Williams, 2005).  
Plasmablasts are a stage of plasma cell development. They are rapidly proliferating 
cells that secrete antibody and along with plasma cells, can be known as antibody-secreting 
cells (ASCs). Plasma cells are terminally differentiated cells that secrete antibody at high 
levels. They have a half-life of over 3 months but can be replenished by memory B cells 
(Jackson et al., 2008). Memory B cells are long-lived cells that reside in the lymphoid tissues 
or blood. They do not secrete high levels of antibody until activated by a secondary 
exposure to antigen.  
 
 
1.3.3. Secondary antigen challenge 
Secondary infection will lead to rapid responses, with a low threshold of activation 
required by the memory B cells. This enables high affinity, hypermutated antibodies to be 
secreted early. Reactivated memory B cells can cycle through the GC reactions to become 
plasmablasts and can therefore accumulate further SHM (Janeway et al., 2008). Naive B cells 
would be stimulated also and undergo the maturation processes for antibody production. 
They have to compete for antigen with the high affinity memory B cells and therefore could 
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represent a smaller population (Abbas & Lichtman, 2003). An interesting study in mice has 
recently reported that naive B cells can be rapidly stimulated in a secondary infection due to 
the presence of pre-existing antibody (Goins et al., 2010). Antibody created in the primary 
response forms complexes with secondary antigen and binds to Fc receptors. This presents 
antigen to naive BCRs and accelerates the activation of T helper cells and the secondary 
response. 
Original antigenic sin (OAS) in the context of secondary infections is the preferential 
activation of memory B cells specific for the primary infecting serotype. These B cells would 
be highly selected and hypermutated but specific for previously encountered epitopes 
(Morens et al., 2010). This is of interest in the dengue field due to the circulation of the 
antigenically related serotypes and existence of enhancing antibodies. OAS has been 
observed in mice and rats infected with strains of influenza (Angelova & Shvartsman Ya, 
1982; Kim et al., 2009). Conversely, Wrammert et al analysed the affinity of influenza 
vaccine-induced B cells in humans and found them to be more specific for the vaccine strain 
epitopes (Wrammert et al., 2008).  
In dengue, early studies showed that in secondary DENV infections, the neutralising 
antibody response is often greater against that of the primary infecting serotype (Halstead 
et al., 1983). However, Kuno et al attempted to demonstrate OAS using the neutralisation 
titre of secondary infection sera but found it was inconsistent. The highest neutralisation 
titre did not always correspond with the primary infecting serotype (Kuno et al., 1993). 
Recently, DENV E domain III antibodies have been shown to portray ‘sin’ characteristics. 
Using an ELISA competition assay, the avidity of these binding antibodies was higher for the 
primary infecting serotype than the secondary (Midgley et al., 2010). Demonstration of OAS 
suggests the cross-reactive memory B cells from primary infection are being stimulated. Not 
only might this lead to poor control of the secondary virus but it may also impact on the 
antibody-dependent enhancement of infection. 
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1.4. Antibodies  
 
1.4.1. Production of monoclonal antibodies 
Analysis of the B cell response and individual antibody function has been made 
easier by production of monoclonal antibodies (mAbs). These antibodies originate from a 
single B cell clone and the methods of their production are rapidly evolving. 
 
1.4.1.1. Hybridoma 
 Production of mAb from murine cells was pioneered by Köhler and Milstein, who 
created immortalised fusion cell lines (Kohler & Milstein, 1975). The method is still used 
today for production of murine mAbs. Mice can be immunised with antigen and the B cells 
within the spleen are harvested. These are then fused with myeloma cells using 
polyethylene glycol. The immortalised myeloma cells are deficient in an enzyme for DNA 
synthesis so the fused cells are grown in selective media to only allow growth of fused cells. 
These fused cell hybridomas maintain long term growth and secretion of specific antibodies. 
Many murine hybridomas specific for DENV have been produced through immunisation of 
mice with virus or DENV E protein (Henchal et al., 1985; Roehrig et al., 1998; Shrestha et al., 
2010) and these antibodies provide well-characterised tools for immunoassays.  
  
1.4.1.2. EBV immortalisation of human B cells 
A method for producing human mAbs is immortalisation of B cells through Epstein 
Barr virus (EBV) infection. EBV is a virus of the Herpesviridae and is capable of latent 
infection of B cells. It causes proliferation and immortalisation of cultured cells and can 
therefore be used to create stable antibody-secreting cell lines. The method for producing 
these stable B cells from peripheral blood mononuclear cells (PBMCs) was optimised by 
Lanzavecchia et al. By addition of CpG oligodeoxynucleotides (CpG ODN), the cloning 
efficiency was enhanced (Lanzavecchia et al., 2007; Traggiai et al., 2004). CpG ODN are Toll-
like receptor (TLR) agonists and bind to TLR9. This binding simulates bacterial activation of 
the B cells through a signalling pathway. Culture of isolated B cells with this agonist and 
other growth factors leads to expansion of the clones and ultimately they can be cloned as 
single cells by limiting dilution. Single cell clones are further expanded and secrete mAb into 
the culture media. This method can be used to produce antibody from memory B cells only. 
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Plasma cells and plasmablasts cannot be transformed by latent EBV. They express a 
transcription factor that activates the EBV gene BZLF-1 and this causes the EBV to enter a 
lytic cycle of replication (Doria-Rose et al., 2009).  
Monoclonal antibody production from memory B cells means the response to many 
previously encountered antigens can be analysed. One study analysed the memory 
response to 5 pathogens encountered over 17 years (Pinna et al., 2009). B cells specific for 
measles virus could be stimulated from PBMCs taken at several timepoints over this period, 
which highlights the longevity of the response. Similarly, antibodies specific for the 1918 
influenza pandemic were made through EBV transformation 90 years after infection (Yu et 
al., 2008b). DENV-specific mAbs have also been produced using this method. Three anti-E 
antibodies were produced from a patient 2 years post-infection (Schieffelin et al., 2010) and 
very recently 70 anti-DENV antibodies were produced from 5 donors at 6 months-8 years 
post-infection (Beltramello et al., 2010). In our laboratory this method has led to production 
of several DENV-specific mAbs and the characterisation of 301 cell lines (Dejnirattisai et al., 
2010). Some of these antibodies are described in this thesis. 
  
1.4.1.3. Recombinant monoclonal antibodies 
Antibody engineering is a method for production of antibody-like molecules and is 
used for many clinical applications (Zola, 2000). Their synthesis on a genetic level means the 
sequence of the antibodies can be analysed or perhaps manipulated alongside production. 
For example, RNA from B cells is used to amplify single chain variable fragments (scFv). 
These consist of variable regions of heavy and light chains joined by a polypeptide linker. 
Alternatively, the Fab fragment can be synthesised, which consists of the variable regions 
plus part of the constant regions. RNA is purified from B cells and reverse-transcribed. The 
cDNA is then used as a template for PCR amplification of the heavy and light chain target 
regions. These can be cloned into expression vectors to create a library of randomly 
assorted heavy and light chains before expressing the protein. Phage display can be used as 
a method of screening them for specificity to a particular antigen. However the 
disadvantage of this approach for producing multiple mAbs is that they contain unnatural 
heavy and light chain pairing and therefore do not represent the in vivo antiviral response.  
Some groups have overcome this issue by using single cells or hybridoma as the 
source of RNA. Fab fragment and scFv specific to DENV have been produced from previously 
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existing murine hybridoma cells and can be used to analyse binding kinetics and 
neutralisation (Bedouelle et al., 2006; Rajamanonmani et al., 2009).  
Weitkamp et al developed a method of culturing single human B cells by providing 
them with CD40L stimulation from feeder cells. Then the cells secreting antigen-specific 
antibody were used for PCR amplification of variable regions and Fab expression (Weitkamp 
et al., 2003b). The variable regions of antibodies specific for respiratory syncytial virus and 
rotavirus have been studied in this way (Kallewaard et al., 2008; Tian et al., 2008; Weitkamp 
et al., 2003b; Williams et al., 2009). However, this method relies on growth of the B cell and 
therefore can be unreliable. PCR amplification of the variable regions without culture of the 
B cells has been achieved and led to the production of Fab fragments specific for tetanus 
toxoid and influenza (Meijer et al., 2006; Poulsen et al., 2007). Yet these methods do not 
yield full length antibody. 
Methods to rapidly clone and express full-length antibody from human B cells have 
been developed and adaptation of these form a large part of this work. Wardemann et al 
sought to analyse B cell subsets in autoimmunity by sequencing and manufacturing mAbs 
from these cells (Tiller et al., 2008; Wardemann et al., 2003). They sorted B cells as single 
cells by fluorescence-activated cell sorting (FACS). RNA from these cells was reverse-
transcribed and the cDNA used for PCR amplification of the heavy and light chain variable 
regions. This PCR included multiple primers specific for all variable region genes and families 
and required a nested PCR step in order to sufficiently amplify the low template 
concentration of single cells. Variable region PCR products were cloned into heavy or light 
chain expression vectors containing constant region genes. Vectors could then be co-
transfected into mammalian cell lines for expression of full-length IgG. Figure 1.8 
demonstrates this technique, which is further described in chapter four. 
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Figure 1.8. Monoclonal antibody production from single sorted B cells (Jackson et al., 
2008) 
 
 
1.4.1.4. Application of recombinant full-length monoclonal antibodies 
The DNA sequence of the variable regions can be analysed and antibody can be 
produced in large quantities for functional assays. It has previously been discovered that a 
high proportion of early B cell precursors produced polyreactive antibody and that this 
could be associated with a long HCDR3 (Tiller et al., 2008; Wardemann et al., 2003). This 
method has also been exploited in two important studies investigating the B cell response to 
vaccine and infection. Memory B cells from HIV patients were used to create mAbs specific 
for the viral envelope (Scheid et al., 2009), creating valuable tools for understanding the 
poor humoral response to this virus. They identified several broadly neutralising antibodies. 
Additionally, influenza has been studied with these methods to identify the breadth of the 
response to vaccination. They found that B cells were rapidly activated and have a high 
affinity for the vaccine antigen not previously encountered strains, disproving a large 
contribution from OAS (Smith et al., 2009; Wrammert et al., 2008). These studies prove how 
applicable these methods are in the study of dengue antibodies. The methods have now 
been scaled up to screen even larger numbers of cells by using microarray chips coated with 
antigen (Jin et al., 2009). Antibodies to hepatitis B virus were produced rapidly and 
characterisation provided information on vaccine response (Tajiri et al., 2010). 
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1.4.2. Antibody repertoires in disease 
 Production of mAbs through cloning of variable regions has led to an increase in the 
analysis of their sequences. Early work on sequencing of these genes was focused on 
understanding the germline repertoires to discover the number of genes, alleles and 
individual polymorphisms. Even today this is not complete, with new additions and new 
sequencing tools being developed (Boyd et al., 2010).  
There have been several studies on gene segment usage, repertoire diversity and 
rates of SHM. Many relate to immune disorders but some analyse the response to vaccines 
and infection. This section aims to highlight those that are of most relevance to this project 
and that shaped the analysis performed within it. 
  
1.4.2.1. Antibody sequence diversity in disease 
 Germline DNA encodes many V, D and J gene segments and allelic variants. The 
heavy chain rearranges to bring together random VDJ combinations. The rearrangements 
that do not form a functional H chain are deleted, already introducing a bias in the 
repertoire. Then light chain genes rearrange (sometimes more than once) and they join this 
selection of heavy chains to form the naive B cell repertoire. Certain gene segments are 
more likely to rearrange than others and it may be their RSS that dictates their inclusion in 
the repertoire (Boyd et al., 2010). Additionally, there may be selection of particular D 
segments in B cell development to promote hydrophilic sequences and therefore more 
favourable antigen binding sites (Corbett et al., 1997; Raaphorst et al., 1997). 
A memory B cell repertoire will be shaped by the selection of antibodies in all 
previous antigenic encounters. However in the case of an acute response, a response to a 
particular antigen, or in an autoimmune disorder, there may be a bias towards particular 
genes. These dominant genes or gene rearrangements can reflect an antibody structural 
preference by the antigen or faulty developmental mechanisms. 
 In the context of autoimmunity, it has been found that a particular VH segment binds 
to a carbohydrate on red blood cells. The VH4-34 gene segment is normally 
underrepresented in plasma cell populations but in systemic lupus erythematosus (SLE) 
patients it is expressed by memory and plasma cells (Cappione et al., 2005; Pugh-Bernard et 
al., 2001). Preferences in light chain gene segments have also been identified but results are 
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often inconsistent due to the low sample numbers (Dorner et al., 1999; Foreman et al., 
2007; Fraser et al., 2003). 
 The response to rotavirus has been shown to be dominated by the VH1-46 gene 
segment in the subset of B cells recruited to the site of infection (Weitkamp et al., 2003a; 
Weitkamp et al., 2005). Interestingly this segment does not require SHM for binding, 
indicating that its germline structure is sufficient for binding to the antigenic viral protein 6 
(VP6) (Kallewaard et al., 2008). A bias has also been identified in respiratory syncytial virus 
(RSV) patients. Differences in the VH gene repertoire and SHM in infants compared to adults 
were used to explain an insufficient antibody response to the virus among infants (Williams 
et al., 2009).  
The VH1-69 gene segment has been shown to be important in antiviral responses. It 
was prevalent in responses to influenza vaccination (Corti et al., 2010). The structure of this 
dominant segment has been shown to be responsible for binding to conserved hydrophobic 
pockets (Sui et al., 2009). It has also been identified as a dominant gene segment in B cells 
responding to hepatitis C virus (HCV) envelope protein and these B cells can go on to form 
lymphomas (Chan et al., 2001). 
 A small number of antibodies were sequenced from rabies virus infections. A 
dominance of certain gene families was observed but this was true of healthy donor 
repertoires also and deemed to not to be a bias in the anti-rabies response (Ikematsu et al., 
1993; Ikematsu et al., 1998). The same conclusion can be inferred from repertoires of 
antibodies specific for other pathogens, where in general there is a dominance of VH3/4, 
Vκ1/3 and Vλ1/2, as seen in healthy donors. Examples of these pathogens include tetanus 
toxoid (Poulsen et al., 2007), hepatitis B surface antigen (Tajiri et al., 2010), Streptococcus 
pneumoniae capsular antigen (Zhou et al., 2004) and HIV antigen gp140 (Scheid et al., 2009). 
However it has also been shown that antibodies specific for a particular region within the 
HIV gp140 antigen are again dominated by the use of VH1-69 (Huang et al., 2004). 
 In summary, the usage of antibody gene segments in B cell repertoires is naturally 
biased but the response to some antigens can be particularly dominated by certain genes.  
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1.4.2.2. Antibody somatic hypermutation in pathogen responses  
 Mutations within antibody variable regions can alter the structure of the antigen 
binding site. SHM is mainly directed within the CDR regions and can increase or decrease 
affinity of antibody binding. The rate of SHM is often used to demonstrate that an antibody 
has been selected during B cell development. Due to the mechanisms involved in mutation 
of the genes, SHM can be discriminated from random mutation by its localisation to CDRs 
and its higher ratio of amino acid replacement mutation to silent mutation (R/S ratio) 
(Rajewsky, 1996). This ratio reflects the targeted mutation of CDRs and selection of those 
mutations that improve antibody binding. 
 In mice, the study of SHM has shown that the primary response to a pathogen 
invokes few mutations to the antibody CDRs, whereas antibodies from a secondary 
exposure have many. Examples of this include responses to vesicular stomatitis virus (VSV) 
and influenza (Clarke et al., 1990; Kalinke et al., 2000). In addition to this, particular 
mutations can be seen at the same position but in different clones. This suggests GC 
selection of antibodies with common binding characteristics. There have been few 
equivalent studies of anti-pathogen responses in humans. Some antibodies have been 
identified that have no mutations and are capable of neutralisation, for example rotavirus 
antibody and tetanus toxoid antibody (Poulsen et al., 2007; Tian et al., 2008). Yet mutations 
via SHM subsequently cause an increased affinity and improvement in function. This action 
has been exploited in studies that have tested manually mutating antibody CDRs in order to 
improve their affinity or the breadth of neutralisation (Montgomery et al., 2009; Ofek et al., 
2010; Sui et al., 2008; Toran et al., 2001). Of note is a study that induced mutation of the 
CDRs in an antibody specific for the flavivirus Japanese encephalitis (JEV). Through random 
mutagenesis of the HCDR2 and HCDR3, a mutant was identified with 3 amino acid changes 
in the CDR3 that could increase the affinity (Hong et al., 2007).  
 Rates of SHM have been shown to be high in the response to influenza (Wrammert 
et al., 2008) and this was assumed to mean response to vaccination is a recall of memory B 
cells. This reactivation of memory has also been suggested for the highly mutated antibody 
response to Streptococcus pneumoniae vaccination (Zhou et al., 2004). Even higher rates 
have been reported in patients with HIV infection, which has been attributed to persistent 
SHM as a chronic immune response (Scheid et al., 2009).  
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 To summarise, the amount of mutation a B cell is subjected to can provoke 
speculation on its origin and provide information on the evolution of antibody affinity. 
 
 
1.4.3. Antibody binding and epitope mapping 
 The highly variable CDR regions of antibodies can bind to antigen in a variety of 
ways. The antigenic surface can have pockets, grooves, protrusions and either 
conformational or linear epitopes. The antibody may bind through any combination of its 
CDRs, for example interaction between hen egg-white lysozyme and antibody Fab involves 
all heavy and light chain CDRs (Janeway et al., 2008). Alternatively an antibody specific for 
HIV uses only its HCDR3 (Kwong & Wilson, 2009). 
 Epitope mapping can be performed by visualising or reconstructing the structure of 
the antigen-antibody complex, so the critical contact points can be identified. The X-ray 
crystal structures of the DENV structural proteins have been resolved in their different 
maturational states. DENV2 and DENV3 have been solved in their dimeric pre-fusion 
conformation (Modis et al., 2003; 2005) and DENV2 and DENV1 have been solved in their 
trimeric post-fusion conformation (Nayak et al., 2009; Zhang et al., 2004). This 
demonstrated which domains were surface-exposed as potential epitopes and receptor-
binding regions. Cryo-electron microscopy (cryo-EM) has been used to determine the 
structure of prM-E in immature virions and its conformational changes at low pH (Li et al., 
2008; Lok et al., 2008; Yu et al., 2008a). This showed how epitopes on the fusion loop would 
be masked by the prM protein in this state. Complexes of antibody Fab regions with 
recombinant protein have been used to define particular antibody binding sites. Cryo-EM 
has demonstrated the binding of a murine Fab (1AID-2) to recombinant DENV EDIII, which 
interestingly caused a rearrangement of the E protein and prevented infection (Lok et al., 
2008). The mechanisms of neutralisation by antibody are discussed further in section 1.4.4. 
 Epitopes can also be identified through screening of peptides. By dividing the 
structural proteins into smaller peptide sequences and probing with antibody, the location 
of non-conformational epitopes can be identified. Several murine anti-DENV antibody 
epitopes have been identified using peptides in ELISA format or immunoblotting (Falconar, 
2008; Roehrig et al., 1998). Peptides can also be presented in a phage display library, which 
is added to mAb bound on a plate. After washing and repeated screening, the peptide phage 
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that has high affinity binding can be sequenced to identify the epitope. This method was 
used to identify the epitope of a cross-reactive murine mAb 4E11; mapped to a 9-amino acid 
sequence in EDIII (Thullier et al., 2001). Its epitope was further mapped by alanine 
mutagenesis of recombinant EDIII. This revealed there are further amino acids involved in 
binding and these lie on a second β sheet (Lisova et al., 2007). Therefore epitope mapping 
using peptides may not represent natural tertiary conformations. Interestingly, this antibody 
is one of very few anti-DENV antibodies that has been analysed on a sequence level. Two 
amino acids within the D segment and one within the light chain CDR3 were shown to 
participate in antigen binding and mutation of amino acids outside of the antigen-binding 
site also leads to decreased affinity (Bedouelle et al., 2006). 
Fine epitope mapping can be achieved by mutating amino acids within the antigen 
and analysing loss of antibody binding to the mutant. This often retains the overall structure 
of the protein but identifies key residues needed for binding. Site-directed mutagenesis of 
EDIII has been performed and the mutant proteins expressed in bacteria (Gromowski & 
Barrett, 2007; Matsui et al., 2009). The recombinant protein was probed with mAbs by ELISA 
and loss of binding mapped the critical amino acids. Using a mutant pseudotype reporter 
virus, prM-E has also been expressed in mammalian cells. Again, site-directed mutagenesis 
was used to create mutant proteins and loss of mAb binding to EDII was determined by 
Western blot (Lai et al., 2008).  
The technique of epitope mapping that is used in this project is that of yeast surface 
display. This was developed as a high-throughput method of fine epitope mapping for West 
Nile virus (WNV) (Oliphant et al., 2005). It exploits a system of protein display through 
fusion with a yeast surface protein (Boder & Wittrup, 1997). By using random mutagenesis, 
many amino acid contact residues can be screened, which is an advantage over site-directed 
mutation. The WNV E was mutated and expressed. Yeast cells could then be screened for 
surface protein expression and a mAb could be mapped by sorting the yeast cells for a loss 
of antibody binding. This method is described in detail in chapter 3. Several epitopes have 
been identified within the 3 domains of WNV E (Oliphant et al., 2005; Oliphant et al., 2007; 
Oliphant et al., 2006; Sultana et al., 2009; Vogt et al., 2009). The method was then adopted 
to analyse epitopes of DENV2 EDIII and more recently EDI-II (Sukupolvi-Petty et al., 2010; 
Sukupolvi-Petty et al., 2007). 
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Much of the analysis of DENV epitope sites has been performed with murine mAbs 
due to the lack of human antibodies produced. A recent meta-analysis was performed on 
the published data for all flavivirus epitopes and shows that most B cell epitopes identified 
exist on E protein, with capsid, M and prM epitopes remaining largely undefined (Vaughan 
et al., 2010). Some antibodies specific for E have been shown to cross-react amongst 
flaviviruses, therefore epitope data from viruses such as WNV and JEV can contribute to the 
expanding data on DENV epitopes. It has been observed that cross-reactive antibody 
binding sites frequently map to the fusion loop of EDII (Lai et al., 2008). This region is highly 
conserved amongst the 4 DENV serotypes and other flaviviruses. However these antibodies 
are often weakly neutralising and therefore may contribute to ADE pathogenesis. 
Interestingly these antibodies within sera can be seen at higher titre following a primary 
infection than a secondary (Crill et al., 2009; Lai et al., 2008). Subsequent work with human 
mAbs has shown that cross-reactive antibodies specific for EDI-II dominate the secondary 
response (Beltramello et al., 2010). Domain III antibodies are often not cross-reactive 
between flaviviruses. They are frequently serotype-specific or partially cross-reactive among 
DENV serotypes (Shrestha et al., 2010). Serotype-specific antibodies are often strongly 
neutralising and can be mapped to the lateral ridge of the EDIII (Gromowski & Barrett, 2007; 
Sukupolvi-Petty et al., 2007). However antibodies to this epitope have been shown to be of 
low titre following primary infection (Oliphant et al., 2007) so the role of the epitope and 
antibody response in protection is unclear. The lateral ridge epitope is not conserved among 
DENV3 genotypes (Wahala et al., 2010) and genotype variation within DENV1 also affects 
antibody binding and neutralisation (Shrestha et al., 2010).  
With recent developments in human mAb production, there is now an opportunity 
to expand upon the repertoire of known epitopes for further understanding of the most 
effective antibodies. 
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1.4.4. Neutralisation 
 Antibodies can neutralise flavivirus infection in a number of ways. Antibody binding 
may lead to neutralisation through complement activation and antibody-dependent cell-
mediated cytotoxicity (ADCC) (Green & Rothman, 2006). Binding may also have a more 
direct effect on virus infection. Antibodies can inhibit binding of the virus to the cellular 
receptor, for example it has been suggested that mAb 4E11 blocks virus binding to heparan 
sulphate receptors (Thullier et al., 2001) and Crill et al showed that anti-EDIII antibodies 
could block virus binding to mammalian Vero cells (Crill & Roehrig, 2001). The anti-DENV 
antibody 1AID-2 binds to EDIII and could prevent infection by direct blocking of cell receptor 
contact or by modifying the arrangement of the E dimers to disrupt the receptor binding 
motif (Lok et al., 2008). Alternatively, bound antibody could prevent the rearrangement of E 
proteins necessary for fusion, for example mAb E16. This WNV antibody binds to EDIII and 
inhibits the pH-dependent rearrangement of E required to expose the fusion loop (Pierson & 
Diamond, 2008).  
Flavivirus neutralisation by antibody has also been described as a ‘multiple hit’ 
phenomenon (Pierson et al., 2008). This proposes that multiple antibodies must bind to the 
virus and they should have sufficient affinity and occupancy of the viral surface to prevent 
infection. In the context of DENV infection, low titre of antibody from previous infection 
may not saturate the viral surface. This leaves the virus capable of infection through 
remaining cell-binding epitopes. Virus should be almost saturated by anti-DIII antibodies for 
100% neutralisation, although occupancy of 10-50% can achieve some level of neutralisation 
(Gromowski & Barrett, 2007). Low occupancy by antibody can also lead to ADE. The Fc 
portion of the bound antibody enhances uptake of the virus into the cell and membrane 
fusion may not be prevented with low antibody concentration. Additionally, low affinity 
antibody could dissociate from the virus at the low pH of the endosome, allowing fusion to 
take place (van der Schaar et al., 2009).  
Antibodies specific for EDI-II have varied neutralisation abilities (Beltramello et al., 
2010; Sukupolvi-Petty et al., 2010). EDII fusion loop antibodies have the potential to 
neutralise infection at the point of fusion of the virus with cell membrane. However, these 
antibodies often have lower neutralising abilities than EDIII antibodies (Beltramello et al., 
2010). It is unclear which target is the most relevant following human infection, because 
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depletion of anti-EDIII antibodies from human sera has little effect on overall neutralising 
activity (Wahala et al., 2009). 
In the mature virion the fusion loop is partially occluded and the cryptic epitope is 
not easily accessible (Stiasny et al., 2006). To overcome this, the array of virus epitopes can 
become available through dynamic structural changes or ‘breathing’ (Lok et al., 2008). It has 
been shown that incubation of virus at 4°C prevents the dynamic motion and a fusion loop-
specific antibody cannot fully neutralise this virus, presumably due to concealed epitopes 
(Sukupolvi-Petty et al., 2010). Antibodies specific for EDI-II and the fusion loop have been 
proven to induce ADE over a broad range of antibody concentration (Beltramello et al., 
2010; Oliphant et al., 2006). The role of such antibodies in an antibody response requires 
further investigation. The maturation state of the virus may also dictate the nature of the 
enhancing antibody response. On immature or partially immature virions, binding of 
antibody to prM renders the particle infectious upon internalisation by an Fc receptor-
bearing cell (Rodenhuis-Zybert et al., 2010). 
 The mechanisms of antibody-mediated neutralisation of DENV are yet to be fully 
elucidated. Important insights will arise with production of new mAbs and tools for 
observing their stoichiometry in complex with virus. 
 
 
1.4.5. Therapeutic monoclonal antibodies 
Human monoclonal antibodies have been created for therapeutic use in oncology, 
infectious disease and autoimmune disease. Several antibodies have been developed for 
treatment of cancer, for example rituximab for non-Hodgkin’s lymphoma or trastuzumab for 
breast cancer. To date, one antibody is clinically available in the infectious disease field, 
palivizumab. This antibody is administered as a prophylactic for babies at risk of respiratory 
syncytial virus (RSV) infection. The antibody is administered monthly during the season of 
high RSV circulation. Delivery of human monoclonal antibodies could be extremely 
beneficial in the prevention and treatment of certain infectious diseases. In dengue 
infection, pre-existing antibodies could be increasing viral uptake and worsening disease. 
Therefore if a strongly neutralising cocktail of monoclonal antibodies were administered 
early in dengue infection it may prevent the severe immunopathology. A selection of 
antibodies that have high affinity and can neutralise at broad concentrations would be 
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required. To avoid virus escape mutants it would also be beneficial for the antibodies to 
have different epitope binding sites and the abilities to neutralise virus at pre-and post-
attachment steps.  
Recently a study proposed a cocktail of antibodies could be used as a treatment for 
DENV. One antibody was specific for EDIII of DENV1, 2 and 3; one antibody was specific for 
EDI-II of DENV4 and the third antibody was a cross-reactive EDI-II antibody. To prevent ADE 
by these antibodies a mutation was engineered into the constant regions to inhibit binding 
to Fc receptors. The combination prevented infection in a vascular-leakage mouse model 
when given post-exposure (Beltramello et al., 2010). 
 Treatment of infection would likely be confined to those with severe disease and 
there needs to be a more reliable method for predicting the outcome of infection in order 
to deliver treatment promptly. It is also important to consider that treatment would not 
confer immunity upon re-infection and DENV is endemic in many parts of the world. 
Therefore vaccine development is crucial for control of this disease. By producing antibodies 
from vaccinated or infected individuals, one could analyse the epitope specificities and 
function of the antibodies with the aim of identifying an important target for vaccine 
research. 
 
 
1.4.6. Vaccine progress 
 There is currently no vaccine clinically available for prevention of DENV infection. 
Vaccine development has had to take into account the principles of ADE and cross-reactive T 
cell responses, meaning that the current goal of vaccine design is to induce a long-lasting 
immune response with equal efficacy for all 4 serotypes.  The induced response would need 
to neutralise virus regardless of infecting serotype and previous flavivirus exposure (Kanesa-
Thasan et al., 2003). 
 Aside from these stringent criteria, another major problem is that there is no reliable 
animal model for DENV pathogenesis. DENV does replicate in animals, often producing high 
viraemia, and can induce immune responses. For example vaccination of mice with DENV 
prM, E or NS1 has been shown to be protective (Babu et al., 2008; Costa et al., 2006; 
Vazquez et al., 2002). However infection of immunocompetent mice and non-human 
primates does not lead to DHF/DSS symptoms. More recently there has been development 
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of more suitable mouse models that can support DENV infection and replicate some of the 
pathology seen in human infection (Balsitis et al., 2010; Mathew & Rothman, 2008).  
There are several DENV vaccines in the process of development and clinical trials. 
One that has reached human clinical efficacy trials is produced recombinantly by introducing 
DENV E and prM into the attenuated yellow fever 17D vaccine strain (Guy, 2009). Another 
attenuated vaccine was created by serial passage of the 4 DENV serotypes in primary dog 
kidney cells and evaluated in humans. This tetravalent vaccine was deemed immunogenic 
and safe (Simasathien et al., 2008) but has encountered problems and not progressed 
(Webster et al., 2009). Infectious clone vaccines are also now in early clinical trials and these 
are based on a DENV4 sequence with deleted untranslated region and inserted structural 
genes for other serotypes (Wright et al., 2009). Vaccines still in the pre-clinical phase of 
development are composed of protein, DNA, whole inactivated virus, replication-
incompetent virus and viral vectors.  
 Although there has been preliminary success in developing a vaccine for DENV, 
further research into the response to infection will provide safer candidates. Perhaps this 
could be achieved through removal of viral epitopes that induce the immunopathology or 
extra safeguards against reversion to virulence in attenuated strains. 
 
 
1.5. Aims of this work 
 Antibodies play an important role in not only neutralisation of DENV infection but 
also in its pathogenesis. Much of the investigation into these antibodies has used murine 
monoclonal antibodies or polyclonal sera and these do not provide sufficient information 
about the human antibody response.  
 This project aims to create an epitope mapping system using yeast surface display 
with the intention that it can be used to map the critical binding sites of new human mAbs. 
These antibodies would originate from EBV-transformed memory B cell clones and also from 
single ASCs of DENV patients. Production of antibodies through cloning of their variable 
regions could then allow analysis of the antibody sequences that would create novel insights 
into the B cell response to DENV. 
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Chapter 2 
Methods and Materials 
 
2.1. Buffers and reagents 
 
TBE buffer (10x) 
54g Tris, 27g Boric acid, 0.5M EDTA, 1L H2O 
Orange G agarose gel loading dye (10x) 
0.2% Orange G, 30% glycerol. 
LB (Luria-Bertani) media 
5g Tryptone, 2.5g Yeast extract, 5g NaCl, 500ml H2O (+7.5g agar for plates) 
Competent E.coli 
DH5α cells were inoculated into ψbroth (4.95g MgSO4, 0.586g NaCl, 0.367g KCl, 20g 
Tryptone, 5g yeast extract) and grown until density reached OD600 of 0.5. The pellet was 
resuspended and incubated on ice for 30minutes in TFB1 (300mM Kac, 100mM RbCl2, 
10mM CaCl2, 50mM MnCL2, 15% glycerol) before adding TFB2 (10mM MOPS, 10mM RbCl2, 
75mM CaCl2, 15% glycerol) for 15 minutes. Cells were aliquotted and stored at -80°C. 
YPD media 
1% yeast extract, 2% peptone, 2% dextrose 
YNB (yeast nitrogen base) agar 
0.67% YNB, 2% glucose, 0.01% leucine, 0.01% tryptophan, 1.5% agar 
YNB-CAA media 
0.67% YNB, 0.5% casamino acids, 2% glucose or galactose 
FACS wash 
PBS with 1% foetal calf serum (FCS) and 0.5% BSA 
FACS fix 
PBS with 5% formaldehyde 
PMSF (paramethyl sulphonyl fluoride) 
10mM stock: 1.74mg in 10ml isopropanol 
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MES FACS buffer 
25mM MES, 150mM NaCl, 1% FCS, 0.5% BSA 
SDS PAGE gels 
12% acrylamide resolving gel: 5ml H2O, 6ml 30% acrylamide, 3.8ml 1.5M Tris pH8.8, 150μl 
10% sodium dodecyl sulphate (SDS), 150μl ammonium persulphate (APS) and 6μl 
tetramethylethylethylenediamine (TEMED) 
5% stacking gel: 5.5ml H2O, 1.3ml 30% acrylamide, 1ml 1M Tris pH6.8, 80μl 10% SDS, 80μl 
APS and 8μl TEMED 
SDS PAGE gel loading buffer (4x) 
4ml H2O, 8ml 0.5M Tris-HCl pH6.8, 1.6g SDS, 8ml glycerol, 4mg bromophenol blue.  
SDS PAGE running buffer 
24mM Tris, 192mM glycine, 1% SDS 
Western blot transfer buffer 
24mM Tris, 192mM glycine, 20% methanol 
RNase inhibitor buffer 
5ml H20, 125μl RNAsin (Promega) 
HEBS (2x) 
2g dextrose, 10g HEPES, 0.74g KCl, 16g NaCl, 0.27g Na2HPO4 up to 1L with H20 
PEI solution (polyethylenimine) 
1mg/ml PEI in water, pH7 and filter-sterilised 
ELISA coating buffer 
50mM sodium bicarbonate was made from 1 tablet of bicarbonate (Sigma) in 100ml H2O. 
ELISA substrate 
1ml BioRad Alkaline phosphatase substrate kit diethanolamine buffer plus 1 tablet BioRad 
AP substrate kit nitrophenylphosphate and 4ml H2O 
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2.2. Yeast surface display of DENV antigens  
 
2.2.1. Wild type DENV envelope protein constructs 
 DNA encoding domains I-II, III and I-III of E were previously inserted into commercial 
yeast expression vector pYD1 (Invitrogen) by Alison Cowper. The DENV sequence templates 
originated from structural sequence of dengue in pBluescript vector (from Siriraj Hospital 
Mahidol University, Bangkok). The sequences represent all 4 serotypes: DENV1 strain Hawaii 
(accession NC_001478), DENV2 strain 16681 (accession M84727), DENV3 strain H87 
(accession M93130) and DENV4 strain H241 (accession AY947539). A vector map can be 
found in the appendix section A.2. 
 
  
2.2.2. Generation of DENV E mutants 
Mutagenic PCR was used to amplify DNA sequence for domains I-II, domain III or full-
length envelope (EDI-II, EDIII or EDI-III). The DNA templates used were envelope genes 
within pYD1 vector as used above for expression of wild type E. Primer sequences can be 
found in appendix A.1. They contained KpnI and XhoI or KpnI and BamHI restriction sites for 
cloning. The optimal concentrations of reagents were 1mM dATP/dGTP; 0.2mM dCTP/dTTP, 
0.4µM primers, 2mM MgCl2, 10mM Tris-Cl, 50mM KCl, 0.3mM MnCl2 and 5 units of Taq DNA 
polymerase (Bioline). The cycling parameters were 35 cycles of 95°C for 30 seconds, 60°C for 
2 minutes and 72°C for 2 minutes. PCR products were purified from 1% agarose gel (in TBE 
buffer) using QIAquick Gel Extraction kit (Qiagen) and cloned into the sequencing vector 
pCR4 TOPO (Invitrogen) according to manufacturer’s instructions. A vector map can be 
found in appendix section A.3. Plasmids were introduced into TOP10 chemically competent 
E.coli (Invitrogen) to increase copy number and plasmid DNA was extracted using QIAprep 
Spin kit (Qiagen). Sequence data was obtained from an in-house single primer extension 
dye-terminator sequencing service. The primers used were commercial T7/T3 primers 
(Invitrogen). These primers anneal near the ends of the multiple cloning site. The resulting 
sequences were aligned against the unmutated PCR template and the NCBI accession 
sequences using ClustalW of BioEdit software.  
For cloning into the expression vector, PCR products were digested with KpnI and 
XhoI/BamHI enzymes (New England Biolabs- NEB) overnight. The pYD1 vector (20µg) was 
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digested with the same enzymes for 3 hours and dephosphorylated with 1 unit of shrimp 
alkaline phosphatase (Roche) for 30 minutes. Once purified, the PCR product was ligated 
into the purified yeast vector using T4 DNA ligase (NEB). Ligation took place overnight at 
16°C with vector and insert at 1:3 molar ratio. Concentrations had been estimated by visual 
determination of band intensity compared to known concentrations of lambda phage DNA. 
Ligation mix was then introduced into chemically competent DH5α E.coli (method of 
production can be found in section 2.1). The cells were plated onto LB agar with 50µg/ml 
ampicillin and incubated overnight at 37°C. Colonies were inoculated into LB broth with 
50µg/ml ampicillin and grown overnight shaking at 200rpm before extracting DNA using 
QIAPrep Spin kit (Qiagen). In order to confirm presence of insert in the vector, small-scale 
digests were performed using 2µg DNA and 2 units of KpnI and EcoRI enzymes. 
 
 
2.2.3. Expression of protein on yeast cells 
Plasmids were introduced into competent Saccharomyces cerevisiae strain EBY100 
(Invitrogen). These cells were produced using S.C. EasyComp transformation kit according to 
the manufacturer’s instructions (Invitrogen). Briefly, cells were grown in YPD media, washed 
and added to a lithium cation solution. The cells were transformed by adding plasmid DNA 
and EasyComp solution containing polyethylene glycol (PEG), with heat shock. The 
transformed cells were plated onto yeast nitrogen base (YNB) media without tryptophan 
(for selection of transformants) and grown at 30°C for 3 days.  
Transformations of yeast with the vector containing DENV sequence or with vector 
alone were carried out. The pYD1 vector alone was used as a negative control for 
expression. It had an oligonucleotide introduced to cause a frameshift and therefore the 
vector will not express any protein (modification performed by Alison Cowper).  
Colonies of transformed yeast were inoculated into YNB-CAA broth with glucose. 
This was grown at 30°C shaking at 200rpm for 24hours. The culture was centrifuged at 1800 
x g for 10mins and the pellet washed in PBS. The cells were resuspended in YNB-CAA with 
2% galactose to induce protein expression. A small volume of culture was taken and stored 
at 4°C as an uninduced control. Induction was carried out, shaking, between 22-30 hours 
(the optimal time determined by a timecourse experiment) and at room temperature. The 
culture was then stored at 4°C or frozen with 40% glycerol in aliquots at -80°C. 
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2.2.4. Testing yeast cells for expression: anti-V5 tag staining 
In order to confirm and optimise expression of protein, staining of the cells with anti-
V5 tag antibody was performed for flow cytometry. 1ml induced and uninduced cultures 
were centrifuged at 3000 x g for 5 minutes to pellet the cells. They were resuspended in 
500µl FACS wash buffer and 100µl duplicates were aliquotted into wells of a 96well plate. 
For staining, one well was left unstained (in FACS wash buffer) and one had 50µl anti-V5-
FITC (Invitrogen) diluted 1/200 in FACS wash buffer. Cells were incubated shaking at 4°C for 
1 hour and were then washed with 200µl FACS wash buffer 3 times before resuspending in 
300µl FACS fix. A FACS Calibur machine (Becton Dickinson) was used for acquisition with 
CellQuest software. A gate was created for the yeast cells and fluorescence identified in the 
FL1 channel for FITC stained cells. FlowJo software was used for data analysis. For optimal 
surface protein expression, a clear shift was seen in the histogram of fluorescence from 
uninduced to induced cells. 
 
 
2.2.5. Production of a mutant library of DENV2 EDI-II 
 Mutagenic PCR for DENV2 EDI-II was carried out in 10 reactions, to increase diversity. 
PCR products were digested and ligated into vector as in section 2.2.2.  These were then 
introduced into 10 aliquots of XL-10 Gold ultracompetent E.coli (Stratagene) and plated 
onto large bioassay plates containing LB agar with 50µg/ml ampicillin. After overnight 
growth, colonies (around 75,000) were removed from the plates by resuspending in LB 
broth with 50µg/ml ampicillin and then inoculated into 500ml. The culture was grown 
overnight and DNA extracted by maxi-prep kit (Qiagen). Then DNA was transformed into 10 
aliquots of competent yeast as above (1µg each). Transformants were plated onto bioassay 
dishes containing YNB agar without tryptophan. Plates were incubated at 30°C for 3 days.  
Colonies were all inoculated into 1L YNB-CAA with 2% glucose. This was grown at 30°C 
shaking for 24 hours. The culture was centrifuged at 800 x g for 10mins and the pellet 
washed in PBS. The cells were resuspended in 1L YNB-CAA with 2% galactose. Some of this 
culture was retained as an uninduced control. The 1L flask was incubated for 22 hours 
shaking at room temperature (23°C). 1ml aliquots were made with 20% glycerol and stored 
at -80°C. 
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2.2.6. Production of murine monoclonal antibodies from hybridoma cells 
Murine monoclonal anti-E antibodies were tested on the DENV E yeast expression 
system: 4G2, 1D10, 2B7, and 1D3-2. These antibodies originated from hybridoma cell lines 
grown at Siriraj Hospital Mahidol University, Bangkok. They were known to be specific for 
DENV1, 2, 3 and 4 E proteins (appendix A.5). Hybridoma cells were thawed from liquid 
nitrogen and grown in RPMI with 15% FCS 50units/ml penicillin and 50µg/ml streptomycin 
at 37°C with 5% CO2. When cell numbers reached approximately 100 million cells they were 
added to 150ml Ultradoma protein-free media (PAA) with 50units/ml penicillin and 5ml 
Glutamax (Gibco). Flasks were incubated for 6 days and the supernatant was harvested and 
then filtered before freezing at -20°C. For purification of the antibody, a column containing 
1ml protein A sepharose beads (Roche) was equilibrated with PBS. The supernatant was 
thawed and run through the column overnight at 4°C. The eluate was run back over the 
column and PBS was used to wash. The antibody was then eluted by running 10ml 0.1M 
glycine pH2.5 and eluted fractions were buffered by adding 100µl 2M Tris-HCl pH8. The 
protein was added to Amicon Ultra centrifugal filters to concentrate the antibody to a 
volume of 1ml in PBS. A spectrophotometer was used to determine the concentration by 
measuring absorbance at 280nm.  
 
 
2.2.7. Antibody staining of expressed DENV2 on yeast 
Aliquots of yeast for the mutant library, the wild type expression and the negative 
control frameshift vector were thawed and aliquotted into a 96 well plate. For FACS analysis 
with the mouse antibodies, 50µl purified antibody at 1-20µg/ml in FACS wash buffer was 
used. For human pooled convalescent serum (PCS) the concentration was 20ug/ml in 50μl 
and goat serum was included in the buffer to block background binding. These were 
incubated at 4°C shaking for 1-2 hours. Cells were washed 3 times with 200µl FACS wash 
buffer. The secondary antibody for mouse antibodies was 50µl goat anti-mouse-IgG-PE 
(Dako) diluted 1/500 in 50μl FACS buffer. For human antibody, the secondary antibody was 
goat anti-human IgG-FITC (Sigma-Aldrich) diluted 1/100 in 50μl. The plate was incubated 
shaking in the dark for 30mins at 4°C. Cells were then washed 3 times with PBS and 
resuspended in FACS fix buffer before analysis. 
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2.2.8. Epitope mapping using DENV2 EDI-II mutant library 
Cells from the yeast library were thawed and pelleted before resuspending in 1ml 
blocking buffer (FACS wash with 1% goat serum) for 5 minutes at room temperature. They 
were then incubated with 1µg 4G2 in 50μl FACS blocking buffer for 45 minutes, shaking at 
4°C. Then they were washed 3 times with FACS wash before incubation with 1µg PCS in 50µl 
FACS wash buffer. The cells were incubated for an hour at 4°C and washed 3 times. 
Secondary antibodies were added at 1/100 for anti-human IgG-FITC (Sigma-Aldrich) and 
1/500 for anti-mouse IgG-PE (Dako) for 30minutes and washed off. The cells were 
resuspended in PBS before sorting by flow cytometry. The cells were sorted on different 
models of FACS sorter by MRC cell sorting facility, Hammersmith Hospital. The FITC positive, 
PE negative population was sorted into YNB-CAA media with glucose for 26 hours growth at 
30°C. The culture was induced with galactose media for 24 hours at room temperature. 3ml 
of culture was removed for 4G2 and PCS antibody staining and then these cells were 
subjected to further sorting. This enrichment and staining protocol was repeated until the 
population was distinct. After the final enrichment the cells were grown on YNB agar for 3 
days at 30°C. 
Single colonies of the enriched cells were inoculated into YNB-glucose broth and 
induced for protein expression. The resulting cultures were then single-stained with 4G2, 
PCS or pooled mouse monoclonal antibodies (1D10, 2B7 and 1D3-2 at 1-2µg each). Results 
were analysed on FACS Calibur. The cells that bound the pooled mouse antibodies and the 
PCS, but not the 4G2 were chosen for DNA extraction. Zymoprep II spin column kit 
(Zymoresearch) was used as per the manufacturer’s instruction and the eluted DNA was 
introduced into TOP10 cells (Invitrogen). Plasmid DNA was purified from colonies using 
QIAPrep spin minikit and sequenced with pYD1 primers. The sequence was aligned with the 
wild-type template sequence to identify the amino acid mutation. 
 
 
2.2.9. PCR of prM and prME for expression on yeast 
 Template for the PCR was DENV2 prME sequence within pBluescript vector. Primers 
were designed manually and sequences can be found in appendix A.1. The reaction mix for 
amplification of prM contained 0.2µM primers with restriction sites, 1x taq PCR buffer 
(Bioline), 0.1mM dNTPs, 2.5units of taq polymerase (Bioline) and 20ng template DNA. 
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Cycling conditions were 30 cycles of 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 
minute.  Expression of prM and prME plasmids was carried out as in sections 2.2.3 and 
2.2.4. When testing staining at low pH, FACS wash buffer was replaced by MES buffer pH5.5 
or 6.5. 
 Overlap extension PCR to mutate the cleavage site between prM and E was carried 
out in 2 stages. PCR amplified 285bp sequence at 5’ end with a prM forward primer and a 
site-directed mutagenesis (SDM) reverse primer with 3 mutations (sequences in appendix 
A.1). Sequence of the remaining 116bp at the 3’ end of prM was amplified using prM 
reverse primer and a forward primer complementary to the SDM reverse primer. These 
products provided templates for PCR using only the prM forward and prM reverse primers. 
Quantities of reagents were the same as prM PCR but cycling conditions were altered with 
an increase of annealing time to 1 minute. 
 
 
2.2.10. Dot blot of lysed yeast cells 
 Cells were lysed using CelLytic Y (Sigma-Aldrich). Induced and uninduced cells were 
pelleted, weighed and resuspended in the lysis reagent as recommended by manufacturer. 
Protease inhibitor PMSF (phenylmethanesulfonylfluoride) was added at 10μM. After 
centrifugation at 10,000 x g, supernatant was dotted onto nitrocellulose membrane 
(Hybond C, Amersham) and allowed to dry. As a positive control for antibody binding, 1µl 
UV inactivated DENV2 infected Vero cell lysate was also added to the membrane. This was 
known to bind 4G2. The membranes were blocked overnight in PBS with 5% skimmed milk 
protein (ASDA). 4G2 mouse antibody (20µg in 100μl milk) was used to detect E, 1H10 mouse 
antibody (neat hybridoma supernatant) and 3-147 human antibody (1µg) were used to 
detect prM and anti-V5 antibody (1/1000) was used to detect expression of the V5 tag. 
Antibodies were incubated for 2 hours at room temperature and washed 3 times with 0.05% 
Tween in PBS. Secondary antibodies were anti-mouse-HRP (Sigma-Aldrich) 1/1000 or anti-
human-HRP (Dako) 1/500 in milk and incubated for 1 hour before washing. 
Chemiluminescent reagent (Amersham) was added to the membranes and photographic 
film (Sigma-Aldrich) used to visualise the signal. 
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2.2.11. Western blot of lysed yeast cells 
 Supernatants from the lysis reactions in section 2.2.10 were added to reducing 
loading dye, boiled for 5 minutes and loaded onto a 12% SDS-PAGE gel (reagents section 
2.1). The gel was run at 80V for 20 minutes and once protein reached the resolving gel, 
voltage was increased to 120V for 1 hour. The gel was transferred onto a nitrocellulose 
membrane in a semi-dry blotting unit with transfer buffer. After transfer at 0.15A for 45 
minutes, the membrane was rinsed and blocked in PBS with 5% milk overnight. Anti-V5 was 
used to probe the membrane, as described in section 2.2.10. 
 
2.3. Production of human recombinant monoclonal antibodies 
 
2.3.1. Production of memory B cells from convalescent DENV patients 
Immortalised B cell clones were produced by others in the laboratory (Dejnirattisai 
et al., 2010). Briefly, PBMCs of the convalescent patients from Thailand were used and a 
healthy donor as a control. The IgG+ memory B cells were isolated using magnetic beads 
coated with anti-CD22 followed by flow cytometric cell sorting and were transformed with 
Epstein Barr virus (EBV). The resulting immortalised cell lines were screened for anti-DENV 
antibodies by ELISA and then cloned by limiting dilution. Additionally, DENV-specific sorting 
was carried out on cells of patient 112 by Amonrat Jumnainsong and Wiyada Wongwiwat. 
EBV transformed B cells were stained with UV inactivated DENV2 and anti-DENV antibody. 
These DENV specific B cells were sorted as single cells into RNase inhibitor buffer. 
 
Clone 
name 
Patient origin 
DENV 
serotype 
Antigen 
specificity 
3-147 147 1,2,3,4 prM 
5F9 277 1,2,3,4 prM 
2F5 277 1,2,3,4 prM 
2G4 277 1,2,3,4 prM 
135.3 277 1,2,3,4 prM 
58/5 147 1,2,3,4 prM 
0112 B9 112 1,2,3,4 prM 
X10F healthy donor neg neg 
 
Table 2.1. EBV transformed B cell clones 
This table provide information on the immortalised B cell clones produced by others in the 
laboratory. These clones were all used in recombinant antibody work. 
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2.3.2. RNA extraction and reverse transcription from EBV transformed B cells 
Between 1x106 and 1x107 cells were harvested from growing cell clone cultures 58/5 
and 3-147. RNA was extracted by following the protocol of RNeasy Mini kit (Qiagen). RNA 
was reverse transcribed using First Strand cDNA synthesis reagents according to the 
manufacturer’s instructions (Invitrogen). Briefly, RNA and random primers were denatured 
and cDNA synthesis was carried out by incubation with Superscript III reverse transcriptase 
at 50°C for 30 minutes. 
 
 
2.3.3. Preparation of PBMCs from acute DENV-infected patients 
8ml of blood was added to 16µl heparin and mixed. The blood was centrifuged at 
1600 x g for 10 minutes and the plasma layer was removed for storage at -80°C. The 
remaining blood was made up to 15ml with RPMI (PAA) and then layered slowly over 15ml 
Lymphoprep (Axis-Shield). The tube was centrifuged at 800 x g for 30 minutes with no 
brake. The PBMC layer was removed and diluted in 50ml RPMI before centrifugation at 800 
x g for 10 minutes. The supernatant was discarded and the cells resuspended in 50ml RPMI 
for centrifugation at 360 x g for 10 minutes and this was repeated for a further spin at 600 x 
g for 5 minutes. The cells were then resuspended in RPMI for counting. 
 
 
2.3.4. Staining and flow cytometry of antibody-secreting cells 
1 million cells were resuspended in 1ml of 10% FCS in RPMI (R-10); these cells were 
used for flow cytometry. As controls, 0.5 106 cells were aliquotted for each fluorophore to 
be tested and one aliquot remained unstained. The following antibodies were added to the 
cells in 50µl R-10 media: CD3-PerCP (BD); anti-CD27-FITC (BD); anti-CD38-APC (BD); anti-
CD20-PerCP (BD); anti-CD19-PE (Dako). Cells were incubated for 30 minutes on ice and 
washed before resuspending in 2ml R-10 media. FACS tubes with mesh filter caps were used 
to strain the cells before flow cytometry. 
Cells stained with single antibodies were used to create compensation controls on 
the FACS Aria cell sorter with FACS DIVA software. PBMCs were gated on FSC and SSC 
including the blasting cell population. Doublets were excluded by gating with FSC-A and FSC-
W. Activated antibody-secreting cells were then gated as CD19-PE+, CD3-PerCP- CD20-PerCP-
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, CD27-FITChigh, CD38-APChigh. For single cell sorting, 96 well PCR plates containing 10µl 
RNase inhibitor buffer in half of the wells were used for collection. For bulk cell sorting, 
1000 cells were sorted into 10µl buffer in 1.5ml eppendorf tubes. Cells were sorted, 
centrifuged briefly and frozen on dry ice before storage at -80°C. Additionally, 1500 cells 
were sorted into FCS for ELISPOT testing.  
 
 
2.3.5. ELISpot determination of IgG/M secreting cells 
This assay was carried out by Amonrat Jumnainsong. ELISpot plates (Amicon) were 
coated with anti-human Ig (Sigma-Aldrich) at 10µg/ml in coating buffer or with UV 
inactivated supernatant from DENV-infected C6/36 cell culture (all 4 serotypes) diluted 
1/50. The concentration of virus used had been previously optimised from cells infected 
with MOI of 0.01. Plates were washed with RPMI and blocked with 1% BSA in RPMI for 1 
hour. Antibody-secreting cells that were isolated from FACS were added at 500 cells per well 
in 50µl R-10 media to the anti-Ig and the DENV wells. Cells from immortalised B cell clones 
(from DENV patient and healthy donor) were used as controls. Plates were incubated 
overnight at 37°C 5% C02. Cells were removed by washing with PBS-Tween 0.1% and 50µl 
anti-human IgG-biotin and anti-human IgM-biotin (Beckton-Dickinson) were added at 
1/2000 in 1% BSA in PBS. Antibody was incubated for 2 hours at room temperature and 
washed off. Then 50µl Alkaline Phosphatase-Streptavidin (Sigma-Aldrich) diluted 1/1000 in 
1% BSA in PBS was added. After 1 hour incubation at room temperature, antibody was 
washed off and the plate dried. Spots were counted using an ELISpot plate reader 
(Autoimmun Diagnostika). 
 
 
2.3.6. RT-PCR for Immunoglobulin Heavy, Lambda and Kappa chains  
Cells were thawed and RT-PCR master mix added directly to them or in the case of 
some memory B cell clones, RNA was extracted from the cells and 0.7μg RNA was used. This 
RT-PCR amplified Gamma, Mu, Lambda and Kappa chains however primer for Mu chains 
was removed when amplifying IgG only. The master mix was made from One Step RT-PCR 
kit (Qiagen) with the following final concentrations of reagents: 1x buffer, 0.4µM of each 
primer (L-VH1, L-VH3, L-VH4/6, L-VH5, L-VK1/2, L-VK 3, LVK4, L-Vλ1, L-Vλ2, L-Vλ3, L-Vλ4/5, L-
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Vλ6, L-Vλ7, L-Vλ8, CγCH1, Cκ543, Cλ, CµCH1 – appendix A.1, primers sequences originate 
from Tiller et al, 2008), 200µM dNTPs, 0.5µl enzyme. Master mix (15µl per reaction) was 
added to 4 wells at the bottom of the PCR plate as negative controls and to a well for the 
positive control. This positive control was 0.7µg RNA extracted from cells of the B cell clone 
3-147. The cycling conditions for PCR were 30 minutes at 50°C, 15 minutes at 95°C and 45 
cycles of 94°C for 30 seconds, 58°C for 30 seconds and 72°C for 1 minute.  
 
 
2.3.7. Nested PCR for immunoglobulin chains  
Master mix was made using Hot StarTaq kit (Qiagen) with the following final 
concentration of reagents: 1x buffer, 0.25µM of each primer (Heavy chain: 5’AgeI VH mix 
and 3’SalI JH mix, Lambda chain: 5’AgeI Vλ mix and CλXhoI, Kappa chain: PanVκ and Cκ494), 
125µM dNTPs and 0.25µl enzyme. To 37µl master mix, 3µl RT-PCR product was added. The 
PCR cycling parameters were: 15 minutes at 95°C and 45 cycles of 94°C for 30 seconds, 58°C 
for 30 seconds and 72°C for 45 seconds. For PCR of IgM heavy chain, 5’Age VH primer mix 
and 3’IgMint primers were used using the same conditions. 
Gel loading dye was added to the PCR products and they were loaded onto a 1.5% 
agarose gel in TBE buffer for electrophoresis. Products were analysed under UV light. Heavy 
chain products were approximately 380bp, Lambda: 400bp and Kappa: 540bp. DNA was 
excised from the gel and purified using QIAquick Gel extraction kit (Qiagen). Kappa chain 
PCR product was sequenced using the reverse primer Cκ494 by in-house single primer 
extension sequencing service. The sequence was entered into an alignment search of the 
international ImMunoGeneTics database (IMGT). The Vκ and Jκ gene designations were 
used to select gene specific primers to amplify the VJ of the kappa chain from the RT-PCR 
product. These cloning primers are listed in appendix A.1. Cloning PCR conditions were the 
same as the nested PCR conditions and the product size was 350bp. 
 
 
2.3.8. Expression vector cloning of immunoglobulin chains 
Purified PCR products for heavy and light chains were digested with the appropriate 
restriction endonuclease enzymes with buffers recommended by the enzyme supplier 
instructions (NEB). In a 50µl reaction, heavy chain product was sequentially digested with 
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2.5 units of AgeI and 10 units of SalI. Lambda chain product was double digested with 2.5 
units AgeI and 10 units of XhoI and kappa chain was digested with 2.5 units of AgeI and 5 
units of BsiWI. Reactions were purified using QIAquick kit (Qiagen). 
 Vectors were provided by Hedda Wardemann and maps are shown in appendix A.4. 
They contained a multiple cloning site, HCMV promoter, amp resistance gene, leader 
sequence and constant region sequence for either IgG1 Cγ, Cκ or Cλ. Vector DNA (20µg) 
were digested using restriction enzymes as above and dephosphorylated with 1 unit of 
shrimp alkaline phosphatase (Roche) before purifying with QIAquick gel extraction kit 
(Qiagen). 
Digested PCR products were inserted into the expression vector through a T4 DNA 
ligase mediated ligation. Vector and insert were added at a 1:3 molar ratio with 200 units of 
ligase (NEB) in a reaction volume of 20µl. Ligation took place at 16°C for 16 hours and 4µl 
was used to transform competent DH5α E.coli cells. Cells were plated onto LB agar with 
50µg/ml ampicillin and grown overnight at 37°C. Three colonies were picked for each chain 
and inoculated into LB broth for overnight growth. DNA was extracted from the cultures 
using QIAprep spin kit (Qiagen). DNA was sequenced using single primer extension 
sequencing with IgGint primer (sequence information in appendix A.1). This primer anneals 
within the vector and allows sequence read of vector and insert. Therefore sequences that 
were in-frame and represented the consensus could be selected. 
 
 
2.3.9. Antibody expression 
Calcium phosphate transfection: 293T cells were seeded at 2x105 cells per well of a 6 
well plate and grown to 50-80% confluency in D-10 at 37°C 5% CO2. In a sterile eppendorf, 
5µg heavy chain DNA and 5µg light chain DNA were added to 100µl 2.5M CaCl2. To this, 
120µl HEBS buffer was added whilst vortexing. Cells were incubated for 8-16 hours and 
media substituted with 2ml UltraCHO protein-free media (Biowhittaker) with 50units/ml 
penicillin and 50g/ml streptomycin. Cells were incubated for 5 days at 37°C 5% CO2 and 
supernatant containing antibody was harvested by pelleting cells at 800 x g for 15 minutes. 
Polyethlyenimine transfection: Cells were seeded as above. To 240µl DMEM, 1µg 
heavy chain, 1µg light chain DNA and 10µl PEI solution were added. After 15 minutes 
incubation at room temperature the transfection mix was added to the cells. Media was 
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changed to protein-free media 24 hours later and supernatant was harvested as in the 
calcium phosphate method. 
 
 
2.3.10. Anti-human IgG ELISA 
96 well ELISA plates were coated with mouse anti-human IgG (γ specific), anti-human 
Kappa chain or anti-human lambda chain (all Sigma-Aldrich) diluted 1/1000, 1/100 and 
1/100 respectively in carbonate buffer. Plates were chilled at 4°C for 16 hours. Antibody was 
washed off with 3x 200µl PBST (0.05% tween in PBS). To block the plates, 200µl PBS with 3% 
BSA was added to wells for 1 hour at room temperature. Plates were washed twice with 
PBST. Supernatant from transfection of 293T cells with antibody DNA plasmids was added to 
the wells. For light chain detection, 50µl neat supernatant was used. For heavy chain wells, 
antibody was diluted 1/50 in blocking buffer. As a standard, a 2-fold dilution series of IgG 
from human serum was used, starting concentration 2µg. Negative controls were blocking 
buffer only or media from transfection without DNA. After an hour-long incubation at 37°C, 
plates were washed 3 times and secondary antibody added. For all wells, this was composed 
of goat anti-human IgG: alkaline phosphatase Fc specific (Sigma-Aldrich) diluted 1/10,000 in 
blocking buffer. Plates were incubated for 1 hour at 37°C and washed 3 times. The substrate 
used was alkaline phosphatase developing solution (BioRad) and plates were incubated until 
colour developed. Absorbance was read at 405nm on a BioRad ELISA plate reader. A 
standard curve was produced using the known concentrations of IgG from serum and the 
concentrations of antibodies were calculated from the trendline equation. 
 
 
2.3.11. DENV dot blot 
 UV-inactivated supernatant from virus-infected C6/36 cells was dotted onto 
nitrocellulose membranes. DENV1, 2, 3, 4, JEV and non-infected mock supernatants were 
used (virus stocks prepared by Wanwisa Dejnirattisai). The titre of virus on the membrane 
was 1 x 104 ffu. For domain III testing, recombinant domain III from DENV1 or DENV2 were 
used at 1ug. This purified protein was produced by Claire Midgley using a bacterial 
expression system. Membranes were allowed to dry and then added to PBS with 5% milk to 
block overnight at 4°C. Primary antibody was cell supernatant from transfection of antibody 
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DNA plasmids diluted 1/4 in milk. Control antibody was supernatant from transfection with 
heavy and light chain plasmids for 0112B9 (anti-prM) and from X10F (DENV negative clone). 
The domain III positive control was mouse monoclonal antibody 2H12. Antibody information 
is within appendix A.5. Antibody was incubated overnight at 4°C and washed 3 times with 
PBST. Secondary antibody anti-human/mouse IgG-HRP (Dako) was diluted 1/1000 in milk 
and incubated for 1 hour at room temperature. Following washing, membranes were 
developed using ECL chemiluminescent substrate (Amersham) and exposed on 
photographic film (Kodak). 
 
 
2.3.12. DENV Western blot 
 Lysate from DENV-infected C6/36 cells (MOI 0.01) was treated with 1% TritonX-100 
in PBS and UV inactivated by Wanwisa Dejnirattisai. Lysate was then centrifuged at 8000 x g 
for 10 minutes to pellet any cell debris and the supernatant was added to non-reducing 
loading dye. This was loaded onto a 12% SDS polyacrylamide gel within a large well. Protein 
was run at 80V for 20 minutes and for an hour at 120V when it reached the 12% resolving 
gel. The gel was blotted onto nitrocellulose membrane in transfer buffer on a semi-dry 
electroblotting system. This was carried out at 0.15A for 45 minutes. The membrane was 
rinsed in PBS and allowed to dry. Then it was cut into strips for antibody probing as per the 
method for DENV dot blot. Control antibodies used were mouse monoclonal antibodies 4G2 
and IF11 for E and NS1 respectively, and the human monoclonal antibody 3-147 for prM. 
 
 
2.3.13. Virus neutralisation tests- Focus Reduction Neutralisation Test (FRNT) 
These assays were performed by Wanwisa Dejnirattisai and Amonrat Jumnainsong. 
Briefly, antibody supernatant was serially diluted in a 10-fold dilution series and incubated 
with 50 ffu virus per well at 37°C for 1 hour. This was added to a monolayer of Vero cells and 
incubated for 2 hours at 37°C. Overlay media (carboxymethylcellulose and MEM media) was 
then added before incubation for 2-3 days. Virus foci were stained with anti-DENV 4G2 and 
anti-mouse-HRP secondary antibody. The foci were visualised with diaminobenzidine 
substrate (DAB) and counted. The number of foci was expressed as focus-forming units/ml 
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(ffu/ml). The reduction in ffu/ml was expressed as a percentage reduction, relative to ffu/ml 
without antibody. 
 
2.3.14. Antibody-Dependent Enhancement tests 
These assays were carried out by Wanwisa Dejnirattisai and Amonrat Jumnainsong. 
Supernatant from transfection of antibody plasmid DNA was diluted in R-10 from 1μg/ml in 
a 10-fold dilution series and incubated with virus for 1 hour at 37°C. This was then added to 
U937 cells and incubated for 4 days. Supernatant was harvested and titrated onto Vero cells 
to determine focus-forming units as above. Enhancement was expressed as fold 
enhancement relative to ffu/ml without antibody. 
 
 
2.3.15. Immunoglobulin variable region sequence analysis 
Sequences were analysed using BioEdit software. ClustalW was used to select 
consensus sequences for transfection and amino acid translation was carried out to ensure 
sequences were in-frame within the expression vector. They were entered into 
ImMunoGeneTics (IMGT) search engine V-QUEST, which aligns input data with known 
variable region germline sequences (http://imgt.cines.fr). This program also provides 
information on length and mutation rates of complementarity determining regions (CDR) 
and framework regions (FWR). In addition to this, V-BASE and IgBLAST were used to confirm 
V, D and J classifications (http://vbase.mrc-cpe.cam.ac.uk, 
http://www.ncbi.nlm.nih.gov/projects/igblast) and sequences were checked manually. 
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Chapter 3 
 
Results 
Yeast Surface Display of Dengue Virus Antigens 
 
3.1. Introduction 
 Synthesis of viral antigens is vital for characterisation of antibodies. Developments in 
monoclonal antibody technology have led to the need for antigen and epitope mapping 
systems. The proteins of particular interest for DENV are structural surface antigens and 
hence targets for antibody neutralisation. The envelope (E) protein has been shown to be 
responsible for target cell receptor binding and membrane fusion. It is composed of 3 
domains, EDI, II and III and exists as homodimers on the surface of the mature virion. EDIII is 
responsible for binding to cell receptors (Crill & Roehrig, 2001). Upon cell entry and 
exposure to the low pH of the endosome, the E proteins form trimers that expose the fusion 
loop within EDII for fusion with the host cell membrane (Modis et al., 2004).  
The critical epitopes within the flavivirus E protein have been investigated with 
several murine monoclonal antibodies (mAbs). West Nile virus epitope mapping has 
revealed EDIII to be the target for strongly neutralising antibodies (Oliphant et al., 2005). 
The fusion loop of EDII was found to bind weakly neutralising antibodies that were flavivirus 
cross-reactive (Oliphant et al., 2006). Epitope mapping of DENV with low numbers of murine 
antibodies produced similar results (Crill & Chang, 2004; Crill & Roehrig, 2001; Sukupolvi-
Petty et al., 2007). EDIII epitopes were identified in the lateral ridge and A-strand then EDII 
epitopes were identified in the fusion loop and central interface. A goal of this project was 
to map the binding sites of human mAbs to domains of the E protein and more specifically 
to map the EDI-II region more thoroughly.  
The prM protein is another target for antibodies yet the epitopes had not been 
identified. The prM protein is a precursor form of the membrane protein (M). It forms part 
of the immature virion surface. As the immature virus passes through the host cell secretory 
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pathway prior to release, the prM protein is cleaved by the host endoprotease furin. This 
conformational change at around pH5.5-6.5 triggers maturation of the virion enabling it to 
become infective on release. However it has been shown that DENV has low efficiency of 
prM cleavage resulting in the secretion of immature or partially mature viral particles 
(Junjhon et al., 2008). These non-infectious particles become the target for antibodies. The 
complex is then susceptible for uptake into cells with Fc receptors, where the virus 
undergoes structural rearrangement to enable infection. Identification of the epitopes 
responsible could lead to techniques that block this enhancing pathway. Consequently 
another goal of this work was to express conformational prM and to progress to mapping 
antibody epitopes. 
Bacterial expression of DENV structural proteins for epitope mapping is challenging. 
There are glycosylation sites and disulphide bridges within EDI and EDII. Full-length E 
requires post-translational modification and purification from inclusion bodies; although 
expression of EDIII alone is more straightforward. DENV E can be expressed in insect cells or 
mammalian cells but these require specialist facilities and do not create high yield of 
protein.  
 The expression of protein on the surface of yeast cells was developed by Boder and 
Wittrup (Boder & Wittrup, 1997). They designed a system of anchoring protein to the 
surface by creating it as a fusion protein with Aga2p, part of a surface receptor. Expressed 
antigen is fused onto Aga2p and anchored onto the yeast surface when the other part of the 
receptor, Aga1p, covalently attaches to the extracellular matrix of the cell wall (figure 3.1).  
Chapter 3 – Results: Yeast Surface Display 
 
 
71 
 
Figure 3.1. Display of protein on the surface of yeast cells (diagram from 
www.invitrogen.com)  
Based on methods of (Boder & Wittrup, 1997). Aga1p is a yeast cell surface protein that is secreted 
from the cell and covalently attaches to a component of the extracellular matrix within the cell wall. 
Aga2p is secreted but remains attached to Aga1p through disulphide bonds (S-S). The target protein 
is expressed as a fusion with Aga2p and hence becomes anchored to the yeast cell surface. Tags for 
detection of protein are Xpress epitope, V5 epitope or His tag. 
 
Expression of the Aga2p fusion is controlled by the GAL1 promoter. GAL1 
transcription is repressed by glucose so yeast cells are grown to log phase in glucose before 
switching the media to galactose to induce transcription and expression. Expression of 
protein can be determined by detection of a tag. The V5 tag is a short epitope encoded by 
the vector and sits at the C terminus of the antigen (figure 3.1). Fluorescent antibody 
specific for V5 can be used to stain the cells and then flow cytometry measures the shift in 
fluorescence of the cells compared to those that do not express protein. 
This fusion method has been exploited as a tool for expression of flavivirus E 
proteins (Oliphant et al., 2005; Sukupolvi-Petty et al., 2007). By expressing the different 
domains of the E protein, this provides antigen for determination of antibody specificity but 
also as a tool for fine epitope mapping. The critical amino acids of the antigen that an 
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antibody binds to are identified by mutating them and analysing loss of antibody binding. 
The epitope targets of several murine monoclonal antibodies specific for flaviviruses have 
been mapped in this way and the method is described in more detail below. 
Mutation of the target protein has to be optimised to create a single amino acid 
substitution per sequence at random positions. Mutation(s) that lead to a loss of antibody 
binding can then be mapped. Mutagenesis can be performed through PCR by encouraging 
error-prone synthesis. Use of a low-fidelity polymerase such as Taq with a high number of 
cycles permits error. Then high concentration of magnesium chloride stabilises non-
complementary pairing (Ling et al., 1991). Addition of manganese chloride, higher 
concentrations of dGTP and dCTP (relative to dTTP and dATP) and increased extension time 
can also make Taq more susceptible to introducing changes (Cadwell & Joyce, 1992). 
Mutated sequence is then cloned into the yeast vector at the multiple cloning site. 
This places the protein proximal to the fusion protein and the tags used for identification of 
expression. Upon translation of the mutant protein, it is exported for surface display. Each 
yeast cell displays a different mutant and this library of mutants is sorted by flow cytometry 
(figure 3.2). First the cells are incubated with the antibody that will be characterised. Then 
this is washed off before staining with a pool of antibodies that ensure that the mutation 
has not vastly disrupted the protein structure. FACS of the cells aims to enrich the mutant 
that has lost binding to the test antibody but has retained binding to the pool of antibodies 
(figure 3.2). The DNA encoding this mutant protein could then be extracted from enriched 
cells within the library and the epitope identified. 
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Figure 3.2. Mapping amino acids of DENV antigen that are responsible for monoclonal 
antibody (mAb) binding  
Yeast cells are first incubated with the test antibody and then with a pool of mAbs or polyclonal 
antibodies. Secondary antibodies are conjugated to fluorescent markers FITC (fluorescein 
isothiocyanate) or PE (phycoerythrin) that can be analysed using fluorescence-activated cell sorting 
(FACS).  
 
The aim was to produce mutant libraries of DENV antigens on yeast for 
characterisation and mapping of human monoclonal antibodies. At the time of 
development, human antibodies were being produced by EBV transformation of B cells from 
convalescent DENV patients. The patient samples originated from Thailand where DENV2 
was circulating and therefore the aim was to first produce DENV2 E protein on yeast. EDIII 
had been investigated previously using yeast surface display yet EDI-II had only been 
mapped in this way for West Nile virus. Therefore the aim of this work was to produce all 
domains of DENV E on yeast but to focus of EDI-II for epitope mapping. Several anti-prM 
antibodies were then produced from the patients. This led to the objective of production of 
prM antigen expression on yeast so that this could be used to map epitopes in the same 
way. 
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3.2. Results 
 
3.2.1. Creation of E mutants 
In order to map the epitopes of DENV E protein that particular antibodies bind, it 
was necessary to create a library of randomly mutated E proteins expressed on yeast cells. 
Yeast expression vectors containing all DENV serotypes EDI-II, EDIII and EDI-III were 
previously made and tested by Alison Cowper. These were used as templates for mutagenic 
PCR with the aim of producing genes with one amino acid substitution per sequence. 
Optimisation of the PCR first involved amplification of DENV4 EDI-II and modifying the 
following reagent concentrations: MgCl2, MnCl2, template, primers and Taq DNA 
polymerase. Altering the reagents led to smeared bands when the PCR product was run on 
agarose gel (figure 3.3B) but concentrations were optimised to give clear bands with 
appropriate mutation rate.  The reaction was optimised with DENV4 and then DENV2. For 
determination of mutation rate, PCR product was cloned into a sequencing vector. 
Approximately 10-20 clones were sequenced and aligned with wild-type sequence. Amino 
acid differences were counted. For the DENV2 EDI-II library the average amino acid 
mutation rate was 1.3 per sequence.  
DENV2 EDI-II is 294 amino acids long so the library had to be large enough to contain 
mutations at all positions and account for silent mutations and frameshift mutations. The 
restriction digest and vector ligation reactions for the mutated PCR products were optimised 
to achieve the highest number of transformants for the library, which was 7.5x104 E.coli 
colonies. The maxi-prep DNA of this library was introduced into yeast cells and these 
transformants grew on selective media. Colonies were first cultured on a small scale to test 
expression conditions. For the large scale transformation the yeast cell yield was 1x104 
colonies. Therefore the number of colonies was likely to be sufficient to represent one 
amino acid difference at all positions of the protein. 
 
 
 
 
 
 
Chapter 3 – Results: Yeast Surface Display 
 
 
75 
 
 
 
 
 
 
 
 
         
Figure 3.3: Mutagenesis of DENV4 E protein. 
1% agarose gel depicting PCR product of DENV4 sequence. (A) mutagenic PCR of E domains I-II, III 
and I-III leading to 1 amino acid substitution per sequence. (B) mutagenic PCR of EDIII with alteration 
of MnCl2 concentration to optimise reaction. 
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3.2.2. Expression of DENV2 EDI-II on yeast cell surface    
The growth conditions for the transformed yeast cells were optimised to achieve 
maximum protein expression. Induction of expression by switching cell media to galactose 
must take place during log growth phase. To calculate when log growth was taking place, 
the optical density of growing culture was tested over a 30 hour time period (figure 3.4). 
The time at which exponential growth was taking place was 22-24 hours and subsequently 
cultures were grown for 24 hours conditions before induction of protein expression. 
Induction conditions were also tested and the duration of induction impacted on expression 
levels. Protein expression was measured by flow cytometry, detecting the V5-tag at the C 
terminus of the protein. The highest expression, as determined by the greatest shift in the 
peak of fluorescence was seen at 22-24 hours of growth at 20-22°C (figure 3.5). Upon 
staining, there was commonly a positive population of cells and a negative one, shown by 
double peaks within the flow cytometry plots. The negative population may consist of cells 
that had not been induced to express protein.  
Negative controls for expression consisted of cells that were not induced in galactose 
or cells that contained vector without insert. A frameshift was engineered into the vector so 
that the tag would not be translated if no insert was present. 
 
Figure 3.4: Growth curve of yeast to determine log phase before induction of protein 
expression.  
Cells transformed with mutated DENV2 EDI-II were grown at 30°C and OD600 measured at intervals. 
This was plotted against time and the log phase was determined as the mid-point of the exponential 
growth, between 22-24hours. 
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Figure 3.5: Optimisation of protein expression induction time.  
Yeast cells transformed with vector only (A) or with mutated DENV2 EDI-II (B and C) were grown to 
log phase before induction with galactose. Cells were stained with anti-V5 antibody that binds to the 
C-terminus tag on the expressed surface protein. Fluorescence was analysed by flow cytometry using 
CellQuest and FlowJo software. Red histograms represent non-induced cells and blue histograms 
show induction for 18 hours (B) or 22 hours (A and C). 
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Once the optimal conditions were established, the library was expressed and 
characterised. Monoclonal antibodies from mouse hybridomas were used to verify correct 
conformation of the E protein. These hybridomas had been made previously so the cells 
were thawed for culture. Cell numbers were scaled up and transferred to serum-free media. 
The cell supernatant containing mAb was purified using a protein A bead column and eluted 
with low pH buffer. Four cross-reactive anti-E antibodies (4G2, 1D10, 2B7 and 1D3-2) were 
purified and added to the yeast library (figure 3.6). Of these antibodies, 3 bound strongly 
but 1D3-2 bound weakly, as determined by the level of shift in the flow cytometry histogram 
data. This could be the result of slightly incorrect conformation of the epitope, as this 
antibody binds to DENV on dot blot. However despite this, the remaining antibodies bound 
strongly and because pooled convalescent serum (PCS) from DENV patients also bound it 
was decided that the conformation of the protein was sufficient for future investigation. The 
epitopes of 3 of the murine antibodies could be mapped and 4G2 was first used to test the 
library mapping system.  
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Figure 3.6. Binding of monoclonal antibodies to DENV2 EDI-II library on yeast cells. 
Mouse monoclonal antibodies specific for DENV2 E were added to yeast cells of the mutant library. 
Anti-mouse IgG-PE was used as a secondary antibody and cells were analysed for fluorescence shift 
with flow cytometry. Red lines show secondary antibody only, green lines show monoclonal 
antibody on uninduced cells and blue lines show monoclonal antibody on induced cells. 
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3.2.3. Mapping the epitope binding site of murine monoclonal antibody 4G2 
 The epitope for 4G2 binding had been previously elucidated using mutated virus-like 
particles (Crill & Chang, 2004) and therefore this antibody was a useful control to test the 
mutant library constructed. In order to map the epitope, cells of the library had to be 
stained with 4G2 followed by a pool of antibodies that would overall bind the antigen 
regardless of mutations. Yeast cells of the DENV2 EDI-II mutant library were incubated with 
4G2, PCS or both. The flow cytometry data from this staining is shown in figure 3.7. Pre-
enrichment plots B and C show distinct populations of cells that bind 4G2 or PCS and pre-
enrichment plot D shows that these cells are double positive. Therefore nearly all cells 
expressing E (PCS positive), also bind 4G2. Less than 1% cells were single PCS positive, which 
shows that any conformationally ‘correct’ mutants that have lost binding to 4G2 are rare. 
This PCS positive, 4G2 negative population of cells were isolated through FACS and grown to 
enrich the population. After the first round of enrichment, double staining looked the same 
as for that pre-enrichment (not shown). Cells that were double positive had out-competed 
the few single PCS positive cells. Therefore this recurrent cell sorting and growing was 
repeated until a population was clearly evident. After 6 sorts, a distinct PCS positive, 4G2 
negative group of cells could be seen, figure 3.7 post-enrichment plot D. 
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Figure 3.7: FACS analysis of the DENV2 EDI-II mutant library before and after enrichment 
of a mutant population. 
Pre-enrichment: Yeast cells from the mutant library were incubated with (A) no primary antibody, 
only anti-human IgG-FITC and anti-mouse IgG-PE, (B) 4G2 and anti-mouse IgG-PE, (C) pooled 
convalescent serum (PCS) and anti-human IgG-FITC, (D) 4G2 and PCS plus secondary antibodies. The 
double stained cells were subjected to FACS to isolate the PCS-FITC postive, 4G2-PE negative 
population (circled). This population of cells was grown and induced to enrich it.  
Post- enrichment: PCS positive, 4G2 negative cells from 6 rounds of enrichment sorting were stained 
as above. The population of collected cells is circled. 
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3.2.4. Characterising a mutant for mapping the epitope of 4G2 
 The cells collected from FACS of the mutant library were predicted to be the mutants 
that had lost binding to 4G2. In order to prove this, isolated cells were collected and plated 
onto yeast agar to produce single colonies. Expression of 10 colonies was tested to confirm 
the result. After growth and induction of each colony, cells were single stained with 4G2, 
pooled mouse monoclonal anti-E (1D10, 2B7 and 1D3-2) or PCS and secondary antibodies. 
Figure 3.8 shows staining of cells from one of these colonies. There was binding of PCS and 
anti-E antibody pool therefore E was expressed but there was no binding of 4G2 therefore 
the mutation(s) within the protein had altered the epitope. DNA was extracted from 3 
colonies that had exhibited similar results in flow cytometry and sequenced to identify 
amino acids that differed from the wild-type sequence (figure 3.9). A single substitution was 
detected. This was G→E at position 106 of the E protein which is within the fusion loop of 
domain II. This confirms the result seen previously using mutant virus-like particles where a 
G→Q substitution at the same position also abolished binding of 4G2 (Crill & Chang, 2004).  
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Figure 3.8: Loss of 4G2 binding by yeast cells expressing mutant E protein. 
Cells from the DENV2 EDI-II mutant library (A and B) and cells originating from a single colony of 
enriched sorted cells (C and D) were stained with 4G2 or PCS (pooled convalescent serum from 
DENV patient). Secondary anti-mouse IgG-PE or anti-human IgG-FITC were added and cells were 
analysed by flow cytometry. After enrichment there was still PCS binding (D), which shows E was still 
expressed but a loss of 4G2 binding (C) showed the epitope to be mutated. 
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Figure 3.9: Amino acid mutation within E protein causes loss of 4G2 binding. 
DNA sequence alignment of yeast mutant sequence with wild type template to identify amino acid 
substitution that results in loss of 4G2 binding (arrow). Sequences were aligned using the ClustalW 
program within BioEdit software and shows EDI-II only. 
 
 
3.2.5. Mapping further epitopes 
 Given the success of mapping the epitope of 4G2, human antibodies were selected 
for testing. The method of producing antibodies from B cell clones by transformation with 
EBV was being performed by others in the laboratory. At this point, 3 antibodies specific for 
E had been produced as B cell supernatants. The yeast library was stained with these 
antibodies and an anti-prM antibody as a control (figure 3.10). Antibody 30 bound well, 
whereas 138 and 310 did not have sufficient shifts in their binding peaks for use in FACS. It 
cannot be ruled out that the conformation of the E was not representative of the mature 
virus and certain epitopes were disguised. Unfortunately, further testing of the antibody 30 
was not possible due to limitations of the cell sorting facility at this time.  
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Figure 3.10: Human anti-E antibody binding using the DENV2 EDI-II mutant yeast library. 
Supernatant from B cell clones was harvested and added to yeast cells of the mutant library. (A-C) 
show anti-E antibodies with anti-human IgG-FITC staining and (D) shows staining with anti-prM 
antibody. Red lines show secondary antibody only and blue lines show monoclonal antibody 
staining. 
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3.2.6. Expression of prM protein on the surface of yeast 
 A number of anti-prM antibodies had been produced by others in the laboratory 
from EBV-transformed B cells. It was therefore decided that a yeast surface display system 
for expression of prM should be established. PCR of the prM gene was set up to clone into 
the yeast vector and the vector was sequenced to confirm the correct insertion. When the 
plasmids had been introduced into yeast, the cells were grown and induced for expression. 
No protein expression was found when staining with anti-V5 tag. The length of induction 
was tested from 4-48 hours but this did not have any effect.  
It was not known if the protein was either not translated or if it was not being 
exported to the surface of the cell. Therefore the yeast cells were lysed and the supernatant 
tested by dot blot and Western blot. The results are shown in figure 3.11. The E yeast 
expression library was used as a positive control. Staining the lysed cell supernatant with 
anti-V5 in dot blot demonstrated that protein was being produced in both the E and prM 
cells. However, staining with E-specific or prM-specific antibodies was negative. It was 
known from the work described above, that the E library was expressed successfully, 
meaning that this negative result was probably due to poor sensitivity of these antibodies. 
More cells may have been necessary to show product.  
In order to ensure E and prM expression, the cell lysates were separated by SDS-
PAGE and transferred to nitrocellulose for Western blot with anti-V5 antibody (figure 
3.11B). A band was observed at approximately 50kDa in the E expression library, which likely 
corresponds to E plus V5. In the prM cell lysate, several bands were observed and the band 
between 12 and 18kDa could constitute prM. This suggested that protein was being 
translated but the presence of other bands suggested that the protein was possibly being 
cleaved and/or aggregated.  
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Figure 3.11: The search for expressed protein in yeast 
(A) Dot blots. Yeast cells were transformed with DENV2 EDI-II or prM sequence and were induced for 
protein expression. Cells were lysed by enzymatic digestion of the cell wall and the lysate was dotted 
onto nitrocellulose. Uninduced cells (U) were used as a negative control alongside the induced (I) 
cells. 
UV-inactivated supernatant from DENV-infected cells (DENV2) was used as a positive control for 
DENV-specific antibody binding. Membranes were blocked and probed with anti-V5 (tag), 4G2 (anti-
E) or 1H10 (anti-prM). Secondary antibody was HRP-conjugated and chemiluminescent reagent was 
used to visualise the result on photographic film. 
(B) Western blot (reducing conditions). Lysed yeast cells were prepared as for dot blot. Lysate was 
separated by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked 
and probed with anti-V5 antibody. 
 
 
Due to the potential aggregation and cleavage of this expressed prM, new prM 
constructs were made. PCR primers were redesigned to exclude the C terminus of the 
protein, which encoded the transmembrane domain. This was likely halting export of the 
full-length protein to the surface. It was also possible that yeast protease Kex2p, which is 
homologous to mammalian furin, was cleaving the protein as this occurs in natural infection 
of mammalian cells during virus maturation. As such, the furin cleavage site between pr and 
M was also mutated using overlap extension PCR. The recognition sequence for furin 
cleavage was R-R-E-K-R (Keelapang et al., 2004) and this was altered to R-K-E-K-K to prevent 
cleavage but not vastly disrupt the structure. 
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 New prM constructs were introduced into yeast cells for expression. The removal of 
the C terminus of the protein allowed high expression of protein (figure 3.12). The anti-V5 
staining proved high expression but staining with anti-prM antibodies was again negative. 
Monoclonal antibodies specific to prM and PCS were used but did not bind. The same was 
true for the constructs with mutated furin cleavage site; protein was expressed but was not 
bound by anti-prM antibodies. Ultimately it was not necessary to alter the cleavage site 
because tagged protein was being exported and if it was being cleaved by yeast proteases 
there would be no C-terminal tag displayed. 
The lack of DENV-specific antibody binding demonstrated that protein was not in the 
correct conformation. Staining at pH 6.5 or 5.5 was attempted in an effort to alter the 
conformation and represent the protein seen in cells as virus enters endosomes or trans-
Golgi network. This yielded negative results. Therefore the prM protein had adopted an 
incorrect conformation.  
 
 
 
Figure 3.12: Expression of prM on yeast cells. 
Flow cytometry histograms showing yeast cells transformed with prM ectodomain sequence. 
Stained with (A) anti-V5 and anti-mouse IgG-PE (blue line) or anti-mouse IgG-PE only (red line)  
(B) anti-DENV pooled convalescent serum with anti-human IgG-FITC (blue line) or anti-human IgG-
FITC alone (green line). The red line in this plot shows PCS staining of uninduced cells to show there 
is no background staining. 
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3.2.7. Expression of prM-E on the surface of yeast 
 The expression of prM protein on the surface of yeast was unsuccessful due to 
conformational problems. To overcome this, prM was expressed in tandem with E protein in 
an attempt to more closely replicate the natural arrangement of protein. PCR of the full-
length prME sequence was carried out and product cloned into the yeast expression vector. 
Additionally, PCR was designed to produce prM sequence without the transmembrane 
domain but with a TEV cleavage site (Tobacco Etch Virus protease) between prM and E. This 
site had been previously engineered into recombinant prM-E to replace the prM 
transmembrane domain and act as a linker (Li et al., 2008). This strategy was used in this 
thesis to link the prM and E but also to allow the cleavage of E from the yeast surface bound 
prM if necessary. It was achieved by using a reverse PCR primer for the prM gene that 
contained the cleavage site sequence. The product was ligated into the yeast vector that 
already contained full-length E protein to create a fusion protein, prM:TEV:E, which would 
enable the E portion to be cleaved off with the intention of leaving conformational prM 
(figure 3.13).  
 
 
 
Figure 3.13: Cloning strategies for production of prME sequences for expression on yeast. 
(A) PCR product of prME was inserted into yeast vector pYD1. (B) prM with TEV cleavage site was 
inserted into yeast vector that contained EDI-III to create prM:TEV:E fusion. 
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Yeast cell transformants for prME and prM:TEV:E were grown and induced for 
protein expression. Anti-V5 antibody was used to detect expression. Very low level 
expression was seen for the prM:TEV:E construct and no expression was seen for prME 
(figure 3.14A and B). Attempts to improve on this expression with different induction 
lengths and temperatures were not successful. Staining with anti-prM antibodies was 
negative and staining with anti-E or PCS was also negative but the lack of binding by anti-V5 
showed that there was a problem with expression. There was a chance that the V5 tag was 
preventing correct conformation of the protein. The C-terminal portion of the prM:TEV:E 
protein (E and V5) was therefore cleaved off by digesting the extracellular protein on cells 
with TEV protease. When the cells were subsequently stained with anti-prM antibodies, still 
no signal was detected (figure 3.14 C).  
In summary, prM expression on yeast was not successful due to conformational or 
expression problems and was not taken further. 
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Figure 3.14: Expression of prME on yeast. 
(A and B) Anti-V5 staining of prM-E transformed yeast cells. Red lines show secondary antibody only, 
blue lines are anti-V5 and secondary antibody.  
(C) Anti-prM staining of the cells after cleavage of E. Red line is secondary antibody only, green line is 
uninduced and uncleaved stained with anti-prM, blue line is cleaved cells stained with anti-prM. 
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3.3. Discussion 
 Constructs for expression of the domains of DENV E had been made previously in 
house though with varying levels of expression. Full-length E had lower expression levels 
than EDIII, as determined by comparison of flow cytometry results with the anti-V5 antibody 
staining. EDIII expression on yeast had been performed by Sukupolvi-Petty et al and had led 
to discovery of new epitopes for murine mAbs (Sukupolvi-Petty et al., 2007). It was 
therefore logical to map epitopes on EDI-II. 
DENV EDI-II was expressed successfully on yeast cells. Staining the cells with anti-V5 
tag, PCS and monoclonal antibodies by flow cytometry demonstrated how this was 
optimised. The length of growth period, length of induction and temperature were altered 
to give maximal protein expression. This antigen display tool has the potential to be used to 
determine which domain of E an antibody binds to. Indeed EDIII on yeast has been recently 
used to screen a number of anti-E antibodies and map their binding domain (Beltramello et 
al., 2010). The DENV2 EDI-II produced here had potential limitations if used in this way. One 
mAb that bound to the virus in dot blot did not bind well to the yeast-expressed protein. 
The epitope of this antibody may have not been in its natural conformation. It did not bind 
to full-length E on yeast either and perhaps binds to a cryptic epitope not available on these 
recombinant proteins.  
Construction of a DENV2 EDI-II mutant library was proven to be effective by mapping 
the epitope bound by 4G2. Optimising the double staining of the library was critical to lower 
the background and produce a signal high enough to create distinct populations of cells with 
FACS. Different fluorescent dyes and conjugations were evaluated and different staining 
protocols tested. This led to clear populations that allowed sorting of the rare population of 
mutants that had lost their 4G2 epitope. There were problems in enrichment of this 
population because other cells appeared to out-grow the target cells. This meant that there 
were several rounds of enrichment required to isolate the 4G2 negative cells. The 
disadvantage of multiple enrichments is that the final population will be dominated by a 
single clone rather than a selection of cells with similar mutations. If more than one 
mutation can cause loss of binding it would be harder to identify. This also highlights the 
limitation of this method in that antibody epitopes with multiple contact points on the 
antigen might prove difficult to map. Pooled convalescent serum was used for the mapping 
experiments to prove the mutated protein had not been structurally disrupted by the 
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mutation. Mutation of critical cysteine residues for example could drastically alter the 
structure by depleting disulphide bridges. However the antibodies within PCS are diverse 
and not characterised so could bind to any epitope of the protein. A well characterised pool 
of mAbs would have been preferable yet still cannot guarantee protein structure has not 
been disrupted. Any epitopes identified would need to be confirmed by another method of 
mapping. 
Despite these limitations, the EDI-II library correctly identified a critical amino acid of 
the 4G2 epitope. The tip of the fusion loop position 106 was confirmed as a critical amino 
acid for binding, as previously determined (Crill & Chang, 2004). Previously this amino acid 
has been mutated from glycine to glutamine which abolished binding of 4G2. Interestingly a 
glycine to valine mutation at this position can also abolish binding of a human cross-reactive 
WNV antibody and a chimpanzee DENV antibody (Goncalvez et al., 2004; Sultana et al., 
2009). The fusion loop is responsible for binding to host cell membrane. It is therefore an 
important site for neutralisation of infection and often the target of flavivirus cross-
neutralising antibodies. Recent publications have characterised EDII and the fusion loop 
further. Antibodies specific for this region are of interest due to their high titre in the human 
response and their ability to enhance infection (Beltramello et al., 2010; Cherrier et al., 
2009; Crill et al., 2009). There were only small numbers of human antibodies specific for 
DENV E available for this work. Two bound to the DENV2 EDI-II only weakly, suggesting their 
epitopes were not easily accessible or they had low affinity. One antibody was a candidate 
for epitope mapping as it bound well to the library. It could have been mapped using a pool 
of murine mAbs in a similar way to the 4G2 mapping. Initially the antibody was tested on 
the fusion loop 106 mutant that had lost 4G2 binding but it did bind, which proved it did not 
share this epitope. Further mapping experiments were unfortunately prevented because 
the cell sorting facility capable of sorting live yeast cells became unavailable.  
The attempts to express prM on yeast cells were unsuccessful. Initially it was 
expressed with its transmembrane domain, which prevented its export through the cell 
membrane. Yeast cells were lysed by digesting the cell wall to show that protein was being 
translated within the cell. Removal of the transmembrane sequence allowed expression of 
protein and mutation of the furin cleavage site was not necessary for export of full-length 
protein. However the protein was not bound by any anti-prM or polyclonal antibodies. The 
prM protein exists on immature or partially mature virus. It forms spikes with E on the 
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surface of the virus and the pr portion covers the fusion loop. Cleavage of pr occurs in the 
low pH environment of the TGN, where the E and prM rearrange to expose the furin 
cleavage site (Yu et al., 2009; Yu et al., 2008a). Based on the conformational differences the 
structural proteins portray at low pH, the yeast-expressed prM was tested for antibody 
binding at low pH. Again no antibody bound so the conformation of prM was not rescued.  
In an attempt to more closely replicate the natural structure of prM it was then 
produced alongside E. By expressing prM as a fusion with E, mutating the furin cleavage site 
and replacing its transmembrane domain, Li et al successfully produced recombinant prME 
in insect cells (Li et al., 2008). Therefore this method was adapted for yeast expression to 
produce a construct of prM, a TEV cleavage site and domains of E. Another construct was 
created of prM and E with the transmembrane domain removed. These did not yield surface 
protein. It is possible that the proteins were too long; full-length E did not express as 
efficiently as shorter sequences so addition of prM introduced further complexity. The 
protein may have had problems folding correctly and could not pass through the secretory 
system. 
The aim of this work was to create a domain-mapping and fine epitope mapping tool 
for screening new human antibodies. At the time of development, there had been few 
reports of epitope mapping experiments in EDI-II. Given the epitope analysis recently 
performed by others it would now be more efficient to create mutants by site-directed 
mutagenesis. Taking all known epitopes, one could specifically mutate amino acids within 
each one to create a panel of mutants for screening. If no epitope was identified then the 
mutant library could be used to analyse that antibody binding. This approach would be 
more rapid and reduce the requirement for specialised sorting of live yeast cells, an obstacle 
that prevented further mapping work in this instance. Future work would also encompass 
the high numbers of human mAbs only recently emerging from production.  
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4.1. Introduction 
 Monoclonal antibodies (mAbs) are valuable in diagnostics, therapeutics and antigen 
characterisation. Methods for producing human mAbs are rapidly evolving and make it 
possible to study the B cell response as well as create antibodies with therapeutic potential. 
This project utilises a method of producing recombinant human antibodies from DENV 
patient B cells. 
 The existing method of mAb production in our laboratory was Epstein Barr virus 
(EBV) transformation of memory B cells. Peripheral blood mononuclear cells (PBMCs) from 
convalescent DENV patients in Thailand were isolated and frozen. The CD22+ cells were 
separated by magnetic beads coated with anti-CD22 and the IgA+, IgM+ and IgD+ cells were 
depleted by FACS. The remaining IgG+ cells were infected with EBV to immortalise them. 
Culture supernatants were screened for DENV-positive antibodies using virus ELISA and NS1 
ELISA. Then the cells secreting DENV-specific antibody could be cloned by limiting dilution to 
produce antibody-secreting clones. This method led to production of 301 DENV-specific B 
cell lines.  
Despite the success of producing so many cell lines, only a small collection of cell 
lines were successfully cloned for monoclonal antibody purification and characterisation. 
The principle disadvantage of the method is the low efficiency of EBV transformation and it 
is difficult to expand cell numbers. It is also restricted to memory B cells because 
plasmablasts and plasma cells cannot be immortalised (Doria-Rose et al., 2009). 
Cells from some of these clones were used in this thesis to establish an alternative 
method for mAb production, previously developed by Wardemann et al. They amplified 
rearranged antibody variable regions from B cells and these were cloned into expression 
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vectors containing the antibody constant regions (figure 4.1) (Wardemann et al., 2003). 
Variable regions are composed of variable (V), diversity (D) and joining (J) gene segments. It 
is the variable regions of heavy and light chains that bind to antigen. Variable regions for 
heavy and light chains were inserted into vectors containing Cγ1 and either Cκ or Cλ. Thus 
full-length IgG1 could be produced upon transfection of mammalian cells when the 
translated heavy and light chain proteins associate through disulphide bonds.  
 
 
 
Figure 4.1. Production of human monoclonal antibodies 
Variable regions (composed of variable (V), diversity (D) and joining (J) regions) can be cloned into 
vectors for heavy (H) or light (L) chain expression upon transfection. Diagram based on methods 
from (Wardemann et al., 2003). 
 
 To produce mAbs through PCR, the starting material must be single B cells or a clone 
in order to obtain correctly matched heavy and light chains. Then there must be multiple 
primers capable of amplification of the diverse gene segments. The source of the B cells can 
be from any subset containing rearranged genes. Here, the antibody-secreting cells (ASCs) 
and some memory B cells were used from DENV patients. ASCs were isolated from patients 
with acute infection. Memory B cells had been immortalised and originated from 
convalescent samples taken within a month of infection.  Section 4.2.1 provides further 
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patient details. Monoclonal antibodies have been previously produced from ASCs after 
influenza vaccination (Wrammert et al., 2008). This study is the first to produce fully human 
mAbs from DENV patients undergoing acute infection and within a week of onset of 
symptoms. It therefore covers the early period of B cell activity following infection. 
 Characterisation of mAbs commonly includes antigen specificity, epitope mapping, 
neutralisation titre and function in vivo. Of specific relevance to DENV, the ability of the 
mAb to enhance infection of virus is also an important characteristic to determine. The aim 
of this work was to produce human mAbs from DENV patients at different timepoints of 
infection. The extent of B cell activation and the percentage of cells producing virus-specific 
antibodies could be evaluated. Then the function of the antibodies could be analysed with 
respect to cross-reactivity among serotypes, antigen specificity, neutralisation titre and 
enhancing activity. The goal was to dissect the immune response of DENV patients amongst 
primary and secondary infections and across the spectrum of disease severity.  
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4.2. Results 
 
4.2.1. Convalescent patients 
 
For antibody production from memory B cells, convalescent samples from DENV 
patients in Thailand were used (table 4.1). Peripheral blood mononuclear cells (PBMCs) from 
Thai patients were taken approximately 2 weeks after defervescence. These cells were 
prepared by staff at Siriraj, Khon Kaen and Songkhla hospitals, Thailand. The memory B cells 
were isolated and immortalised with EBV by members of our laboratory. Many clones were 
produced and some of these were used in this thesis (table 4.1). 
 
 
 
Patient 
ID 
Primary/ 
Secondary 
Classification 
of  
symptoms 
DENV 
PCR 
serotype  
Timepoint of sample  
(post defervescence) 
Name of B 
cell clones 
produced 
147 Secondary DHFI PCR neg day 15 3-147, 58/5 
112 Secondary DHFI 2 day 17  
277 Secondary DHFI 1 day 17 5F9, 2F5 
 
Table 4.1. Information on convalescent patients in Thailand 
 
  
 
4.2.2. Optimisation of immunoglobulin PCR using memory B cell clones 
 Production of monoclonal antibodies from EBV-transformed memory B cells by 
others in the laboratory was challenging. Many clones would not expand in numbers 
sufficient to produce high yield of antibody. Therefore the method of producing the 
antibodies by PCR was introduced. Cells were harvested from one of the EBV clones 3-147 
and total RNA was extracted and reverse-transcribed using random primers. Heavy chain 
PCR amplification of leader, variable, diversity and joining regions and part of the constant 
region was carried out using previously designed primers (Tiller et al., 2008). These were a 
mix of primers specific for each of the different heavy chain leader regions and a primer 
specific for the gamma constant region (figure 4.2 first round PCR). 
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Figure 4.2. PCR amplification of heavy chain variable regions 
 
When this product was run on agarose gel there was only smeared product, 
demonstrating that nested PCR was necessary. Nested PCR amplified variable, diversity and 
joining gene segments and inserted restriction sites (figure 4.2 2nd round PCR). This PCR 
utilised pools of primers that could anneal to all varieties of VH and JH gene segments.  
 Light chain PCR reactions were carried out in a similar way to the heavy chain PCR. 
Kappa chain and lambda chain reactions were carried out independently. First round PCR 
incorporated a pool of primers specific for all leader regions and a primer for the kappa or 
lambda constant region. Second round PCRs utilised a pool of primers specific for the array 
of variable region gene segments and an inner primer for the constant region (figure 4.3). 
Nested PCR products were sequenced and aligned with germline sequences using 
the IMGT alignment tools (Ruiz et al., 2000). This allowed identification of any primer-
encoded mutations introduced by using a pool of similar primer sequences (i.e. non-specific 
primer annealing). Then nested PCR could be repeated using only gene-specific primers (i.e. 
one set of primers from the pool). In order to improve efficiency of the protocol, nested PCR 
products were directly cloned without sequencing (figure 4.3). This was carried out on the 
heavy and lambda chains only, as performed within the original methods (Tiller et al., 2008). 
The nested kappa chain PCR did not incorporate restriction sites and therefore the 
sequencing step and additional cloning PCR were required. 
Justification for direct cloning was made after comparing sequences from PCR using 
pooled primers and those from gene-specific primers. It was noted that there were rarely 
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amino acid differences and any differences that did occur were only one amino acid 
difference in the VH forward primer region. Due to the position of this difference in relation 
to antibody structure (in the framework and not in the CDR) it was presumed to make little 
impact on the function of the produced antibody.  
 
 
 
Figure 4.3. Strategy for amplification and cloning of immunoglobulin variable regions 
Leader (L), Variable (V), Diversity (D), Junction (J) and partial Constant (C) region genes were 
amplified by RT-PCR with pooled primers specific for all families of genes. Product from this was 
used in nested PCR, again using pools of primers specific for all families. Heavy chain and Lambda 
chain primers contained restriction sites which allowed direct cloning into expression vectors. Kappa 
chain PCR product first had to be sequenced to identify the genes and then PCR using gene-specific 
primers was performed using the RT-PCR product. 
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The heavy chain nested PCR product was visible as a band of approximately 380bp 
on agarose gel (figure 4.4). Lambda chain product was approximately 400bp and kappa 
chain was 540bp (figure 4.4). To remove the requirement for a separate reverse 
transcription step, one-step RT-PCR was carried out on RNA from B cell clone 58/5. RT-PCR 
and nested PCR for heavy and light chains were optimised (figure 4.4). The success of one-
step RT-PCR followed by nested PCR meant the separate reverse transcription was 
unnecessary in future amplifications. 
 
 
 
 
 
 
Figure 4.4. Agarose gel with nested PCR product for heavy and light chain immunoglobulin 
variable region genes. 
RNA from memory B cell clone 3-147 was extracted and reverse transcribed. PCR containing primers 
for heavy, lambda and kappa chain genes was performed and 3 separate nested PCR were carried 
out for the 3 chains. This clone had a heavy and a kappa chain. RNA from 58/5 clone was not reverse 
transcribed separately but amplified in the gene-specific one-step RT-PCR. The product was used in 
nested PCR for the 3 Ig chains and was positive for heavy and lambda chains. Nested PCR products 
were run on agarose gel. Heavy chain products were expected to be approximately 380bp, lambda 
400bp and kappa 540bp.  
 
 
Chapter 4 – Results: Human Monoclonal Antibodies 
 
 
103 
Nested PCR product (or cloning PCR product for kappa) was purified from agarose 
gel. Heavy and light chain PCR products were then cloned into expression vectors and 
transformed into E.coli to increase copy number. Ligation of PCR product was >95% 
successful, with kappa and lambda chains showing a higher rate of insertion than heavy 
chain.  
 
 
4.2.3. Single cell PCR optimisation 
 To test PCR amplification of immunoglobulin genes from single cells, B cell clone 3-
147 cells were diluted with RNase inhibitor to yield 1 cell per well in a 96 well plate. Cells 
were then frozen at -80°C and thawed, which lysed the cells. RT-PCR master mix could be 
added directly to the cells for thermocycling. Product was then used for nested PCR specific 
for heavy chain. Concentrations of reagents within both PCR master mixes were modified to 
obtain the highest number of positive wells. This optimisation showed that halving the 
reaction volume of the nested PCR yielded more product. 
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4.2.4. Production of antibody from memory B cell clones 
 Three antibodies were produced from memory B cells of convalescent patients that 
were not expanding well, 58/5, 2F5 and 5F9. Heavy and light chain PCR products within 
expression plasmids were co-transfected into 293T cells for expression. Supernatants from 
the cultures were tested on DENV dot blot to determine binding specificity to the 4 
serotypes (figure 4.5). All 3 were cross-reactive amongst the 4 DENV serotypes and this 
correlated with the testing performed on the original B cell clone supernatants. 
 
 
 
 
   
 
 
Figure 4.5. DENV dot blot of recombinant antibodies made from memory B cell clones of 
Thai DENV patients. 
Supernatant from DENV-infected (or mock-infected) mosquito cells was dotted onto nitrocellulose 
membranes and blocked. Recombinant supernatant from mammalian cells transfected with heavy 
and light chain DNA was added. The negative blot shows media from mammalian cells transfected 
with no DNA. Secondary antibodies conjugated to HRP were used and signal developed using 
chemiluminescent substrate and photographic film. 
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Next, a method was tested that would negate the need for cells to be EBV-
transformed and grown as clones. The goal was to isolate memory B cells from the 
convalescent PBMCs of patient 112 and select those that expressed surface anti-DENV. UV 
inactivated DENV2 was incubated with the CD19+ B cells and 4G2 antibody used to sort the 
positives as single cells (performed by Wiyada Wongwiwat and Amonrat Jumnainsong). 
When performing the flow cytometry, the cell sorter was calibrated to drop cells precisely 
into the well containing RNase inhibitor and the plates were frozen as quickly as possible. 
Then RT-PCR and nested PCR for heavy chain genes were performed on 24 single cells in a 
96 well plate. Only one well was positive, B9. This low rate of success may have been due to 
inefficient staining and sorting protocols. However, for this same cell, a light chain was also 
successfully produced, enabling both chains to be cloned for expression. After transfection, 
supernatant was tested on DENV dot blot and was shown to bind all 4 serotypes.  Western 
blots of DENV2 cell lysate were carried out with antibody supernatants and all bound to 
protein of the same size as prM (figure 4.6).  
 These experiments not only allowed production of antibodies from memory B cells 
but also served as optimisation for transfer of the techniques to activated B cells in acute 
patients in Vietnam 
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Figure 4.6. Western blot of DENV proteins 
Western blot was made from DENV2-infected cell lysate on SDS PAGE and transferred to 
nitrocellulose. Membrane strips were probed with 0112 B9 recombinant antibody or control mouse 
monoclonal antibodies specific for NS1, E and prM proteins, 1F11, 4G2 and 5.1 respectively. 
Secondary antibodies conjugated to HRP were used and signal developed using chemiluminescent 
substrate and photographic film. The marker shows the size of the proteins in kDa. 
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4.2.5. Acute DENV patients 
Once techniques for antibody production had been optimised with memory B cells, 
sections 4.2.2 – 4.2.4, acute patients were recruited so the early B cell response could be 
investigated. For antibody production from acute DENV-infected individuals, 10 patients 
were recruited at the Hospital for Tropical Disease, Ho Chi Minh City, Vietnam. 5 patients 
were admitted to the general ward and the other 5 were admitted to intensive care. All 
were male between the ages of 18 and 46. Patients were recruited by Dr The Trung Dinh 
and classification of disease severity was based on World Health Organisation guidelines 
(WHO, 1999). Blood samples were taken from the patients on admission and then 2-4 days 
later. Timepoint refers to the number of days after the patient presented symptoms. 
Samples were named according to their patient ID (e.g. 750) and second timepoint samples 
were followed by 2 (e.g. 750-2). Further samples were taken during convalescence 
approximately 4 weeks after hospital discharge. 
Laboratory diagnostic tests were carried out by hospital staff. These included DENV 
serotype PCR, NS1 antigen lateral flow test and anti-DENV IgM/IgG ELISA. The results of 
these tests are shown in table 4.2. Positive PCR result, NS1 antigen test or DENV IgM titre 
indicated a current infection. If these tests were negative then a four-fold increase in IgG 
titre in paired sera indicated seroconversion and acute infection. Determination of 
primary/secondary infection status was based on DENV IgM/IgG ELISA result. An IgM to IgG 
ratio of less than 1.4 indicated secondary infection. In this study, one patient was diagnosed 
with primary infection and the remaining patients had secondary infections. It was not 
possible to recruit equal numbers of primary and secondary patients. This was because, 
firstly, diagnostic ELISA was only carried out 6 weeks after samples were taken, meaning 
that we were not aware of the outcome upon selection. Secondly the numbers of primary 
patients in this DENV endemic country were low. Therefore, 1 primary patient and 9 
secondary patients were initially included in the study. 
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Patient 
ID 
Primary/ 
Secondary 
Classification 
of  
symptoms 
DENV PCR 
serotype 
Timepoint of sample 
 (post onset of 
symptoms) 
NS1 
Ag 
IgM 
744 Secondary DHFII PCR neg day 4 and 7 Neg Pos 
745 Secondary DF 4 day 4 and 6 Pos Pos 
746 Secondary DHFII PCR neg day 5 and 7 Neg Pos 
747 Secondary DHFII 2 day 6 and 10 NT* Pos 
748 Secondary DF PCR neg day 4 and 7 Neg Pos 
749 Secondary DF 1 day 4 and 7 Pos Pos 
750 Secondary DHFIII 1 day 5 and 7 Pos Pos 
751 Secondary DF 1 day 4 and 6 Pos Pos 
752 Primary DHFII PCR neg day 4 and 6 Neg Pos 
753 Secondary DHFIII 1 day 5 and 7 Neg Pos 
 
Table 4.2. Information from acute DENV patients in Vietnam 
Results of diagnostic tests performed by clinical laboratory are shown. Primary or secondary disease 
status was based on ELISA IgM/IgG results. Severity of disease was assigned using WHO guidelines, 
DF (dengue fever), DHF (dengue haemorrhagic fever), DSS (dengue septic shock). Serotype of 
infection was determined by PCR and presence of NS1 antigen was determined using an NS1 lateral 
flow device. IgM result refers to ELISA titre and is based on both timepoint samples. *NT - not 
tested. Patient data in bold means these samples were used for antibody production.  
 
 
4.2.6. Isolation of antibody-secreting cells from acute DENV patients in Vietnam 
 The aim of this work was to recruit several DENV patients and sort their ASCs for 
recombinant antibody production. The ASC population is a subset of CD19+ B cells that has 
high CD27 and CD38 marker expression.  In healthy uninfected individuals, the population is 
very small but upon infection or vaccination there is a burst of cells (Doria-Rose et al., 2009; 
Wrammert et al., 2008). 
PBMCs were sorted by flow cytometry. Cells were first gated on forward scatter 
(FSC) and side scatter (SSC) to select lymphocytes and the blasting cell population where the 
ASCs could be seen (figure 4.7 A and C). In most patients this blasting cell population was 
large at the first timepoint with smaller populations at their second timepoint.  This was 
perhaps to be expected as the burst of cells would naturally wane over time (Wrammert et 
al., 2008). The particularly small population for patient 747 supports this as their second 
sample was taken at day 10 and is therefore approximately 2 weeks post-onset of infection.  
Lymphocyte gates were set to select the CD3-/CD20- and CD19+ cells (figure 4.7 B) 
and the ASC gate was then branched from this to select the CD38high CD27high cells (figure 4.7 
C). This population was collected. Figure 4.8 compares the FACS analysis data from the six 
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patients chosen for variable region PCR. Cells from patients 744, 745, 746 and 748 were not 
used for PCR for several reasons. Patient 745 had low sorted cell numbers and low numbers 
of cells in the desired population led to slower sorting and therefore more risk of cell lysis 
and RNA degradation. Patients 744, 746 and 748 had lower percentages of DENV-specific 
IgG/M secreting cells (as determined by ELISpot: section 4.2.7).  
 
 
 
 
Figure 4.7. Raw FACS data from the PBMCs of patient 753. 
PBMCs were separated from blood and stained for sorting. These FACS DIVA plots show forward 
scatter (FSC) versus side scatter (SSC) to highlight the size of the lymphocyte and ASC population (A, 
gates circled). On day 5 there is a larger population of blasting cells that reduces by day 7. These cells 
were then gated for CD19+ CD3/CD20- cells (B). This population was then plotted with CD27 and 
CD38 to obtain only those cells that express these markers at high levels (C). It can be clearly seen 
that these target cells in purple originate from the blasting cell population in the FSC SSC plots. 
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Figure 4.8. FACS data showing B cell populations and antibody-secreting cells from 6 
patients across 2 timepoints. See also figure 4.7. 
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4.2.7. ELISpot determination of IgG/M secretion from sorted cells 
 It was important to identify that cells from patients used in the study were producing 
high percentages of DENV-specific antibodies. Therefore ELISpot was performed by Amonrat 
Jumnainsong on patient PBMCs and isolated ASCs immediately after cell sorting. Cells were 
added to anti-human capture antibody or to a mix of DENV serotypes. The IgG and IgM 
secreted from the cells was detected using secondary antibodies and alkaline phosphatase 
substrate visualisation. Spots were counted using an ELISpot reader and visual confirmation. 
Numbers of cells secreting IgG/M were counted and the number of cells secreting DENV-
specific antibody were counted. 
The percentage of cells secreting antibody in ELISpot assay can be lower than the 
actual number of ASCs because some cells may die or do not secrete antibody in the assay. 
Furthermore, detection is based on only IgM and IgG so any other class of antibody would 
not be counted. The percentage of sorted cells that were IgG/M positive in ELISpot ranged 
between 3% and 62%. The range of DENV-specific sorted cells was between 2% and 47% 
and the mean was 25%. In samples which contained low dengue-specific responses, the 
total number of IgG/M positive cells was also low, indicating low cell viability. There was 
substantial variation between patients, which could in part be explained by the differences 
in virus exposure during infections. However, by comparing numbers between patient 
samples, they could be selected based on their high anti-DENV titre relative to each other 
(figure 4.9). These patient samples were used for PCR of antibody variable regions and 
production of antibody because they would lead to a high proportion of DENV-specific 
antibody being produced. 
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Figure 4.9. ELISpot data 
Sorted CD19+ CD3/CD20- CD27high CD38high cells from patients were added to wells coated with mixed 
supernatants from C6/36 cells infected with either DENV1,2,3 or 4. After overnight incubation the 
cells were washed off and a mixture of biotinylated anti-human IgG and anti-human IgM was added. 
Streptavidin conjugated alkaline phosphatase reaction was used to visualise the number of cells that 
secreted antibodies. The chart shows the percentages of antibody-secreting cells that were IgG/M 
positive (light grey bars) and DENV-specific IgG/M positive (dark grey bars) amongst all patients 
tested. The percentages were calculated as the number of IgG/M secreting cells relative to the total 
number of cells plated. Patient 745 had only 90 cells plated due to a small cell population but others 
had between 200-500 cells. 
 
 
4.2.8. PCR for antibody production from acute DENV patients 
Methods for amplification of heavy and light chain variable regions were optimised 
using memory B cell clones as described in section 4.2.2. The methods were then applied to 
the sorted ASCs from Vietnam. Thousands of cells were sorted as single cells into 96 well 
plates and frozen. The plates were shipped back to the UK for RT-PCR to be carried out. PCR 
was performed on 10 plates of cells from 6 patients. RT-PCR mix was added to thawed 
plates. Cells would have been lysed by the freeze-thaw process so the RT-PCR mix was 
added directly to the plates and the RNA was reverse-transcribed and amplified by one-step 
RT-PCR. Product from this reaction was used first in heavy chain (gamma-specific) nested 
PCR and the product separated by agarose gel electrophoresis for visualisation. The number 
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of positive wells and the intensity of the PCR product band varied between plates (figure 
4.10). Throughout the investigation, the range of heavy chain positives was 33-92% per 
plate of cells. Low rates may have been due to the degradation of some cells and RNA, even 
though the cells were stored in RNase inhibitor. Negative wells may alternatively have 
contained other isotypes of antibody. When no band was detected in the PCR, the PCR was 
not repeated due to time constraints. If a band of low concentration was detected, a higher 
concentration of DNA was used in the following stages of cloning.  
    
 
  
Figure 4.10. Agarose gel with nested PCR product for Ig heavy chain variable region from 
single sorted cells, patient 751 
Antibody-secreting cells were sorted into a 96 well plate and frozen. RT-PCR and nested PCR 
amplified the variable, diversity and joining gene segments of the heavy chain and products were 
run on 1% agarose gel. DNA ladder shows sizes in base pairs. The PCR product was approximately 
380bp. Three negative controls were set up on the cell plate where no cells had been sorted and RT-
PCR and nested PCR were performed. A fourth negative control was a nested PCR control and the 
master mix had water instead of RT-PCR product. The positive control was nested PCR product 
originating from RNA of a memory B cell clone 3-147. 
 
 
When a well was confirmed as having heavy chain DNA, light chain nested PCRs were 
carried out. Both kappa and lambda PCR were carried out simultaneously for each cell in 
order to identify any wells that may have both. The occurrence of this or of no light chain 
being present was approximately 2% of all wells.  If two types of light chain were detected, 
it implies more than one cell may have been sorted. However this has been observed in a 
small minority of cells before, whereby PCR suggested that a cell may have two functionally 
rearranged transcripts (Tiller et al., 2008). Where this occurred, the PCR product was not 
further analysed. 
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Lambda and heavy chain PCR products were digested for vector cloning whilst the 
kappa chain PCR product was sent for sequencing. Sequence data was entered into IMGT 
alignment tool to identify which gene-specific primers to use for cloning PCR. For example 
kappa chain from well A1 would align with Vκ gene family 1-5 and Jκ gene 1 so the primers 
AgeVκ1-5 and BsiWIJκ1/2/4 would be used to amplify product for vector cloning (primer list 
appendix A.1). 
 
 
4.2.9. Expression of antibody from transfection of single cell heavy and light chain DNA 
 Heavy and light chain PCR products were cloned into the expression vectors for 293T 
transfection. Antibody yield was determined by ELISA. Cell supernatants containing antibody 
were harvested from the 293T cells and added to ELISA plates coated with anti-gamma 
chain, anti-lambda chain or anti-kappa chain capture antibodies. After secondary antibody 
and substrate addition, the OD405 could be read. In order to quantify the concentration of 
the antibody in the cell supernatant, known concentrations of IgG were added to the anti-
gamma chain wells in a dilutions series to create standard curves (figure 4.11).  
 The total number of positive supernatants was 112 from 6 patients at one or both 
timepoints. Antibody yield varied from 0.5μg/ml to over 100μg/ml. In cases where the yield 
was under 5μg/ml, transfection was repeated. The volume obtained from small wells of a 6-
well plate was 2.5ml and some antibodies were scaled up in large tissue culture plates to 
obtain higher volume. Although 3 antibodies were purified from this larger volume, it was 
deemed unnecessary to purify all antibodies because the yield was high enough in the small 
volume. 
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Figure 4.11. Standard curve plot for a dilution series of known IgG concentrations 
IgG was captured onto ELISA plates using anti-human IgG (γ chain) and incubated. Secondary 
antibody was anti-human IgG (Fc) conjugated to alkaline phosphatase and substrate was added to 
develop yellow colour. Absorbance was read at OD405. The concentration of antibody was plotted on 
the y axis and the OD on the x axis so that a trendline equation could be set. This equation was used 
to calculate the concentration of antibodies using their OD value. 
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4.2.10. DENV dot blot analysis of recombinant antibodies  
 Transfection of heavy and light chain DNA from sorted ASCs yielded 112 antibodies 
positive on ELISA.  To determine the specificity of these antibodies, they were first tested on 
dot blot. Nitrocellulose strips were dotted with supernatants from DENV/JEV infected cells 
or uninfected cells and probed with antibody. Of the 112 antibodies tested, 89 were positive 
for DENV.  No antibodies bound to the mock-infected supernatant.  
Of the 89 DENV-positive antibodies, 44 were fully cross-reactive amongst the DENV 
serotypes and JEV (figure 4.12). To break down these numbers by patient, 3 patient 
responses were dominated by fully cross-reactive antibodies and 3 were dominated by 
partially cross-reactive antibodies. It was anticipated that the primary DENV patient 752 
would have more serotype-specific or partially cross-reactive antibodies. This was true, yet 2 
of the secondary patients, 749 and 747 demonstrated this also. The full list of antibodies can 
be found in table 4.3. 
 
 
 
Figure 4.12. DENV dot blot results 
Supernatant from cells infected with DENV 1,2,3,4 or Japanese encephalitis (JEV) or no virus (mock, 
M) were dotted on nitrocellulose membranes. The approximate concentration of virus added was  
1x104 ffu. Recombinant antibody within 293T transfected cell supernatants were added to the 
membranes overnight and peroxidase conjugated antibody and substrate used to visualise the dots. 
The membranes shown represent an example of fully cross-reactive antibody 751 D6, DENV 
serotype cross-reactive antibody 750 B12, partially cross-reactive antibody 749 A4 and a serotype-
specific antibody 750-2 B7. The 89 antibodies tested were included in a pie chart to show the 
frequency of each type of cross-reactivity. 
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Many of the antibodies that did not appear to bind to DENV originated from patient 
747 and patient 750. Patient 747 had a DENV2 infection and so the negative antibodies 
were subsequently screened by dot blot against a panel of DENV2 virus isolates from 
Vietnam. This was intended to identify any antibodies that were specific only to particular 
strains of the virus and not the reference strain 16681 used initially. However the antibodies 
did not bind to any of the strains and it is likely that these antibodies were not DENV-
specific. 
  
 
4.2.11. Western blot analysis of recombinant antibodies 
 Antibodies produced from acute DENV patients were next tested on Western blot to 
identify their antigen specificity. Cell lysate from DENV-infected cells was run on non-
reducing SDS-PAGE and transferred to a nitrocellulose membrane. All DENV serotypes were 
used and the choice of serotype depended on the results from dot blot analysis. The 
membranes were cut into strips and antibody supernatants added to them.  Control 
antibodies were used to compare band sizes on the developed blots. These were murine 
mAbs specific for E, prM or NS1. Other DENV proteins are expected to be represented in this 
form of Western blot, although control antibodies were not included. Size markers would 
reveal the size of any bands that did not correlate with the control antibody bands. 
Examples of E, prM and NS1-specific antibodies are shown in figure 4.13A.  
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(A) 
 
(B) 
 
 
Figure 4.13. Western blot analysis of recombinant antibodies 
Cell lysate from DENV-infected cells was separated on non-reducing SDS PAGE and transferred to 
nitrocellulose membranes. The membranes were blocked and antibody incubated on them 
overnight. Peroxidase-conjugated antibody and substrate were used to visualise the binding of 
antibody to protein bands. (A) The serotypes of virus used in these examples were, from left to right, 
DENV2, DENV1, and DENV4. Control antibodies used were mouse monoclonal antibodies 4G2 and 
1F11 for E and NS1 and human monoclonal antibody 3-147 for prM. Bands seen for the test antibody 
were compared to control bands and to the protein marker for identification. (B) Pie chart shows the 
Western blot specificity of the 112 antibodies produced. 
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Anti-E antibodies dominated the anti-DENV response (figure 4.13B). This was not 
surprising given that E is a displayed structural antigen. To further map the E protein, 
antibodies were tested for reactivity with EDIII. All anti-E antibodies were tested on a 
recombinant EDIII dot blot, but no antibodies were positive. This indicates that the E 
antibodies are specific for EDI-II and indeed peptide epitope mapping has recently 
confirmed that this is the case. Of the total antibodies made, 37 did not bind in Western 
blot, despite testing with more than 1 serotype. Many of these were DENV-specific but 
perhaps required conformational epitopes. Although the SDS-PAGE used was non-reducing, 
the presence of SDS could still alter the conformation of antigen. All antibodies that were 
negative in DENV dot blot were also negative in Western blot, indicating they bind to either 
non-DENV proteins or to DENV strain-specific epitopes that were not tested. Anti-prM and 
anti-NS1 antibodies represented only 6.25% of the total antibodies.  
It is important to compare the specificity of antibodies between patients, to search 
for links to disease severity, serotype or sequence of infection (figure 4.14). From the few 
patients tested there was no apparent correlation between antigen specificity and 
symptoms. Interestingly the anti-prM antibodies produced originated from those with more 
severe disease, conforming to the observation that prM antibodies enhance infection 
(Dejnirattisai et al., 2010)  However the number of antibodies produced from some patients 
is too low to make these comparisons statistically significant. 
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Figure 4.14. Antigen specificity of antibodies  
Antigen specificity, as determined by Western blot, is shown for antibodies produced from 6 
patients. Numbers of antibodies are shown as labels within each pie chart. Patients are divided 
according to their disease severity, from dengue haemorrhagic fever grade III (DHFIII) to dengue 
fever (DF). The patient with primary DENV1 infection (752) and the patient with DENV2 infection 
(747) are labelled with this information. The remaining patients are DENV1 secondary infections. 
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4.2.12. Neutralisation and enhancement properties of 53 anti-E antibodies 
 Antibodies specific for E protein were selected for in-vitro neutralisation and 
antibody-dependent enhancement assays. Not all 67 anti-E antibodies were tested because 
only 53 had been produced at the time of these experiments. The assays were performed by 
Wanwisa Dejnirattisai and Amonrat Jumnainsong. 
 Neutralisation tests were based on mixing virus with antibody and adding the mix to 
Vero cells. A semi-solid overlay was added to allow only direct cell-to-cell spread and after 
2-3 days virus infection was determined by staining with anti-DENV antibody and counting 
the foci this produced. Neutralisation was expressed as a percentage, i.e. 100% foci 
reduction = 100% neutralisation. This was carried out on all 4 DENV serotypes to indicate 
how effective an antibody would be at preventing virus infection. The data for neutralisation 
tests is in table 4.3 but figure 4.15 shows examples of particular antibodies. 751 B11 reaches 
100% neutralisation of all 4 serotypes at 1μg/ml and 752 A4 did not fully neutralise DENV3 
and DENV4.  
Of the antibodies tested, 34% had high neutralisation for all serotypes at the 
concentrations of antibody tested (>80%). The remaining antibodies had lower 
neutralisation for at least 1 serotype. The serotype of infection was not known for patient 
752. Excluding this patient, it can be seen that 80% antibodies neutralise the infecting 
serotype by more than 80%. For antibodies that did not efficiently neutralise the infecting 
serotype, one could speculate the cell originated from a previous DENV infection and may 
conform to the theory of original antigenic sin. For example 747 A6 did not neutralise the 
infecting DENV2 serotype but the highest neutralisation was of DENV4. 
The concentration of antibody required for efficient neutralisation is important 
because the titre of antibody in serum will not always be optimal. It was not possible to 
accurately calculate a neutralising titre (NT) such as NT50 because ideally calculation requires 
a plateau in neutralisation at higher antibody concentration. The dilution series of 
antibodies used did not permit this plateau because this required large quantities of 
antibody. However, an approximate value was assigned to indicate the antibody 
concentration where neutralisation reached 50% (table 4.3). 
Comparison of total neutralising properties between patients was not practical 
because 2 patients had only 3 antibodies tested. However it could be seen that both DF and 
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DHF patients have antibodies that neutralise 100% and also have antibodies with weak 
titres, indicating there was no clear difference between disease manifestations. 
 
 
 
 
 
Figure 4.15. DENV neutralisation properties of recombinant antibodies (by Wanwisa 
Dejnirattisai) 
DENV serotypes were mixed with dilutions of antibody and incubated for 1 hour to allow binding. 
This was added to a Vero cell monolayer for infection and overlay added. Cells were incubated for 2-
3 days and foci were stained and counted. The percentage reduction in foci, as compared to 
infection in the absence of antibody, was calculated. This was plotted against antibody 
concentration. Red lines represent DENV 1, blue lines DENV2, green lines DENV3 and black lines 
represent DENV4. Examples of a non-DENV antibody (X10F) and 2 antibodies from patients are 
shown.  
 
 
Although many of the antibodies neutralised infection of Vero cells, they could still 
enhance infection on Fc receptor-bearing cells. Antibody-dependent enhancement assays 
were performed on the 53 anti-E antibodies. Dilutions of antibody were mixed with DENV 
serotypes and added to U937 cells, which have FcγRI/II for uptake of antibody bound to 
virus. With a strongly enhancing antibody, virus uptake would be high and therefore higher 
viral titre would be observed. Results were plotted as fold enhancement of viral titre 
compared to having no antibody present (figure 4.16). In these examples, a strongly 
enhancing antibody 747 A6 and a weakly enhancing antibody 752 A4 are shown. All 
antibodies tested enhanced infection of U937 cells to some degree. It is difficult to compare 
which serotype was enhanced the most because there could be differences between the 
virus stocks that perhaps allow DENV2 to be enhanced more easily. In general, antibodies 
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from primary DHF patient 752 showed the lowest enhancement.. The full list of 
enhancement data can be found within table 4.3. 
  
 
 
 
Figure 4.16. Antibody-dependent enhancement of DENV infection by recombinant 
antibodies (by Wanwisa Dejnirattisai) 
Antibody was mixed with DENV virus and added to U937 cells. After 4 days, supernatant was 
harvested and virus titre determined by infecting Vero cells and counting foci. The fold increase in 
number of foci was calculated relative to foci produced when no antibody was present. Fold 
enhancement was plotted against the concentration of antibody. X10F was a DENV negative 
monoclonal antibody. Examples of 2 recombinant antibodies from patient 747 and 752 are shown. 
Red lines represent DENV1, blue lines DENV2, green lines DENV3 and black lines represent DENV4. 
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Table 4.3. Table of human monoclonal antibodies (legend below) 
 
Antibody 
Specificity 
(Western 
blot) 
Serotype  
(dot blot) 
Neutralisation 50% (μg/ml**) Enhancement*** 
DENV1 DENV2 DENV3 DENV4 DENV1 DENV2 DENV3 DENV4 
753 A1 E 1,2,3,4,JE 0.007 0.007 0.03 0.007 ++ ++++ +++ +++ 
753 B9 NS1 1,2,3                 
753 B12 E 1,2,3,4 0.1 0.06 0.1 0.06 ++ +++ + ++ 
753 C1 E 1,2,3,4,JE 0.01 0.03 0.2 0.01 ++ ++++ +++ +++ 
753 C5 E 1,2,3,4,JE > > > >0.38 ++ +++ + ++ 
753 C6 E 1,2,3,4,JE 0.004 0.03 0.06 0.02 +++ ++++ +++ +++ 
753 C8  E 1,2,3,4,JE 0.04 0.05 0.07 0.03 ++ ++++ +++ ++ 
753 C9 prM 1,2,3                 
753 C12 E 1,2,3,4,JE 0.005 0.005 0.02 0.005 ++ +++ ++ ++ 
751 A1 E 1,2,3,4,JE 0.2 0.07 0.2 0.07 ++ +++ +++ +++ 
751 A2 E 1,2,3,4,JE 0.04 0.003 0.1 0.04 ++ +++ ++ +++ 
751 A12 E 1,2,3,4,JE 0.04 0.01 0.3 0.04 ++ ++++ +++ +++ 
751 B1 E 1,2,3,4,JE 0.1 0.02 0.05 0.1 ++ ++ ++ ++ 
751 B2 E 1,2,3,4,JE 0.05 0.02 0.02 0.02 ++ +++ ++ ++ 
751 B3 E 1,2,3,4,JE 0.05 0.005 0.06 0.03 ++ +++ ++ ++ 
751 B6 E 1,2,3,4,JE 0.04 0.04 0.1 0.04 ++ +++ +++ ++ 
751 B7 E 1,2,3,4,JE 0.07 0.04 0.2 0.04 ++ ++++ ++ +++ 
751 B10 E 1,2,3,4,JE 0.1 0.02 0.2 0.2 ++ ++ ++ ++ 
751 B11 E 1,2,3,4,JE 0.03 0.03 0.07 0.03 ++ ++++ +++ ++ 
751 B12 E 1,2,3,4,JE 0.04 0.04 0.06 0.04 +++ ++++ +++ +++ 
751 C4 E 1,2,3,4,JE 0.008 0.02 0.05 0.02 +++ ++++ +++ +++ 
751 C5 E 1,2,3,4,JE 0.02 0.05 0.1 0.02 ++ +++ +++ +++ 
751 C7 E 1,2,3,4,JE 0.3 0.07 0.3 >1.25 ++ +++ ++ ++ 
751 C8 neg neg                 
751 C10 E 1,2,3,4,JE 0.01 0.1 0.1 0.01 ++ ++ ++ +++ 
751 D1 neg neg                 
751 D3 neg neg                 
751 D6 E 1,2,3,4,JE 0.3 0.07 0.07 0.07 ++ +++ ++ +++ 
751 D11 E 1,2,3,4,JE 0.02 0.03 0.05 0.01 ++ ++++ +++ +++ 
752 A4 E 1,2,3 0.02 0.04 >1.25 > ++ ++ ++ + 
752 A5 E 1,2,3 0.007 0.5 >1.25 >1.25 ++ ++++ +++ ++ 
752 B3 E 1,2,3,4,JE 0.5 0.1 >1.25 >1.25 ++ +++ +++ +++ 
752 B6 neg 1                 
752 B8 neg 1,2,3                 
752 B10 E 1,2,3 0.02 0.002 0.04 0.002 ++ ++ ++ ++ 
752 B11 E 1,2,3 0.02 0.007 0.02 0.007 ++ +++ ++ +++ 
752 C2 E 1,2,3,4,JE 0.06 0.06 0.02 0.02 ++ ++ + ++ 
752 C8 neg 1                 
752 C9 neg 1,2,3                 
752-2 A2 E 1,2,3 0.03 0.004 0.03 0.3 ++ + ++ ++ 
752-2 A4 E 1,2,3 0.02 0.01 0.07 0.2 ++ +++ ++ ++ 
752-2 A5 E 1,2,3 0.02 0.01 0.04 >0.3 ++ ++ + ++ 
752-2 A7 E 1,2,3,4,JE 0.04 0.01 0.1 0.1 ++ ++ ++ +++ 
752-2 A9 E 1,2,3 0.02 0.003 0.04 0.02 ++ ++ ++ +++ 
752-2 B2 E 1,2,3 0.02 0.005 0.02 0.06 ++ ++ ++ +++ 
752-2 B3 E 1,2,3 0.02 0.003 0.04 0.01 ++ ++ ++ +++ 
752-2 B4 E 1,2,3 0.02 0.004 0.04 0.02 ++ + + +++ 
752-2 B6 NS1 1,2,3,4,JE                 
752-2 B7 E 1,2,3 0.04 0.01 0.2 >1.25 ++ + ++ +++ 
752-2 B11 E 1,2,3 0.02 0.003 0.008 0.02 + ++ + +++ 
752-2 B12 neg 1,2,3,4                 
752-2 C4 E 1,2,3 0.02 0.01 0.05 >0.2 ++ ++ ++ +++ 
752-2 C8 E 1,2,3 0.03 0.005 0.07 0.1 ++ ++ + +++ 
752-2 C11 neg neg                 
749 A4 NS1 2,3,4                 
749 A8 neg 1,2,3                 
749 A10 neg neg                 
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Antibody 
Specificity 
(Western 
blot) 
Serotype 
(dot blot) 
Neutralisation (μg/ml**) Enhancement*** 
DENV1 DENV2 DENV3 DENV4 DENV1 DENV2 DENV3 DENV4 
749 A12 E 1,2,3,4                 
749 B2 E 1,2,3,4,JE 0.04 0.04 0.3 0.04 ++ +++ +++ +++ 
749 B4 E 1,2,3,4,JE 0.02 0.02 0.05 0.03 ++ +++ +++ +++ 
749 B6 E 1,2,3,4,JE 0.1 0.1 0.2 0.1 +++ +++ +++ ++ 
749 B12 E 1,2,3,4,JE 0.01 0.007 0.1 0.01 ++ ++++ +++ ++ 
749 C2 neg 1,2,3                 
749 C10 E 1,2,3                 
749 D3 E 1,2,3 > 0.01 > > ++ +++ ++++ +++ 
750 A3 neg neg                 
750 B12 prM 1,2,3,4                 
750 C5 neg neg                 
750 C6 E 1,2,3,4 0.2 0.03 0.03 0.03 ++ +++ ++ ++ 
750 C9 E 1,2,3,4,JE 0.1 0.1 0.2 0.1 ++ ++++ +++ +++ 
750 D1 neg neg                 
750 D7 E 1,2,3,4,JE 0.08 0.07 0.4 0.07 ++ ++++ +++ +++ 
750p4 A2 neg neg                 
750p4 A6 neg neg                 
750p4 C2 E 1,2,3,4,JE                 
750p4 C5 neg neg                 
750p4 C10 E 1,2,3,4,JE                 
750p4 C12 prM 1,2,3,4                 
750p4 D5 E 1,2,3,4                 
750p4 D7 neg neg                 
750-2 B1 E 1,2,3,4,JE                 
750-2 B2 E 1,2,3,4,JE                 
750-2 B7 neg 2                 
750-2 B10 neg neg                 
750-2 C4 E 1,2,3,4,JE                 
750-2 C5 E 1,2,3,4,JE                 
750-2 C6 E 1,2,3,4,JE                 
750-2 C7 E 1,2,3,4,JE                 
750-2 C10 neg neg                 
750-2 C12 E 1,2,3,4,JE                 
750-2 D8 neg neg                 
750-2 D9 neg neg                 
750-2 D10 prM 1,2,3,4                 
750-2 D11 E 1,2,3,4,JE                 
747 A6 E 1,2,3,4,JE 0.3 > 1.25 0.1 +++ ++++ +++ +++ 
747 A11 neg neg                 
747 A12 neg 1,2                 
747 B2 neg 1,2,3                 
747 B6 neg neg                 
747 B8 E 1,2,3                 
747 C2 E 1,2,3 0.002 > 0.002 > ++ ++ ++ + 
747 C3 neg neg                 
747 C4 neg 1,2,3                 
747 C7 neg 1,2,3                 
747 C9 prM 1,2,3,4                 
747 D2 neg neg                 
747 D3 neg neg                 
747 D5 neg 1,2,3                 
747 D8 E 1,2,3 0.1 0.01 0.2 0.3 ++ + ++ +++ 
747 D9 neg neg                 
747 D11 neg 1,2,3                 
747 D12 neg neg                 
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Antibody 
Specificity 
(Western 
blot) 
Serotype  
(dot blot) 
Neutralisation (μg/ml**) Enhancement*** 
DENV1 DENV2 DENV3 DENV4 DENV1 DENV2 DENV3 DENV4 
3-147 prM 1,2,3,4 0.1 >2 >2 0.1 ++++ ++++ +++ +++ 
5F9 prM 1,2,3,4 >2 >2 >2 0.1 ++++ ++++ ++++ ++++ 
2F5 prM 1,2,3,4 >2 >2 0.01 >2 ++++ ++++ ++++ +++ 
58/5 prM 1,2,3,4 >2 >2 >2 0.1 ++++ ++++ +++ +++ 
0112 B9 prM 1,2,3,4                 
X10F neg neg > > > > - - - - 
 
Table 4.3. Binding specificity, neutralisation and infection enhancement characteristics of 
mAbs. 
 Recombinant antibodies were created from 112 ASCs or 6 EBV-transformed memory B cells. 
**Neutralisation.  Minimum concentration of antibody required to neutralise infection by 
approximately 50%, based on dilutions of antibody. 
 “>value” means the highest concentration in the dilution series did not reach 50% neutralisation.  
 “> no value”: there was no neutralisation at any dilution of antibody tested. 
***Enhancement. Highest fold enhancement reached within antibody dilution series    
+  0-10 fold enhancement 
++ 10-100 fold enhancement 
+++ 100-1000 fold enhancement 
++++ 1000+ fold enhancement 
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4.3. Discussion 
 Production of monoclonal antibodies through immortalisation of B cells is of low 
efficiency and can only be performed with memory B cells. This thesis has demonstrated 
that by using single cell PCR of variable region genes, mAbs can be efficiently produced from 
3 sources of B cells from DENV patients. Firstly, methods were optimised using EBV 
transformed memory B cells. These B cell clones were not growing well so recombinant 
antibody production negates the need for ongoing culture of these cells. Techniques were 
optimised to allow rapid and high-throughput production. Secondly, memory B cells with 
surface IgG specific for DENV were sorted from frozen convalescent PBMCs. Antibody PCR 
with these cells yielded one antibody. Finally, 112 antibodies were produced from ASCs 
from acute patients. These results demonstrate that the techniques can be widely applied to 
produce DENV-specific mAbs.  
Ideally, the method of sorting DENV-specific memory B cells would be used in 
conjunction with sorting of ASCs. This would enable one to produce many antibodies from 
any timepoint of infection. Further work should include optimising the DENV-specific 
staining of memory B cells so that convalescent samples taken from the patients here can 
be used. Perhaps using recombinant DENV proteins for sorting cells, a higher efficiency sort 
could be performed and yield more cells for PCR; although this limits the repertoire to 
defined protein-specific B cells. 
 The population of ASCs amongst the 10 acute patients was always large and distinct. 
This was to be expected based on peaks in population size observed in response to other 
immune challenges, for example vaccinations with tetanus and influenza (Odendahl et al., 
2005; Wrammert et al., 2008). The FACS cell sorter calculated the percentage of ASCs sorted 
as a fraction of the total events analysed. This ranged from 0.3% to 24% of the total PBMCs 
and the mean was 9%. The data show that a very large ASC response is seen in DENV 
patients and can last until at least day 7 post-onset of symptoms.  It was not feasible to 
accurately compare cell numbers between the different severities of infection due to the 
small sample numbers. However the DHFIII patients both showed high numbers of ASCs and 
the DF patients had lower numbers. There was no difference in population in the primary 
DENV patient compared to the secondary patients. This would suggest that the primary 
patient was capable of a strong newly-formed plasmablast response.  
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ELISpot provided percentages of DENV-specific cells within sorted cells. The 
percentage of DENV-specific cells was expressed as a percentage of the total number of cells 
plated. Less than two thirds of the cells plated secreted IgG or IgM antibody. Several cells 
either died or likely secrete other antibodies such as IgA. However, if one expressed the 
number of DENV-specific cells relative to the total number of secreting cells then the 
percentage was as high as 90%. ELISpot provided a rough indication of which patient 
samples would be best for PCR because it allowed selection of those with the most DENV-
specific antibodies. 
The efficiency of variable region PCR was diverse and this ultimately determined the 
number of antibodies that could be produced from a particular plate of cells. In some 
patients IgG and IgM variable regions were amplified, however the heavy chain expression 
vector had constant region sequence for IgG1 only. So although some IgM variable region 
sequences were cloned and produced, they were not fully characterised because of this 
divergence from their natural structure. These IgM antibodies were not characterised here 
though it is still important to consider that the IgM-secreting cells contribute to the anti-
DENV response.  
The isotype and subclass restriction were also a limitation of these methods in terms 
of being unable to produce other IgG subclasses. Any IgG2, IgG3 or IgG4 antibodies would 
have been converted to IgG1. This deviation would affect the function of the antibody in 
vivo although would not affect the binding of the variable region. IgG2 has lower affinity for 
Fc receptors than other subclasses (Janeway et al., 2008). It is possible to identify which of 
the antibodies produced originated from alternative subclasses through PCR. However, by 
developing all antibodies with an IgG1 constant region, the function of their variable 
domains can be more easily compared. Future optimisation of these methods could perhaps 
permit expression of other subclasses and isotypes and this is discussed further in chapter 6.  
 Of the 112 antibodies produced from acute patients, 89 were DENV positive. In 4/6 
patients tested, a very high proportion of their antibodies were DENV specific (>85%).  
This shows that the IgG+ cells are highly specific during infection. In the remaining 2 patients 
38% of IgG antibodies made did not produce DENV-specific antibody. It is possible that some 
of these antibodies bind only to genotype-specific epitopes, or bind with low affinity. The 
alternative is that they represent the bystander B cell response (Odendahl et al., 2005). 
Chapter 4 – Results: Human Monoclonal Antibodies 
 
 
129 
Non-specific B cells could be activated and mobilised to secrete antibody during the 
response (Lanzavecchia et al., 2006).  
Approximately half the DENV-specific antibodies produced were fully cross-reactive 
across DENV serotypes and JEV. It was not possible to compare the strength of binding of 
antibody between serotypes because the quantity of virus and antibody in the dot blots 
varied. Therefore dot blot provided a qualitative result. It would be possible to quantify the 
differences in binding if the virus titre was controlled, or perhaps by comparing avidity of 
antibodies with recombinant protein in ELISA format. 
The cross-reactive antibodies were all specific for E and likely to be EDI-II because 
they were negative for EDIII in dot blot. In light of recent published work, it is also likely that 
these antibodies are specific for the fusion loop because this region is conserved across 
certain flaviviruses (Beltramello et al., 2010; Cherrier et al., 2009). Epitope mapping using 
the antibodies will confirm they are negative for domain III and confirm their binding site  
Most anti-E antibodies neutralised the serotype that the patient was infected with 
by more than 80%. Three antibodies had weak titre for this serotype and it could be 
speculated that they originated from a previous infection. In general most antibodies were 
able to neutralise virus fully at high antibody concentration and could neutralise infection by 
50% at an antibody concentration of <0.1μg/ml. A strong DENV neutralisation titre (NT50) 
has previously been classified as approximately <1μg/ml of antibody and a weak titre as 
>2μg/ml (Sukupolvi-Petty et al., 2007). Alternatively, an NT50 of >0.1μg/ml has also been 
described as weak potency (Beltramello et al., 2010). It is important to consider that the 
neutralisation titres in these studies and this thesis were not based on human cells. It can be 
inferred that the acute DENV responses analysed in this thesis are dominated by moderate 
to strong neutralising antibodies although the titres should be analysed using cells of human 
origin. Ideally neutralisation and enhancement assays should next be performed on PBMCs 
such as monocytes, in order to more closely mimic the natural target cells. This model 
allows the interplay between neutralisation and enhancement to be investigated in the 
same cell type rather than viewing neutralisation in Vero cells but yet enhancement at the 
same concentration of antibody with U937 cells. 
Antibodies specific for prM did not make up a significant proportion of all antibodies 
produced. Here it can be seen that the early ASC response is dominated by anti-E specificity, 
followed by a small contribution of anti-prM and then anti-NS1. The prM antibodies were 
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found in patients with more severe disease but the NS1 antibodies originated from patients 
with and without vascular leakage. The neutralisation and enhancement properties of anti-
prM antibodies were not established although it has been previously shown that human 
mAbs specific for prM do not efficiently neutralise and can enhance infection (Dejnirattisai 
et al., 2010).  This study also showed that prM antibodies are prevalent in the memory B cell 
population (Dejnirattisai et al., 2010). However, another recent study showed memory B 
cells producing anti-prM antibodies occupied less than 10% of the total antibodies 
produced. The next step in clarifying these differences would be to analyse the convalescent 
samples taken from the patients described in this thesis and to recruit more patients.  
The main findings of this work are that the early response to DENV infection shows a 
highly specific burst of IgG+ ASCs, as shown by the large population of cells and the high 
numbers of IgG sequence obtained by PCR. Most antibodies secreted at this time were 
cross-reactive amongst the DENV serotypes. The E protein was the primary target for 
antibodies, which were capable of neutralising infection of non-FcR-bearing cells. Despite 
this, in certain situations in vivo, these anti-E antibodies may enhance infection as 
demonstrated by ‘neutralising’ antibody causing pathology in mice and chimpanzee (Balsitis 
et al., 2010; Goncalvez et al., 2007). The conclusions of this chapter are discussed further in 
chapter six. 
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Chapter 5 
 
Results 
Characterisation of Monoclonal Antibody Sequences 
 
 
5.1. Introduction 
 Production of recombinant monoclonal antibodies using PCR also serves as a tool for 
sequence analysis of immunoglobulin genes. Heavy and light chain variable regions were 
amplified and sequenced. Heavy chain variable regions are composed of 3 gene segments, 
variable (V), diversity (D) and joining (J) segments and light chain variable regions contain V 
and J only. The V and D genes can be grouped into families. There are approximately 50 
functional VH gene segments divided into 7 families, 40 Vκ in 6 families, 30 Vλ in 10 families 
and 25 DH genes in 6 families. There are 6 JH, 5 Jκ and 4 Jλ. In addition to this there are 
different alleles of these gene segments. Germline sequences have been collated by V-BASE, 
a database produced by MRC centre for protein engineering and by Immunogenetics (IMGT) 
services (Lefranc et al., 2003; Ruiz et al., 2000). These services have tools that are widely 
used in antibody sequence analysis. 
Random rearrangement of these gene segments occurs in developing B cells in the 
bone marrow and leads to highly diverse sequence combinations (Janeway et al., 2008). 
RAG enzyme complex causes DNA breaks at the V(D)J regions and the segments are joined 
by non-homologous end joining (NHEJ) (Jung et al., 2006). At the junctions between 
segments, DNA polymerase extends the sequence ends by addition of P nucleotides and 
terminal deoxyribonucleotidyl transferase (TdT) mediates addition of N nucleotides. N 
nucleotide additions can be up 20 non-template encoded nucleotides and therefore 
contribute to the diversity of the sequences (Abbas & Lichtman, 2003). 
Mature B cells in peripheral lymphoid tissues become activated upon antigen binding 
to surface IgM and IgD and upon other stimuli such as T cell signalling. This leads to 
Chapter 5 – Results: Monoclonal Antibody Sequences 
 
 
133 
proliferation and differentiation of these antigen-specific cells. Subsequently, somatic 
hypermutation of the immunoglobulin variable regions allows affinity maturation. This 
process of mutating nucleotides is mediated by activation-induced deaminase (AID) enzyme 
(Neuberger et al., 2003).  AID deaminates the cytosine residues of the DNA, which converts 
them to uracil. Then error prone polymerases attempt to correct the sequence.  
Mutations have been shown to be focused in complementarity regions (CDRs) of the 
sequences. This is as a result of the selection process of B cell receptors in the germinal 
centre and means that the repertoire of antibodies can possess mutations that lead to high 
affinity antibody binding. It is also a result of certain sequence hotspots for mutation and 
mutations can also occur in the framework regions (FWRs) (Zheng et al., 2005). In the 
selection process, mutations that encode an amino acid replacement (R) are preferentially 
selected over silent (S) mutations in the CDRs (Rajewsky, 1996). In the FWRs, silent 
mutations are selected to conserve antibody structure (Ohlin & Zouali, 2003). The ratio of 
replacement to silent mutation (R/S) can be compared between CDRs and FWRs as a marker 
for SHM rate.  
This study investigated the diversity and trends of the antibody repertoire in 
response to DENV infection by analysing the sequence of B cell clone variable region genes. 
This expands upon the characterisation of antibodies in chapter 4. The aim of this work was 
to identify features that show how the B cell response develops in infection. This includes 
the clonality of the response, which when linked to antibody specificity and functional data, 
can identify which clones of neutralising or enhancing antibodies dominate the repertoire. 
Then the gene segment usage could be compared for all anti-E antibodies to identify any 
structural preference for antibody binding. Finally, the rate of somatic hypermutation was 
analysed with the aim of identifying B cell clones that had undergone repeated stimulation 
and therefore could have originated from previous infection. Comparison of mutation 
variation within clonal sequences could also then reveal sequence that alters or retains 
antibody function. 
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5.2. Results 
 
5.2.1. Antibody gene sequences from single cells 
 Single cell PCR of ASCs allowed identification of 174 variable region sequences for 
IgG heavy chain, with 167 corresponding light chain sequences. The sequences of the 
antibodies show that some had the same variable region gene rearrangements for both 
their heavy and light chain. Upon alignment with each other, it could be seen that only 2 
pairs of antibodies were identical but several others could be identified as clones. That is, 
they differ in somatic mutations but not in gene segments or junctions between them. Of 
174 sequences, 135 were unique clonal expansions and the remaining sequences were 
clonally related to some of these (table 5.1). Where sequences were amplified from 2 
timepoints of infection, it is interesting to see that the number of clonally related antibodies 
(clonality) increases, indicative of selection of high affinity B cell clones over time. However, 
the yield of sequence data from these single cells was low and therefore bulk analysis on 
multiple cells was performed.  
 
 
Patient 
Number of 
unique 
clonal 
expansions 
Total number 
of cells 
sequenced 
% clonal 
753 (day5) 15 16 6.3 
753-2 (day7) 9 11 18.2 
752 (day4) 12 17 29.4 
752-2 (day6) 9 19 52.6 
751 (day4) 32 35 8.6 
750 (day5) 17 18 5.6 
750-2 (day7) 16 21 23.8 
749 (day4) 10 13 23.0 
747 (day6) 15 24 37.5 
 
Table 5.1. Number of variable region sequences obtained from antibody-secreting cells 
Unique sequences refer to the number of sequences that do not share gene usage, CDR length or 
homology with others. Clonality was calculated as percentage of clonal sequences from the total 
sequences per patient/timepoint. 
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5.2.2. Bulk PCR and clonality 
In addition to single cell PCR, bulk PCR was necessary for amplification of a large 
number of sequences. Bulk PCR was a PCR amplification of multiple cells. The aim was to 
match up the clones from single cell and determine their frequency on a larger scale. This 
would not only indicate the clonality of the anti-DENV antibodies but also allow their 
sequences to be analysed for trends. Heavy chain (gamma) sequences were chosen for 
analysis because this would represent all IgG sequences.  
Bulk PCR was optimised to identify the maximum number of cells it was possible to 
amplify with the same methods as single cell PCR. A dilution series of cells from the EBV-
transformed cell line 3-147 was made for RT-PCR and heavy chain nested PCR. Product was 
obtained in amplification of genes from 1000 cells but not of 4000. With the latter, PCR was 
likely inhibited by high cell number perhaps because of interference by cell debris. For this 
reason, 1000 cells were chosen as the number of ASCs to sort.  
RT-PCR and nested PCR for IgG heavy chains were carried out and the products were 
cloned into the expression vector. Plasmids were transformed into E.coli and 100 
transformants per PCR were picked for sequencing. Sequences were analysed using IMGT V-
QUEST (http://imgt.cines.fr/) and were grouped according to their gene segment 
arrangements. As no corresponding light chains were amplified, CDR alignments were used 
to confirm if sequences were of the same clone. Bulk PCR was carried out on aliquots of 
cells for 5 patients. Patient 747 was not analysed because there was a low percentage of 
DENV-specific cells in ELISpot and single cell PCR, which would make interpretation more 
complex.  
Sequences from 100 cells were obtained from patients 751, 752-2, 753, 750-2 and 
749 and the clones were assembled as pie charts (figure 5.1). Each segment of the pie 
represents a clonal pool and the diversity of the response can be seen. There was high 
diversity in the sequences with an average of 35 different clones per patient. 752-2 appears 
to demonstrate the highest level of clonality. Only 16 clones were identified in the bulk 
sequences. The remaining secondary patients had more diversity in their bulk sequences, 
amplifying between 32 and 45 different clones.  
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Figure 5.1. Diversity of Ig heavy chain variable region sequences 
From 1000 antibody-secreting cells, 100 heavy chain variable regions were amplified (V,D,J). 
Sequences were aligned with germline gene segments in order to group the sequences according to 
their V,D,J gene segment families and by the length of the CDRs. Each slice of the pies represents a 
unique clone. 
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To determine if the frequency of the clones from bulk PCR was the same as single 
cell clones from the same patients, they were plotted alongside each other (figure 5.2). The 
sequences from patient 752-2 correlated well (figure 5.2A), whereby the clone that 
dominated the bulk sequences also dominated the single cell sequences. This is 
demonstrated by paired red and blue bars. Where a clone was identified in the bulk 
sequences but not in the single cell sequences, the clone was plotted as a blue bar only. A 
clone identified in the single cell sequences but not in the bulk sequences was plotted as a 
red bar only.  
Analysis of the remaining patient bulk sequences revealed that there was very poor 
correlation between the clones identified in bulk compared to single cell sequences (figure 
5.2B-E). The predominant sequence in the bulk was not necessarily even present in the 
single cell sequences. For example patient 751 had a clone with the genes VH3-21, DH2-2, 
JH6, which occupied 20% of all bulk sequences but was not present in the 31 single cell 
sequences. Likewise, predominant single cell sequences did not appear at all in bulk 
sequences for 3 patients. This discrepancy would suggest a bias in the bulk PCR that results 
in the frequency of clonal sequences becoming disproportionate. An explanation for this 
could be that the concentration of RNA amongst the cells was variable. If particular cells had 
higher RNA template concentrations then their contribution to the repertoire would be 
artificially high in bulk sequencing. Therefore, despite providing an indication of diversity, 
bulk sequences may not reliably be used to study the repertoire of cells.  
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Figure 5.2 Frequency of clones within bulk and single cell Ig sequences 
Ig heavy chain variable regions of antibody-secreting cells were PCR amplified from aliquots of 
multiple (bulk) cells or from single cells (SC). PCR products were cloned and sequences were grouped 
by clonality (VDJ gene segment usage, CDR length and homology). The frequency at which a clonal 
sequence occurs within either the bulk sequences (blue) or single cell sequences (red) is plotted. 
Each bar along the x axis represents a unique clone and these are plotted with bulk sequences on 
the left and single cell sequences on the right but red and blue bars are paired when the clone is the 
same in bulk and single cell sequences.  
The number of bulk sequences analysed was 100 per patient but the number of single cell sequences 
varied and excluded any sequences that were incomplete: 752-2 n=19; 751 n=28; 753 n=16; 750-2 
n=20; 749 n=13. 
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5.2.3. Anti-DENV antibody sequences 
Investigation of clonality was carried out on all single cell sequences obtained but 
data from those of defined specificity is most relevant. Whilst sequences were obtained for 
every antibody from the DENV patients, only 112 functional antibodies were produced. 
Some sequences had insertions or deletions that caused frameshifts and others did not yield 
one or both chains when transfected, despite having sequences in frame. Therefore 
sequences of known specificity were analysed in more depth. Antibodies that were DENV-
negative were excluded as they may have been bystander B cells and would not be 
representative of the anti-DENV response. The remaining DENV-positive antibodies were 
made up of 67 anti-E, 5 anti-prM, 3 anti-NS1 and 14 of unknown specificity. Sequences were 
aligned with germline variable regions and clones were grouped. Of the 67 anti-E antibodies, 
51 were unique. Clonality among sequences was usually supported by identical dot blot and 
Western blot analysis. There were 3 antibodies that were related to E antibodies but did not 
bind in Western blot. These antibodies did bind in dot blot but were at low concentration 
and therefore it was assumed that the Western blot was not sensitive enough to detect the 
binding to E. No clonality was identified for prM and NS1 antibodies presumably because of 
their low frequency in the single cells. 
As the most prevalent antibodies were anti-E, these were used for analysis of gene 
usage, CDR3 length and somatic hypermutation. The aim was to discover trends among 
these antibodies in order to characterise the B cell response to this antigen. Clonal 
antibodies were removed from analysis to leave 51 anti-E antibodies. It was impractical to 
compare this population to non-E antibodies because that would require no false negatives 
in dot blot or Western blot analysis (some antibodies may have been low concentration or 
low affinity and appear negative). They also could not be compared to the anti-prM or NS1 
antibody sequences due to their low numbers. Therefore, where possible the sequences are 
compared to published data from healthy donors or those with other viral infections. 
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5.2.4. Anti-E antibody sequences 
5.2.4.1. Light chains 
The usage of kappa/lambda light chains in human total antibodies is reported to be 
65% kappa and 35% lambda (Janeway et al., 2008). For a selection of specific antibodies, 
this ratio may not be the same. The light chain usage for the anti-E antibodies was 47% 
expressing kappa chains and 53% with lambda chains. This is very divergent from the normal 
ratio and from other anti-viral repertoires that show >65% kappa chain usage: HIV gp140 
(Scheid et al., 2009), respiratory syncytial virus (Williams et al., 2009) and hepatitis C virus 
(Tajiri et al., 2010). 
However, one study of RSV showed that randomly selected B cells in 2 healthy adults 
also had 47% kappa and 53% lambda chain ratio (Williams et al., 2009). This therefore 
suggests that the ratio in healthy donors is not always higher in kappa usage. On an 
individual level, patient 752 anti-E response was dominated by kappa chain usage (100% 
kappa in 6 antibodies). This patient had a primary infection and it would be interesting to 
see if this kappa bias occurs in other primary patients. Now that these ratios have been 
determined, it would be interesting to stain sorted cells with anti-light chain antibody to 
confirm these findings on a larger scale. 
 
5.2.4.2. Gene segment usage 
The diversity of the anti-E antibodies can also be measured by analysing the gene 
segment usage. Preference for a particular V, D or J segment in the heavy or light chains 
could indicate a structural link between antibodies. The V, D and J segments are not 
normally found in equal ratios and there is a natural bias towards particular families of 
genes. The frequency of families of gene segments was compared to healthy repertoires 
(figure 5.3). The heavy chain shows no preference for particular gene families (figure 5.3 A-
C) but the light chains have skewed V gene family usage (figure 5.3 D and F). Non-anti-E 
antibodies analysed did not show this bias (not shown). However it is important to note that 
the numbers of lambda or kappa chain sequences is too low to draw significant conclusions 
here. The dominant Vκ and Vλ gene families are made up of diverse gene segments, which 
show that the dominance is not due to preference of a gene segment. There was also no 
significant bias in the heavy chain V gene segments in this anti-E repertoire, therefore 
germline genes are not over-represented in anti-DENV repertoires. 
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Figure 5.3. Ig gene segment usage 
Variable regions were sequenced for DENV E specific antibodies (*blue bars, 6 donors n=51). Gene 
segments were assigned based on germline sequence alignment with IMGT database and plotted as 
frequency of total anti-E antibodies (excluding clones). The frequencies of other B cell variable 
region gene segments are plotted alongside this for comparison. **Red bars show healthy CD19+ B 
cell repertoire from 2 donors (Williams et al., 2009) n=117. ***Green bars show naive peripheral 
IgM+ B cell repertoires from 2 healthy donors (no DH reported). VH n=206, Vκ n=321, Vλ n=172. 
(Brezinschek et al., 1997; Farner et al., 1999; Foster et al., 1997).  
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5.2.4.3. CDR3 
As well as the random assignment of particular gene segments, the structure of an 
antibody can also vary through characteristics of the CDR3. The heavy chain CDR3 (HCDR3) 
is an important antigen binding surface and is therefore the most diverse sequence within 
the antibody (Raaphorst et al., 1997; Sanz, 1991). Most mature and naive B cells have a 
HCDR3 length between 10-14 amino acids (Tiller et al., 2007; Wardemann et al., 2003). The 
average length of anti-DENV E antibody HCDR3 is 18 amino acids (figure 5.4). Although 
longer than average, the anti-E CDR3 does not have a defined length and ranges from 7 to 
26 amino acids long. The length of HCDR3 adheres roughly to a normal distribution, 
although a length of 19 amino acids is underrepresented. The reason for this may be a 
reflection of a previously reported preference for HCDR3 with an even number of amino 
acids (Johnson & Wu, 1998). It is possible that a HCDR3 of 19 amino acids does not have an 
optimal loop structure for binding to DENV E.  
All anti-E antibodies had N nucleotide additions within the CDR3 and some had P 
nucleotides also. This occurred at the stage of somatic recombination in B cell development 
and this method of increasing diversity suggests germline sequences alone are insufficient 
for binding the DENV E epitopes.  
Perhaps with knowledge of precise epitope specificity, a correlation would be seen 
between these CDR3 properties and antibody function. 
 
Figure 5.4. HCDR3 length of anti-E antibodies 
Amino acid length of CDR3 was calculated using IMGT numbering and the frequency of length was 
plotted for the 51 anti-E antibodies. 
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5.2.4.4. Somatic hypermutation 
 The accumulation of mutations within antibody CDRs is described as somatic 
hypermutation (SHM). This affinity maturation process occurs in response to antigen 
stimulation. Therefore one might expect antibodies analysed after repeated antigen 
exposure to have accumulated more mutations than those from early primary responses. 
Analysis of the ratio of replacement (R) to silent (S) mutations in the CDRs compared to the 
FWRs provides a rough measure of SHM. It has been shown that the heavy chain is more 
mutated than the light chain (Ikematsu et al., 1998; Kalinke et al., 2000; Zhou et al., 2004) 
and therefore it was focused on here.  
Sequencing of 5 IgM variable regions was carried out (top of table 5.2). The low 
number of mutations supports the knowledge that IgM+ B cells do not undergo extensive 
SHM. However the influence of PCR mutation cannot be ignored. The taq polymerase used 
in these experiments has a low rate of mutation of 2x10-5/nucleotide and cycle leading to an 
error rate of 0.6 mutations per product. PCR error has previously been determined based on 
the methods used in this thesis and were found in less than 10% sequences (Tiller et al., 
2008). Analysis of the mutations as replacement/silent ratio reduces the impact of these 
infrequent mutations on the overall rates of SHM. Replacement and silent mutations for 50 
anti-DENV E antibodies were counted. One of the 51 anti-E sequences had poor sequence 
data in FWR1 and was excluded from this analysis. Also excluded from the count were those 
mutations caused by using pooled primers, as these were experimentally induced and not 
part of the affinity maturation.  
The number of replacement mutations was on average higher than silent mutations. 
The average ratio of CDR replacement: silent mutation (R/S) was approximately 4:1 for CDRs 
and 1.7 for FWRs. These calculations had been previously performed for a repertoire of anti-
influenza ASCs (Wrammert et al., 2008). For the CDRs this was 3.7:1 and the FWR ratio was 
1.8:1. Similar ratios were also seen for booster tetanus toxoid-induced plasma cells 
(Jimenez-Gomez et al., 2010). It can therefore be seen that on average, the DENV-specific 
antibody mutation ratios are comparable to other antigen-induced responses. The higher 
CDR R/S ratio relative to the FWR ratio suggests SHM-driven selection of high affinity 
antibodies. 
Most amino acid substitutions occurred in CDR2. The average numbers of amino acid 
differences (from germline) were 1.7 for CDR1 and 2.8 for CDR2. The number of mutations 
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in CDR3 is lower but does not take into account N and P nucleotide induced diversity, which 
introduces several amino acid differences from germline and therefore the region is still 
highly diversified. The higher rate of mutation in CDR2 is not unexpected, as this has been 
reported to be more mutable (Shapiro et al., 1999).  
Mutations of individual antibodies are shown in table 5.2. It can be seen that some 
antibodies had a high replacement to silent ratio for CDR but not FWR. These antibodies 
could then be predicted to have undergone recurrent rounds of selection and potentially 
originated on a previous exposure to antigen. For example, 747 A6 had a particularly high 
R/S ratio of 19:1 in the CDRs. 747 A6 also showed low neutralisation titre for the infecting 
virus (DENV2), which again may indicate it originated in a previous response to a 
heterologous serotype.  
An important observation is that some antibody sequences derived from the primary 
DENV patient 752 also show high levels of SHM or total mutations (752 A4 and B3). These 
mutations must have been acquired during the current infection. The average mutation 
ratios of the primary patient antibody sequences do not differ from those of the secondary 
patients. This data means that it becomes difficult to predict the primary or secondary 
origins of an antibody using SHM rates because mutations appear to accumulate early in 
infection.  
Antibodies with low numbers of mutations (751 C5 or 749 C10) do not share 
common characteristics such as their neutralisation capabilities. Additionally, correlation of 
mutation rate with gene segments, CDR3 length or specificity did not reveal any patterns. 
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Antibody CDR R:S FWR R:S Total mutations 
IgM 751 C2 4:0 0:1 5 
IgM 749 A2 0:0 1:0 1 
IgM 749 A9 1:0 2:2 5 
IgM 749 B5 0:0 1:0 1 
IgM 750 D8 0:2 3:3 8 
753 A1 5:1 15:11 32 
753 B12 3:1 6:2 12 
753 C1 4:1 7:4 16 
753 C5 10:1 12:3 26 
753 C6 11:1 10:11 33 
753 C8  9:1 7:4 21 
753 C12 7:0 11:7 25 
751 A1 3:2 11:9 25 
751 A2 2:0 4:6 12 
751 A12 9:1 6:3 19 
751 B1 5:3 14:4 26 
751 B2 7:0 4:3 14 
751 B3 4:1 8:2 15 
751 B6 10:1 5:6 22 
751 B7 5:2 8:6 21 
751 B11 9:2 11:6 28 
751 C4 6:1 8:4 19 
751 C5 2:0 3:2 7 
751 C7 7:0 5:2 14 
751 C10 5:1 4:4 14 
751 D6 8:0 2:5 15 
752 A4 10:0 6:8 24 
752 A5 4:3 2:0 9 
752 B3 9:3 14:4 30 
752 B10 8:2 6:7 23 
752 C2 6:2 10:4 22 
752-2 A4 4:3 4:8 19 
749 A12 2:0 7:2 11 
749 B2 6:1 8:3 18 
749 B4 3:3 6:4 16 
749 B6 2:2 8:4 16 
749 B12 6:2 14:3 25 
749 C10 6:0 3:0 9 
750 C6 5:4 6:5 20 
750 C9 7:1 5:4 17 
750 D7 9:3 17:5 34 
750p4 C2 8:2 6:6 22 
750p4 C10 5:0 5:3 14 
750p4 D5 8:1 14:6 29 
750-2 B1 3:1 5:5 14 
750-2 B2 5:1 7:5 18 
750-2 C4 4:1 15:7 27 
750-2 C5 3:0 5:2 11 
750-2 C6 5:0 7:4 17 
750-2 C7 2:1 6:3 12 
750-2 C12 7:1 7:4 19 
750-2 D11 5:1 6:6 18 
747 A6 19:1 11:5 36 
747 C2 6:4 10:3 23 
747 D8 5:3 4:4 16 
 
Table 5.2. Somatic hypermutation of 50 anti-E antibodies 
Heavy chain variable regions were sequenced and aligned with germline sequences using IMGT V-
QUEST. Numbers of nucleotide mutations are shown and categorised as replacement (R) if they 
cause an amino acid substitution, or silent (S) if they do not cause a change in amino acid. 
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5.2.5. Somatic hypermutation within clones 
 Sequences from the largest clonal pool were analysed with respect to their 
mutations. Differences among sequences in a clone would show how an antibody evolves 
through affinity maturation and if it impacts on its function. Patient 752 had a highly clonal 
response and sequences from the dominating VH3-64 DH6-19 JH6 clone were aligned with 
the germline VDJ sequences (figure 5.5). Sequences included in the alignment originated 
from single cells of the first timepoint (day 4) and single and bulk cells from the second 
timepoint (day 6). Bulk sequences chosen for comparison were 4 randomly selected 
sequences from the 33 sequences in the clonal pool. It can be seen that the areas of 
mutation (differences from the germline) are focused in the 3 CDRs, as expected. There are 
also mutations within the FWR3, which has been shown to contain hotspots for mutation 
(Zheng et al., 2005). Regions of the sequences that determine the loop structure are 
conserved, for example cysteine and tryptophan residues flanking the CDR3 (Chothia & Lesk, 
1987). The differences between clones highlighted in this study appear similar to those 
previously published (Poulsen et al., 2007; Wrammert et al., 2008). 
It is expected that the accumulation of somatic mutations occurs at several locations 
but with selection of those that improve antibody affinity. However, there does not appear 
to be progressive mutation between first and second timepoints, as shown by the 
cladogram (figure 5.5). This is likely to be due to the short time difference between the 
samples. Sequences shown in this alignment and others within the clonal pool all differ from 
each other. These differences were likely to have arisen through SHM or as random 
mutation as part of DNA replication but also may have been caused by taq polymerase in 
PCR. Regardless of the origin, the functional effect of these clonal differences was next 
analysed using the sequences from the recombinant antibodies within this clone.  
These 9 antibodies all bound to E of DENV1, 2, 3 and 4 and had similar virus 
neutralisation profiles (figure 5.6). One antibody had lower neutralisation efficiency for 
DENV4 (752-2 A2). Within this antibody there were no differences in the HCDRs and so the 
light chain CDR sequences were analysed. Only 1 amino acid difference between clones was 
identified in LCDR3. One could speculate that this mutation from a histidine, a polar amino 
acid, to non-polar aliphatic leucine disrupted the structure and altered the neutralisation 
capability. The impact of this was seen only for neutralisation of DENV4 and therefore it is 
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possible that DENV4 occupies a different relative position within the antibody binding site 
compared to the other serotypes.  
Amongst the other clonal sequences, up to 6 differences in heavy and light chain 
CDR amino acids were detected but did not visibly affect antibody binding or neutralisation 
activity. The locations of these mutations do not necessarily allude to the points of contact 
between antigen and antibody because improvement of affinity by SHM can also be 
modification of neighbouring structure (Hong et al., 2007). However precise measurement 
of the affinity/avidity in conjunction with mutation data over a broader time frame could 
demonstrate how the antibody response was evolving. This would be particularly interesting 
in the context of ADE, where weak avidity antibodies could lead to increased viral infection.  
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Figure 5.6. Neutralisation properties of 9 clonally related antibodies 
Each of the DENV serotypes were mixed with dilutions of antibody and added to a Vero cell 
monolayer for infection and overlay added. Cells were incubated for 2-3 days and foci were counted. 
The percentage reduction in foci, as compared to infection in the absence of antibody, was 
calculated. This was plotted against antibody concentration. Red lines represent DENV1, blue lines 
DENV2, green lines DENV3 and black lines represent DENV4.  
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5.2.6. Recombinant antibodies with substituted chains 
 Heavy chain-only recognition of antigen has been documented among antibodies 
(Kwong & Wilson, 2009). The contribution of heavy or light chains in binding to DENV E was 
next examined for a selection of antibodies by substituting one of the antibody chains with 
that of the DENV-negative antibody, X10F. The aim was to investigate if a particular chain 
could be responsible for antigen binding in a selection of antibodies. X10F antibody was 
produced recombinantly from a healthy donor memory B cell clone and it had the following 
gene segments: VH3-23 DH2-21 JH4 with Vκ3-15 Jκ2. First, the kappa chain of X10F was 
expressed alongside heavy chains from 753 B9, 751 B2 and 751 C10. Then the heavy chain 
of X10F was expressed with 751 A1λ, 751 C5κ or 751 C10κ. After confirmation of expression 
by ELISA, the antibodies were tested on DENV dot blot and were not positive. What is 
particularly interesting to note is that 751 C10 has the same VH, Vκ, JH and Jκ gene segments 
as X10F but different CDR sequences. This highlights the importance of the CDRs from both 
chains and that binding is not based on structure alone. 
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5.3. Discussion 
Immunoglobulin variable regions were sequenced from ASCs of DENV patients. 
These sequences were aligned with germline variable regions to identify the gene segment 
families that made up these recombined regions. This allowed sequences to be allocated 
into clonal groups, which had very similar sequences and shared V and J gene segment 
usage and length of CDRs. Of 174 antibodies sequenced from single cells, 135 were unique 
sequences and the remaining sequences were clones (22% clonality). This represents a very 
diverse B cell response in these 6 patients. The high number of different clones stimulated 
could be a reflection of the number of epitopes available. Even if only the E-specific clones 
are analysed, there is still wide diversity (24% clonal). Responses to other antigens have 
often been described as highly clonal. ASC responses to influenza vaccination were on 
average 43% clonal but could be up to 70% (Wrammert et al., 2008). ASCs specific for 
hepatitis B virus surface antigen were 62% clonal (Jin et al., 2009). In contrast, randomly 
selected naive and memory B cells are rarely clonal (Wrammert et al., 2008). These 
comparisons show how diverse the anti-DENV response is. Analysis of the DENV patients on 
an individual level shows that clonality was highest in the primary patient. This could reflect 
the absence of memory B cells to contribute to clonal diversity. More primary patients are 
required to determine if this relative lack of diversity is common or can be linked to 
pathogenesis. 
Analysis of the IgG repertoire using bulk cells was performed with the intention of 
extending the single cell repertoire analysis and tracking particular clones. However, its 
limitations became clear when the frequency of sequences was compared with single cell 
sequences. There was a bias that meant those sequences that appeared to dominate the 
single cell sequence response were not seen in the bulk cell sequences and vice versa. 
Differences in total RNA concentration within individual cells could have led to this uneven 
distribution in the bulk cells. It is also possible that the particular primers from the pool 
annealed preferentially in the bulk cell RNA and skewed the result. These factors would not 
have impacted upon clonality from single cells. Bulk sequence analysis was previously 
performed by Wrammert et al, but RNA was extracted from 10,000 cells before PCR. The 
sequences obtained (average 36 per patient) were verified by comparison with single cell 
sequences and they did not report a discrepancy. However the number of sequences 
obtained from their bulk analysis was low and their PCR amplified only VH3 and VH4 families 
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so the correlation between bulk and single cell was not accurate. The data presented here 
shows caution should be applied when analysing bulk sequences. The data could be of use 
when investigating individual sequences or the estimated breadth of a response but 
percentage clonality could be skewed by unequal cellular RNA concentrations. The methods 
for analysing clonality should in the future be optimised to expand upon the results found 
here. 
  The DENV anti-E antibodies were selected for analysis of sequence characteristics. 
Numbers of anti-prM or anti-NS1 antibodies were too low for comparison and antibodies 
with unknown specificity were also excluded but all were checked for unusual features. 
Comparisons were made between the anti-E sequences and those from previously 
published data. Healthy donor and other virus/vaccine-specific repertoires were used. This 
was not ideal due to the different methods of cell isolation and PCR amplification. However, 
isolation of an identical antibody-secreting population from a healthy donor would be very 
difficult due to the low cell numbers without antigenic stimulation (Doria-Rose et al., 2009). 
Further justification for these comparisons is that this work aimed to screen the antibodies 
for interesting features and identification of characteristics would then have to be followed 
up by a screen of more antibodies and more patients, particularly more primary infections.  
Through these comparisons, several points were identified as noteworthy in the anti-
E response. There was nearly equal light chain usage with an average of 47% kappa chains. 
This shows there is no light chain preference for antibodies binding to E. Yet this differs from 
other anti-viral repertoires and from the expected total repertoire of 65% kappa chains 
(Scheid et al., 2009; Tajiri et al., 2010; Williams et al., 2009). This indicates that lambda chain 
usage is potentially higher than expected. There also appeared to be a preference for 
particular light chain variable region gene families. Vκ1 and Vλ1 and 2 were enriched 
compared to other repertoires (Farner et al., 1999; Foster et al., 1997; Scheid et al., 2009; 
Williams et al., 2009). The immunological significance of this is unknown and the result 
could simply be a result of a small population analysed. Gene segments within these families 
were not over-represented in the ways seen for rotavirus, hepatitis B virus, influenza and 
HIV (Chan et al., 2001; Sui et al., 2009; Weitkamp et al., 2005). The next stage in further 
work would be sequence analysis of more antibodies followed by epitope mapping. 
Although no patterns were identified in gene usage, this may not be the case if antibodies 
were subdivided by their binding specificity. 
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There was a range in HCDR3 lengths between the antibodies, meaning that a 
particular CDR structure was not required for binding. However all antibodies had N 
additions and some had P additions. Although this diversification occurred prior to antigenic 
stimulation, it shows that germline sequences alone are insufficient for recognition of the 
antigen and a degree of complexity is required, unlike examples such as unmutated anti-
rotavirus antibodies (Tian et al., 2008). The range in the CDR3 lengths presented here could 
reflect the differences in specific epitope binding sites. It was interesting to see that the 
average length of the HCDR3 was longer than that of naive B and mature cell repertoires 
(Tiller et al., 2007; Wardemann et al., 2003). Longer CDR3 potentially allow access to 
complex antigen surfaces. It was speculated that this leads to more contact points with 
antigen and therefore improved affinity. This has been predicted to be another indication of 
the B cell selection process (Poulsen et al., 2007). Despite this, there appeared to be no 
observable correlation of SHM rate with CDR3 length or between the primary DENV patient 
CDR3s compared to the secondary patient. Again, the characteristics of the CDRs may be 
better correlated to antibody binding if the precise epitopes are known. 
Mutation analysis of the anti-E antibodies showed all sequences differed from 
germline sequences. The ratios of replacement mutations to silent mutations and CDR to 
framework indicated the rates of somatic hypermutation. Comparison with IgM sequences, 
which showed few mutations, proved these rates to be reliable. In IgG sequences, there was 
a range in mutation rate and the average was similar to that seen following influenza 
vaccination (Wrammert et al., 2008) and tetanus toxoid booster vaccination (Jimenez-
Gomez et al., 2010). This shows that DENV infection stimulated B cell clones to undergo 
maturation, mutating the CDRs to improve affinity. It had been previously concluded that 
many of the highly mutated anti-influenza clones had originated from memory B cells from 
previous activation and presumably the same was expected of the boosted tetanus 
response also. Therefore the similarity between these values and of the anti-DENV E 
mutations also suggests this recall of memory. However, the mutation rate of primary DENV 
patient 752 antibodies was similar to the average of the secondary DENV patients. Without 
the previously mutated memory B cell clones, it was anticipated that the primary anti-E 
response would be less mutated. This was because memory B cells would be restimulated 
and mutate during GC reactions, and early B cells in primary patients may have fewer 
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rounds of selection. From the data presented here it therefore seems that high rates of SHM 
are detected early in severe primary infection. 
 Alignment of variable region sequences from clones was used to study individual 
mutations. The most predominant clone was used and 14 sequences were included. Other 
clones were independently aligned but had fewer sequences available for comparison. 
Alignment of clonal sequences showed that amino acid substitutions were focused in CDR 
regions. There was divergence from both the germline and also between the sequences but 
there did not appear to be a progressive accumulation between antibodies isolated 2 days 
apart. In order to analyse this accumulation and selection further, memory B cells could be 
isolated in the future.  
Several amino acid differences between clonal sequences did not have any 
noticeable effect on the function of the antibodies. This highlights how mutations often 
occur at positions that are not detrimental to function. There was a reduction in the NT50 for 
one antibody, 752-2 A2, when neutralising DENV4. This could be a result of amino acid 
mutation in the light chain CDR3 causing a serotype-specific effect on antibody binding. 
Similar alterations in antibody binding to a conserved epitope have been observed between 
different strains of yellow fever virus (Cammack & Gould, 1986). Further investigation could 
reveal more about the differences between the antibody binding footprints amongst DENV 
serotypes. The differences in antibody affinity should also be analysed and would require 
calculation through surface plasmon resonance with the Fab portion. This could likely prove 
maturation of the response over time. There was not a recombinant E antigen available in 
the laboratory for affinity or avidity determination. 
In conclusion the anti-DENV repertoire is genetically diverse. A broad variety of B cell 
clones were stimulated and anti-E antibodies were analysed. The sequences of antibodies 
specific for E do not show common gene usage or HCDR3 characteristics. Quantifying the 
SHM in these antibodies demonstrated that most antibodies are highly mutated. This 
cannot be consistently correlated to binding or neutralisation capabilities, nor can it indicate 
the history of the B cell stimulation. However, sequence analysis of clones that produce 
highly neutralising antibody could be in future be useful for targeting mutations within them 
to produce optimised therapeutic antibodies. More patients and antibodies are required to 
substantiate the findings here. 
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Chapter 6 
 
Discussion 
 
This study aimed to investigate immunopathogenesis in DENV infection. The 
increased incidence of DHF in secondary infections implicates the immune response in 
pathology. The focus of this work was the role of antibodies in severe disease and hence it 
forms a prelude to prevention of such pathology. 
 
6.1. DENV patients 
 The challenge when studying DENV in patients is recruiting a range of individuals 
covering all 4 serotypes and primary and secondary infections of varying severity. 
Production of mAbs from convalescent patients has the advantage of being able to 
characterise the serotype and sequence of infection before selecting the sample. It can also 
be performed on frozen PBMCs allowing further flexibility. In this study mAbs were 
produced from convalescent patient B cells but also acute patients at the earliest possible 
timepoint of infection. This was the first study to investigate the B cell response within the 
first 2 weeks of infection. It therefore covers some of the first B cell clones that can 
contribute to the control of viraemia.  
The diversity of acute patients was limited by the number of admissions during the 
recruitment in Vietnam. Only 1 DENV2 patient and 1 DENV4 patient were recruited and 
some with unknown serotypes. The difficulty in finding primary infections in a DENV 
endemic country was demonstrated by recruitment of only one primary patient. This patient 
had DHFII and therefore was one of a small percentage of patients that develop DHF during 
a primary infection. Moreover the serotype of infection was not determined, presumably 
due to low viraemia at the point of sampling. Serology may have been useful for predicting 
the serotype, although ELISA of early timepoints indicated a low IgG titre so convalescent 
samples need to be tested. Ideally more primary patients should now be included in this 
study to provide better representation of this population. The low numbers of patients 
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recruited has meant that comparisons between severity of disease and serotype have been 
limited. However this study has piloted the methods for producing mAbs from acute 
infection and has led to creation of 89 DENV-specific antibodies. These will substantially 
contribute to dengue research. 
 
 
6.2. Antibody-secreting cell response in DENV patients 
 The burst of ASCs during DENV infection was captured for all patients. Patient 751 
had a smaller population of ASCs but sufficient numbers were sorted. The ASC population 
was large in the DHFIII patients and could reflect high viral titre prior to sampling but this is 
difficult to ascertain. The populations of ASCs were distinct but the stringency of sorting 
could be improved in the future. If one is not limited by the number of fluorescent channels 
then additional markers could be used such as a marker for proliferation. Additional staining 
for IgG+ or DENV+ could also increase the yield of target antibodies. However the sorting 
protocol used here provided broad starting material for repertoire analysis and cells could in 
future be used to isolate other isotypes of antibody and antibodies that are stimulated but 
do not bind to DENV. In particular it would be interesting to study the IgM responses. The 
contribution of natural antibodies during infection is a first-line defence (Hangartner et al., 
2006). Secretion of low-affinity IgM antibodies during this early time period would be 
interesting to investigate in terms of their role in protection. The DENV-negative antibodies 
stimulated would also be of interest. Patients 749 and 747 produced higher numbers of 
these negative antibodies. These were not highly clonal and could represent bystander B 
cell activation. Full characterisation of these antibodies could include screening them with 
other flaviviruses or immature DENV particles. This would contribute further understanding 
to the breadth of the B cell response to DENV if these antibodies bound to epitopes only 
presented on immature particles or were stimulated from previous infection or vaccination. 
 The ASC response to DENV was shown to be diverse because clonal expansions did 
not dominate responses and many unique B cell clones could be identified. Clonality did not 
correlate with severity of disease in the patients studied therefore one can speculate that 
pathology is not due to lack of diversity or dominance of a clone with poor neutralisation 
efficiency. The antibodies with the highest level of clonality were those from the primary 
patient. A clone of ASCs secreting anti-E antibody was abundant at day 4 and to a greater 
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extent at day 6. This antibody clone neutralised virus infection of Vero cells although it 
enhanced infection of Fc receptor-bearing cells.  
 One might expect the B cell response to be diverse during primary infection and 
become more limited to the high affinity clones upon secondary challenge (Janeway et al., 
2008). The breadth of response to DENV has been explained by the variety of epitopes 
available and the cross-reactivity of the antibodies (Crill & Chang, 2004; Se-Thoe et al., 
1999). Primary DENV infection could stimulate several naive B cells to become activated and 
form memory B cells. Upon secondary infection the cross-reactive B cells are reactivated 
and they join the naive response to the infecting virus. This creates a diverse response and a 
few days later the response appears to become more finely tuned, i.e. occupied by clonal 
expansions. The data showed that clonality increased by the second timepoint amongst the 
patients tested and this could potentially represent the accumulation of selected clones.  
The serotype of the previously encountered DENV was not established amongst the 
secondary patients. If the secondary infection is homotypic, the response could in theory be 
more clonal whereas a heterotypic infection may induce a wider range of clones. The 
patient sera should be evaluated to identify the serotype of previous infection. This could be 
performed in house through competition ELISA (Midgley et al., 2010). The number of 
antibody sequences would need to be higher to analyse the percentage clonality fully. The 
bulk PCR results here showed that single cell PCR is the more reliable way of determining 
the diversity of the B cell repertoire. Sequences of several hundred DENV-specific B cells 
would be required in future analysis.  
 
 
6.3. Antibody variable regions 
 Antibodies from DENV patients were characterised on a sequence level in an effort 
to investigate the stimulation of the B cells. The ability to predict if an antibody had been 
stimulated in a prior infection or in a newly formed response would be invaluable in 
demonstrating original antigenic sin. Previous studies reported that SHM rates were higher 
on secondary activation (Clarke et al., 1990; Janeway et al., 2008). It proved difficult to apply 
this theory to the DENV antibodies. The degree of SHM in antibodies from the primary 
patient was similar to the average rate within the secondary antibodies. Therefore 
mutations accumulate rapidly in activated cells. More primary patients are required to 
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confirm this result, particularly because this patient had DHFII and this is not typical of a 
primary infection.  
Mutation analysis on EBV-transformed memory B cells is also not reliable. EBV 
infection causes upregulation of AID and consequently SHM (Chezar et al., 2008; Epeldegui 
et al., 2007). Future work should incorporate the memory B cells of the patients, taken 1 
month after hospital discharge. These B cells should not be transformed with EBV but 
should be sorted on the basis of DENV positivity and used for PCR. This method was trialled 
in this thesis and led to the production of a DENV-specific mAb, 0112 B9, so with further 
optimisation many antibodies can be created from these samples. This could then allow 
tracking of the antibodies made from early B cells into the memory compartment.  
Variable region sequencing was however used to examine the EBV-transformed 
memory B cell clones produced by others in the laboratory. This was performed in order to 
determine if prM and E antibodies produced were clonally related and has contributed to 
their characterisation. This published work made a significant impact on the field of 
immunopathology in DENV infection by proving that a range of anti-prM antibodies 
occupied the memory B cell pool and can enhance infection in vitro (Dejnirattisai et al., 
2010). 
 Analysis of the ASC antibody variable regions revealed there was no bias in the DENV 
antibody gene usage or HCDR3. This meant the anti-E antibodies had no obvious structure in 
common and a range of B cells can be stimulated. Analysis of the binding sites on DENV may 
reveal that certain gene segments or CDRs show preference for particular epitopes. There 
was a preference for lambda chain antibodies in both the anti-E response and within all 
antibodies. It was not a strong bias but kappa chain usually dominates the normal ratio 
(Janeway et al., 2008). This was an interesting feature but the reason for this was not 
established and potentially requires another IgG+ ASC population to compare to. 
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6.4. DENV epitopes 
The antibodies produced from ASCs largely mapped to the E protein. As a structural 
antigen, this was not unexpected. The E protein has been shown to be an immunodominant 
protein in response to DENV and many mAbs have now been synthesised from mice and 
humans (Beltramello et al., 2010; Gromowski & Barrett, 2007; Henchal et al., 1985; 
Schieffelin et al., 2010; Shrestha et al., 2010). 
It was interesting that the anti-E antibodies produced in this thesis all appear to be 
specific for EDI-II and not EDIII. EDIII was identified as an important antigen for strongly 
neutralising antibodies and blocking of cell-receptor binding (Crill & Roehrig, 2001). Only 
recently did studies produce a number of convalescent human mAbs or begin to map the 
domains of E. Antibodies specific for EDIII were shown to be of low titre in human serum 
(Crill et al., 2009). Additionally, antibodies specific for EDI-II have been shown to be most 
prevalent (Beltramello et al., 2010; Crill et al., 2009). The results presented in this thesis 
support the notion of dominant EDI-II responses in humans and this study was the first to 
create mAbs from B cells early in the acute response. 
The anti-E antibodies produced are currently being analysed through a mutant 
peptide screen and the data will soon become valuable in further interpretation of these 
results. Creation of an epitope mapping tool using yeast surface display successfully proved 
that a fusion loop antibody could be finely mapped to its critical amino acid. The process of 
mapping was time-consuming and relied upon cell-sorting facilities capable of processing 
live yeast cells. The conclusion from this part of the work was that a panel of mutants should 
be created using recent epitope data (Sukupolvi-Petty et al., 2010; Vaughan et al., 2010). 
This could then provide a rapid screen for loss-of-binding mutants. Furthermore, the 
unmutated DENV E proteins on yeast could still be used to determine the domain specificity 
of antibodies. 
 Antibodies specific for prM made up a small fraction of the response. These 
antibodies would presumably also cause ADE, as previously demonstrated by panels of 
human mAbs (Beltramello et al., 2010; Dejnirattisai et al., 2010). Attempts to create a yeast 
epitope mapping system for the prM protein were not successful. Although protein was 
expressed on the yeast cell surface, the conformation was not recognisable by prM-specific 
antibodies. Alternative strategies need to be utilised for characterising binding to this 
antigen. 
Chapter 6 - Discussion 
 
 
161 
 Antibodies that tested negative for DENV could potentially bind to other virus 
strains. A limitation of the characterisation of these antibodies was the use of prototype 
virus strains. Some DENV2 strains isolated from Vietnam were included in screening one 
patient but recent DENV1 isolates should next be probed with remaining antibodies. 
A further piece of work to be performed would be measurement of antibody affinity 
or avidity. Although this may not reveal the function of the antibodies in protection, it 
would provide a useful tool for comparing the impact of mutations in sequences. Perhaps by 
creating Fab fragments of the antibodies and by obtaining recombinant DENV proteins, the 
affinity could be analysed. 
 
 
6.5. Properties of DENV antibodies 
The neutralisation and enhancement properties of the antibodies provided an 
indication of their protective nature. Only anti-E antibodies were studied but the remaining 
anti-DENV antibodies can be analysed in the future. Antibodies specific for EDI-II have 
previously been shown to be more weakly neutralising than EDIII antibodies and capable of 
ADE (Beltramello et al., 2010). The antibodies created here were often strongly neutralising 
of at least one serotype. However they all enhanced infection of FcR-bearing cells at a range 
of concentration. When at low concentration, the threshold of occupancy may be too low to 
allow neutralisation and so ADE occurs (Pierson & Diamond, 2008). When at higher 
concentration it is possible that the antibody is enhancing infection through binding to 
immature virions (Cherrier et al., 2009). Further experiments with the antibodies presented 
here have since shown that the antibodies do bind to immature virus created from a furin-
deficient cell line. Therefore they could permit uptake of immature virus into FcR-bearing 
cells, where the virus becomes infective (Cherrier et al., 2009).  
The anti-E antibodies tested were likely to neutralise infection at the stage of virus 
binding to receptor. Upon incubating virus and antibody with Vero cells all antibodies tested 
neutralised infection; often with a 100% reduction of infection. However when tested in an 
FcR cell model the antibodies did not neutralise at the same concentration as seen on Vero 
cells. Presumably the antibodies were not capable of neutralising virus post-entry (within 
the endosome) when internalised by the FcR. At high concentration most antibodies could 
prevent infection of the U937 cells, perhaps through saturation of the fusion loops. Two 
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mAbs were capable of enhancing infection in U937 but were not efficient at neutralisation 
(753 C5 and 749 D3). These antibodies may not bind to the receptor-binding regions of E or 
cannot hinder receptor interaction through binding proximally to these regions. When 
considering the action of the anti-E antibodies produced, they should ideally be tested on 
cells that better represent the natural human target cells. The mechanism of blocking entry 
and therefore the ability to neutralise may be different with alternative host cell receptor 
distribution. 
Further work could also include, making Fab fragments of the antibodies. Cryo-
electron microscopic analysis of antibody binding to protein could be performed and images 
could provide insights into their structural mechanisms of neutralisation and exposure of 
epitopes such as the fusion loop (Lok et al., 2008). 
 The subclass of antibodies produced were IgG1 because the heavy chain vector 
encodes this constant region. The method upon which this work was based amplifies all 
subclasses of IgG for cloning (Tiller et al., 2008). Sequence of the constant region is required 
to determine which of the antibodies have alternative subclasses. This remains to be 
performed for these antibodies. Most will be of the IgG1 subclass (Janeway et al., 2008; 
Koraka et al., 2001) but those that are not should ideally be excluded from neutralisation 
and ADE analysis (Rodrigo et al., 2009). Development of vectors containing alternative 
subclass and isotype constant regions would be beneficial.   
 
6.6. Therapeutics and vaccines 
 Production of human mAbs has the potential to create therapeutics for treatment of 
severe disease in the early stages of infection (Pai et al., 2009). Many of the anti-DENV 
antibodies produced in this study were highly cross-reactive amongst DENV serotypes and 
had the capability to neutralise infection. There is still potential, however, for these 
antibodies to cause ADE in vivo. Furthermore, it has since been found that they bound to 
immature virus from furin-deficient cells, meaning there is potential for these antibodies to 
facilitate immature virion uptake. Recently a cocktail of antibodies was created that had 
mutated Fc regions to prevent FcR binding and consequently ADE (Beltramello et al., 2010). 
The antibodies were administered to mice pre- and post-exposure to infection. This was 
protective upon lethal inoculation of virus, even though an enhancing polyclonal serum was 
inoculated also. This Fc modification approach provides a much safer concept for antibody 
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therapy in DENV patients. Upon further neutralisation analysis, candidates for Fc 
modification may be identified here that can inhibit infection and severe pathology. 
The sequence analysis on antibody variable regions performed could also contribute 
to the ideal therapeutic antibody. Analysis of clones can identify CDR mutations responsible 
for improvement in function and such mutations can be engineered into potential 
candidates. Further searches should be undertaken in patients with mild disease to try and 
isolate more protective antibodies. 
 For vaccine production, it has already been suggested that vaccines should minimise 
the anti-prM response to prevent ADE (Dejnirattisai et al., 2010). In light of the data 
presented here, perhaps mutation of particular EDI-II epitopes could also be considered in 
the future to drive the response away from the enhancing cross-reactive antibodies. 
Furthermore, epitopes mapped that induce favourable antibodies could alternatively be 
incorporated into peptide vaccines. 
 
 
6.7. Conclusions 
 These findings strongly contribute to the progressive understanding of the humoral 
immune response to DENV. The severe pathology of infection seen in DHF can be attributed 
to a multi-factorial combination of immune processes. The antibody response has been 
previously shown to play a role in pathogenesis and cross-reactive antibodies provide a risk 
factor for severe disease. 
A method for production of human monoclonal antibodies was successfully 
deployed and led to production of over 100 antibodies from acute and convalescent DENV 
patients. This study is the first to demonstrate that the diversity of the B cell response in 
both DF and DHF was extensive on a sequence level but largely confined to EDI-II specificity 
on a functional level.  
 The data will now form part of ongoing experiments that will further characterise the 
antibodies and recruit more patients. Ultimately it could be possible to use this data and the 
methods to evaluate the response to new vaccines or to contribute to their design. It may 
also be possible to create new therapeutics to limit the pathology of severe disease.  
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Appendix 
A.1. Primer sequences 
Application Name Sequence 5' - 3' 
Yeast display     
DENV E Forward DEN4 DM1-3 Kpn CCGGGGTACCAATGAGATGTGTGGGAGTAGGAAC 
  DEN4 DM3  CCTGGGTACCGGGAGATCTGAAGGGAATGTCATACACGATGTGC 
  DEN2 DM1-3 CCGGGGTACCAATGCGCTGCATAGGAATATCAAATAG 
  DEN2 DM3 CCGGGGTACCGGGAGATCTGAAAGGAATGTCATACTCTATGTGC 
DENV E Reverse DEN4 DM2 CCGGGGGATCCAATTCTCAATTTCTCCATGCGAACTTTGC 
  DEN4 DM3  GGCCCGGATCCCATCTTGCCCAATGGACTCGTTTCC 
  DEN1-4 Xho GGCCCTCGAGGACATTTTGCCAATGGAACTTCCTTTC 
  DEN2 DM2 Xho GGCCCTCGAGGAGCTGTAGTTTGTCCATTCTCAGC 
DENV PRM Forward DEN2 PRM CCGGGGTACCGTTCCATTTAACCACACGTAACGGA 
  DEN2 PRM SDM GGAGAACATAGAAAAGAAAAAAAATCAGTGG 
  DEN2 PRME CGGGCTAGCTTCCATTTAACCACACGTAACG 
DENV PRM Reverse DEN2 PRM CCGGGGGATCCTGTCATTGAAGGAGTGACAGCTGT 
  DEN2 PRM ecto CCGGGGGATCCTGGATGTCTCAAGATCCAAGTTTCAAT 
  DEN2 PRM SDM CCACTGATTTTTTTTCTTTTCTATGTTCTCC 
  DEN2 PRM TEV 
CGGGTACCATCCTTGAAAATAAAAATTTTCCCCTGGATGTCTCAAGATCC
AAG 
Sequencing PYD1 FORWARD AGTAACGTTTGTCAGTAATTGC 
  PYD1 REVERSE GTCGATTTTGTTACATCTACAC 
  TOPO T3 FORWARD ATTAACCCTCACTAAAGGGA 
  TOPO T7 REVERSE CCCTATAGTGAGTCGTATTA 
Antibody PCR     
Heavy chain RTPCR 5' L VH1 ACAGGTGCCCACTCCCAGGTGCAG 
  5' L VH3 AAGGTGTCCAGTGTGARGTGCAG 
  5' L VH4/6 CCCAGATGGGTCCTGTCCCAGGTGCAG 
  5' L VH5 CAAGGAGTCTGTTCCGAGGTGCAG 
  3' Cγ CH1 GGAAGGTGTGCACGCCGCTGGTC 
Kappa chain RTPCR 5' L VK1/2 ATGAGGSTCCCYGCTCAGCTGCTGG 
  5' L VK3 CTCTTCCTCCTGCTACTCTGGCTCCCAG 
  5' L VK4 ATTTCTCTGTTGCTCTGGATCTCTG 
  3' CK 543 GTTTCTCGTAGTCTGCTTTGCTCA 
Lambda chain RTPCR 5' L Vλ1 GGTCCTGGGCCCAGTCTGTGCTG 
  5' L Vλ2 GGTCCTGGGCCCCGTCTGCCCTG 
  5' L Vλ3 GCTCTGTGACCTCCTATGAGCTG 
  5' L Vλ4/5 GGTCTCTCTCSCAGCYTGTGCTG 
  5' L Vλ6 GTTCTTGGGCCAATTTTATGCTG 
  5' L Vλ7 GGTCCAATTCYCAGGCTGTGGTG 
  5' L Vλ8 GAGTGGATTCTCAGACTGTGGTG 
  3' Cλ CACCAGTGTGGCCTTGTTGGCTTG 
Continued 
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Application Name Sequence 5' - 3' 
Antibody PCR     
Heavy chain nested 5' AgeI VH1/5 CTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG 
  5' AgeI VH3 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG 
  5' AgeI VH4 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG 
  5' AgeI VH3-23 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG 
  5' AgeI VH4-34 CTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG 
 
5’ AgeI VH1-18 CTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG 
 
5’ AgeI VH1-24 CTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG 
 
5’ AgeI VH3-33 CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG 
 
5’ AgeI VH3-9 CTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG 
 
5’ AgeI VH4-39 CTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG 
 
5’ AgeI VH6-1 CTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG 
  3' SalI JH1/2/4/5 TGCGAAGTCGACGCTGAGGAGACGGTGACCAG 
  3' SalI JH3 TGCGAAGTCGACGCTGAAGAGACGGTGACCATTG 
  3' SalI JH6 TGCGAAGTCGACGCTGAGGAGACGGTGACCGTG 
Kappa chain nested 5' Pan VK ATGACCCAGWCTCCABYCWCCCTG 
  3' CK 494 GTGCTGTCCTTGCTGTCCTGCTC 
  5' AgeI VK1-5 CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC 
  5' AgeI VK1-9 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT 
  5' AgeI VK1D-43 CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC 
  5' AgeI VK2-24 CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC 
  5' AgeI VK2-28 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC 
  5' AgeI VK3-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC 
 
5’ AgeI VK2-30 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC 
  5' AgeI VK3-15 CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC 
  5' AgeI VK3-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT 
  5' AgeI VK4-1 CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC 
  3' BsiWI JK1/2/4 GCCACCGTACGTTTGATYTCCACCTTGGTC 
  3' BsiWI JK3 GCCACCGTACGTTTGATATCCACTTTGGTC 
  3' BsiWI JK5 GCCACCGTACGTTTAATCTCCAGTCGTGTC 
  3' BsiWI JK1 50/3 GCCACCGTACGTCTGATTTCCACCTTGGTC 
Lambda chain nested 5' AgeI Vλ1 CTGCTACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG 
  5' AgeI Vλ2 CTGCTACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG 
  5' AgeI Vλ3 CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACWCAG 
  5' AgeI Vλ4/5 CTGCTACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA 
  5' AgeI Vλ6 CTGCTACCGGTTCTTGGGCCAATTTTATGCTGACTCAG 
  5' AgeI Vλ7/8 CTGCTACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG 
  3' XhoI Cλ CTCCTCACTCGAGGGYGGGAACAGAGTG 
IgM 3'CμCH1 GGGAATTCTCACAGGAGACGA 
  3'IgMint GGGTTGGGGCGGAGGATGCACTCC 
Sequencing 3'IgGint GTTCGGGGAAGTAGTCCTTGAC 
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A.2. Vector map pYD1.  
 
 
A.3. Vector map TOPO 
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A.4. Antibody expression vectors 
 
 
 
 
 
 
 
 
 
A.5. Hybridomas 
 
1PF27F 1D10 DENV1-4 E 
1PF13F 2B7 DENV1-4 E 
BF2 1D3-2 DENV1-4 E 
4G2 DENV1-4 EDII 
2H12 DENV1-4 EDIII 
1H10 DENV1-4 prM 
IF11 DENV1-4 NS1 
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A.6. Human monoclonal antibodies 
*Clonal sequences.  
 
Antibody 
Specificity 
(Western 
blot) 
Serotype  
(dot blot) 
VH DH JH κλ Vκλ Jκλ 
753 A1 E 1,2,3,4,JE 3-11 6-19 6 K 3-15 4 
753 A2     3-64 3-9 5 λ 2-14 7 
753 A12     3-23 3-3 3 K 1D-39 1 
753 B1     3-30 2-2 2 K 1-5 5 
753 B4     3-30-3 2-2 3 K 3-20 3 
753 B6     3-22 2-2 4 λ 2-14 7 
753 B8*     3-7 3-9 4 λ 2-23 3 
753 B9 NS1 1,2,3 4-61 3-22 4 λ 3-1 3 
753 B12 E 1,2,3,4 4-34 2-21 5 K 1-NL1 1 
753 C1* E 1,2,3,4,JE 3-7 3-9 4 λ 2-23 3 
753 C5 E 1,2,3,4,JE 3-21 3-22 5 K 1D-12 3 
753 C6 E 1,2,3,4,JE 4-39 5-12 3 λ 2-8 1 
753 C7     4-30 4-17 6 K 1D-12 1 
753 C8  E 1,2,3,4,JE 3-30 6-6 1 λ 1-40 3 
753 C9 prM 1,2,3 1-69 2-2 5 λ 3-21 3 
753 C12 E 1,2,3,4,JE 4-30-4 2-2 6 λ 2-8 3 
753-2 A3*     1-46 3-3 6 K 2D-28 3 
753-2 A11     3-23 3-3 6 λ 7-46 3 
753-2 A12     3-43 2-2 3 K     
753-2 B5*     1-46 3-3 6 K 2D-28 3 
753-2 B12     1-18 5-12 5 K 3-15 5 
753-2 C7     3-23 3-3 3       
753-2 C8     1-69 5-5 6       
753-2 C9*     3-23 3-3 4       
753-2 D3*     3-23 1-20 4 λ 7-46 3 
753-2 D7     3-9 2-21 6       
753-2 D10     3-15 3-3         
751 A1 E 1,2,3,4,JE 3-23 n/a 5 λ 2-8 3 
751 A2 E 1,2,3,4,JE 3-53 6-13 4 λ 1-40 3 
751 A3     3-74 6-6 6 K 4-1 3 
751 A4     4-39 1-7 1 λ 1-40 1 
751 A5     3-43 6-6 3 K 4-1 3 
751 A8     3-9 3-10 4 λ 6-57 3 
751 A9     1-58 3-3 6 K 3D-7 4 
751 A11     3-30 1-26 4 λ 6-57 3 
751 A12 E 1,2,3,4,JE 4-39 4-4 4 λ 1-40 3 
751 B1* E 1,2,3,4,JE 3-74 3-3 6 K 1-5 2 
751 B2 E 1,2,3,4,JE 3-30 6-19 4 K 1D-39 3 
751 B3 E 1,2,3,4,JE 4-30 2-2 4 λ 1-47 3 
751 B5     4-39 6-19 6 K 3D-7 5 
751 B6 E 1,2,3,4,JE 3-23 2-2 4 K 3D-15 2 
751 B7 E 1,2,3,4,JE 3-23 6-19 4 λ 1-47 3 
751 B8     3-23 2-2 4 K 3D-15 2 
751 B9     3-7 2-8 4 λ 2-14 2 
751 B10* E 1,2,3,4,JE 3-74 3-3 6 K 1-5 2 
751 B11* E 1,2,3,4,JE 4-39 5-5 5 K 1-9 5 
751 B12* E 1,2,3,4,JE 4-39 5-5 5 K 1-9 5 
751 C1     3-33 6-6 6 K 1-5 4 
751 C3     1-3 3-22 6 K 1D-39 2 
751 C4 E 1,2,3,4,JE 1-69 6-13 3 λ 2-23 3 
751 C5 E 1,2,3,4,JE 3-23 4-17 4 K 1D-12 1 
751 C7 E 1,2,3,4,JE 3-30-3 5-5 4 λ 2-23 3 
751 C8 neg neg 4-39 6-19 4 K 1D-39 2 
751 C9     3-30-3 6-6 5 λ 2-23 3 
751 C10 E 1,2,3,4,JE 3-23 2-2 4 K 3-15 2 
751 D1 neg neg 1-69 2-2 3 λ 1-40 3 
751 D3 neg neg 1-69 1-26 3 λ 2-14 3 
751 D4     4-39 3-16 2 λ 2-8 3 
751 D6 E 1,2,3,4,JE 3-23 3-3 6 K 4-1 4 
751 D8     3-74 3-16 6 K 3D-15 2 
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Antibody 
Specificity 
(Western 
blot) 
Serotype  
(dot blot) 
VH DH JH κλ Vκλ Jκλ 
751 D11* E 1,2,3,4,JE 4-39 6-19 5 K 1-9 5 
751 D12     4-39 5-5 5 λ 1-9 5 
752 A4 E 1,2,3 3-48 3-10 6 K 1-5 1 
752 A5 E 1,2,3 3-33 6-13 4 K 1-16 2 
752 A8*     3-64 3-10 6 K 1-5 1 
752 B3 E 1,2,3,4,JE 3-48 3-3 6 K 1-5 3 
752 B4     4-59 1-26 3 λ 1-44 3 
752 B6 neg 1 1-46 3-3 6 K 2D-28 1 
752 B8 neg 1,2,3 1-18 1-26 4 K 1D-39 2 
752 B10* E 1,2,3 3-64 3-22 6 K 3-11 2 
752 B11* E 1,2,3 3-64 3-22 6 K 3-11 2 
752 C2 E 1,2,3,4,JE 3-30 5-5 4 K 3-15 1 
752 C6*     3-15 2-2 4 λ 8-61 3 
752 C8 neg 1 3-15 6-13 4 λ 8-61 3 
752 C9* neg 1,2,3 3-64 6-19 6 K 3-11 2 
752 D1     3-48 2-21 4 K 1-5 2 
752 D9     3-11 6-13 6 λ 2-14 3 
752 D10     1-18 6-25 5 K 3-11 5 
752 D11*     3-64 6-19 6 K 3-11 2 
752-2 A1*     3-64 3-22 6 K 3-11 2 
752-2 A2* E 1,2,3 3-64 3-22 6 K 3-11 2 
752-2 A3     1-2 1-1 6 K 1-12 4 
752-2 A4* E 1,2,3 1-18 1-26 4 K 1D-39 2 
752-2 A5* E 1,2,3 1-18 1-26 4 K 1D-39 2 
752-2 A7 E 1,2,3,4,JE 3-48 3-3 6 K 1-5 3 
752-2 A9* E 1,2,3 3-64 3-22 6 K 3-11 2 
752-2 B1     1-2 1-1 6 K 3-11 2 
752-2 B2* E 1,2,3 3-64 3-22 6 K 3-11 2 
752-2 B3* E 1,2,3 3-64 2-2 6 K 3-11 2 
752-2 B4* E 1,2,3 3-64 6-13 6 K 3-11 2 
752-2 B6 NS1 1,2,3,4,JE 1-46 4-23 3 K 1D-39 1 
752-2 B7* E 1,2,3 1-18 1-26 4 K 1D-39 2 
752-2 B11* E 1,2,3 3-64 6-25 6 K 3-11 2 
752-2 B12 neg 1,2,3,4 3-23 6-13 4 λ 3-1 1 
752-2 C4 E 1,2,3 1-46 1-20 6 K 1-5 4 
752-2 C8* E 1,2,3 3-64 2-21 6 K 3-11 2 
752-2 C11 neg neg 3-23 2-2 4 λ 3-21 3 
752-2 C12*     3-64 3-22 6 K 3-11 2 
749 A4 NS1 2,3,4 4-4 6-25 4 λ 2-11 1 
749 A8* neg 1,2,3 3-21 6-19 4 K 1-13 5 
749 A10 neg neg 3-7 2-8 5 λ 3-21 3 
749 A12 E 1,2,3,4 1-69 2-2 5 λ 2-11 1 
749 B2 E 1,2,3,4,JE 3-30 6-19 4 λ 1-51 3 
749 B4 E 1,2,3,4,JE 3-7 3-3 5 λ 2-23 3 
749 B6 E 1,2,3,4,JE 4-39 3-10 5 λ 1-40 3 
749 B12 E 1,2,3,4,JE 1-69 2-2 3 λ 1-47 3 
749 C2 neg 1,2,3 3-13 3-3 3 K 1-17 3 
749 C10* E 1,2,3 3-21 6-19 4 K 1-13 2 
749 D1*     5-51 3-22 4 λ 2-11 6 
749 D3* E 1,2,3 3-21 6-19 4 K 1-13 2 
749 D7*     5-51 3-22 4 λ 2-11 3 
750 A3* neg neg 3-15 2-2 5 λ 7-46 1 
750 B12 prM 1,2,3,4 5-51 3-22 3 K 1-12 3 
750 C5 neg neg 7-4-1 3-10 4 K 1D-39 4 
750 C6 E 1,2,3,4 1-69 1-26 6 K 1-27 1 
750 C9 E 1,2,3,4,JE 4-39 3-10 5 λ 2-14 3 
750 D1 neg neg 3-23 6-19 4 K 1D-12 1 
750 D7 E 1,2,3,4,JE 3-53 3-10 5 λ 1-40 3 
750 D12     3-33 5-12 2 λ 1-40 1 
750p4 A1*     3-15 2-15 5 λ 7-46 1 
750p4 A2 neg neg 1-8 6-19 6 λ 2-8 3 
750p4 A4     4-31 2-8 5 λ 2-14 3 
750p4 A6 neg neg 1-46 1-26 4 K 1-5 4 
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Antibody 
Specificity 
(Western 
blot) 
Serotype  
(dot blot) 
VH DH JH κλ Vκλ Jκλ 
750p4 C5 neg neg 4-30-4 3-10 6 λ 1-40 1 
750p4 C10 E 1,2,3,4,JE 1-69 2-2 6 λ 1-47 3 
750p4 C12 prM 1,2,3,4 4-39 3-22 5 K 3-15 2 
750p4 D5 E 1,2,3,4 3-23 3-22 3 λ 2-14 3 
750p4 D7 neg neg 4-39 6-19 5 K 3-15 5 
750-2 B1 E 1,2,3,4,JE 3-7 3-9 4 λ 1-51 2 
750-2 B2 E 1,2,3,4,JE 3-30-3 3-22 4 λ 2-8 2 
750-2 B6*     4-30-4 2-15   K 1-33 4 
750-2 B7 neg 2 4-59 3-9 5 K 3-15 4 
750-2 B8*     3-15 3-22 5 λ 7-46 1 
750-2 B10* neg neg 3-15 2-21 5 λ 7-46 1 
750-2 C4* E 1,2,3,4,JE 4-30-4 2-8 4 K 1-33 4 
750-2 C5 E 1,2,3,4,JE 3-23 6-19 4 λ 1-47 2 
750-2 C6 E 1,2,3,4,JE 3-30-3 3-22 3 λ 1-51 2 
750-2 C7 E 1,2,3,4,JE 3-11 3-22 6 K 1-33 4 
750-2 C10* neg neg 3-15 2-2 5 λ 7-46 1 
750-2 C11     4-39 6-19 4 K 1-9 3 
750-2 C12 E 1,2,3,4,JE 1-69 2-2 6 λ 1-47 2 
750-2 D1     3-48 3-22 4 K 1D-39 3 
750-2 D2     5-51 3-22 4 K 1-5 1 
750-2 D5     3-30 5-5 6 K 1D-39 2 
750-2 D8* neg neg 3-15 2-2 5 λ 7-46 1 
750-2 D9 neg neg 3-53 3-10 4 λ 2-14 3 
750-2 D10 prM 1,2,3,4 4-39 3-10 4 K 3-20 4 
750-2 D11 E 1,2,3,4,JE 4-39 3-10 3 K 1-12 1 
750-2 D12*     3-15 2-2   λ 7-46 1 
747 A6 E 1,2,3,4,JE 3-21 3-9 4 K 1-27 4 
747 A10     4-31 3-3 5 λ 2-14 3 
747 A11 neg neg 4-59 3-22 6 λ 7-46 3 
747 A12 neg 1,2 7-4-1 7-27 6 K 2D-28 2 
747 B1     1-18 3-10 5 λ 2-14 1 
747 B2* neg 1,2,3 3-74 3-22 5 K 1D-39 4 
747 B3*     7-4-1 5-5 3 K 3-11 4 
747 B6* neg neg 3-74 3-22 3 K 1D-39 2 
747 B8* E 1,2,3 3-74 3-22 6 λ 2-23 3 
747 C2 E 1,2,3 3-64 5-12 6 K 2-30 4 
747 C3 neg neg 3-23 3-9 4 K 3-15 3 
747 C4* neg 1,2,3 3-74 3-22 6 λ 2-23 3 
747 C5* 
  
4-59 3-22 6 λ 7-46 3 
747 C7 neg 1,2,3 3-48 3-22 6 K 2D-28 4 
747 C8*     7-4-1 5-5 3 K 3-11 4 
747 C9 prM 1,2,3,4 4-61 3-10 4 K 1D-39 2 
747 C10*     4-59 3-10 4 λ 1D-39 2 
747 D2* neg neg 3-74 3-22 5 K 1D-39 4 
747 D3 neg neg 1-69 3-3 3 K 1D-39 1 
747 D5* neg 1,2,3 3-74 3-22 5 K 1D-39 4 
747 D8* E 1,2,3 3-74 3-22 6 λ 2-23 3 
747 D9* neg neg 3-74 3-22 6 λ 2-23 3 
747 D11 neg 1,2,3 1-69 5-24 5 λ 3-21 3 
747 D12 neg neg 5-51 3-10 5 K 3-20 4 
3-147 prM 1,2,3,4 3-53 2-8 4 K 1-9 3 
5F9 prM 1,2,3,4 4-59 3-22 4 λ 1-40 1 
2F5 prM 1,2,3,4 4-30 2-2 5 λ 3-21 2 
2G4 prM 1,2,3,4 3-9 3-10 6 K 1D-12 4 
135.3 prM 1,2,3,4 4-4 1-1 6 K 1D-33 5 
58/5 prM 1,2,3,4 1-69 2-15 5 λ 3-21 3 
0112 B9 prM 1,2,3,4 3-15 2-2 4 λ 1-44 1 
30 E 1,2,3 3-7 2-2 4 K 1D-39 2 
5.1 E 1 3-30 3-9 6 K 1-12 4 
8 E 1,2,3,4 3-48 4-17 3 λ 2-23 1 
X10F neg neg 3-23 2-21 4 K 3-15 2 
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Table A.7. Neutralisation titres 
*Approximate concentration of monoclonal antibody (μg/ml) capable of neutralising virus 80% 
>value = 80% neutralisation not seen at highest dilution tested.  
>no value = no neutralisation seen at any dilution 
Antibody 
Neutralisation 80% (μg/ml)* 
DENV1 DENV2 DENV3 DENV4 
753 A1 0.125 0.125 0.125 0.125 
753 B12 >0.4 0.4 0.4 0.4 
753 C1 0.125 0.125 0.125 0.125 
753 C5 > > > >0.38 
753 C6 0.08 0.8 0.8 0.08 
753 C8  1.25 1.25 1.25 1.25 
753 C12 0.125 0.125 0.125 0.125 
751 A1 1.25 1.25 1.25 1.25 
751 A2 0.125 0.125 1.25 0.125 
751 A12 1.25 1.25 1.25 1.25 
751 B1 1.25 1.25 1.25 1.25 
751 B2 1.25 1.25 0.125 0.125 
751 B3 1.25 0.125 1.25 1.25 
751 B6 1.25 1.25 1.25 1.25 
751 B7 1.25 1.25 1.25 1.25 
751 B10 1.25 1.25 1.25 1.25 
751 B11 0.125 1.25 1.25 1.25 
751 B12 1.25 1.25 1.25 1.25 
751 C4 0.125 1.25 1.25 0.125 
751 C5 0.3 0.3 0.3 >0.3 
751 C7 >1.25 >1.25 >1.25 >1.25 
751 C10 1.25 1.25 1.25 1.25 
751 D6 1.25 1.25 1.25 1.25 
751 D11 0.5 0.5 0.5 0.05 
752 A4 0.125 1.25 >1.25 > 
752 A5 0.125 >1.25 >1.25 >1.25 
752 B3 >1.25 >1.25 >1.25 >1.25 
752 B10 0.125 0.0125 0.125 0.125 
752 B11 0.4 0.04 0.4 0.04 
752 C2 0.6 0.6 0.6 0.6 
752-2 A2 0.125 0.0125 0.125 1.25 
752-2 A4 0.23 0.23 0.23 >0.23 
752-2 A5 0.04 0.04 0.4 >0.4 
752-2 A7 1.25 0.125 1.25 >1.25 
752-2 A9 0.06 0.06 0.6 0.6 
752-2 B2 0.125 0.125 0.125 0.125 
752-2 B3 0.4 0.04 0.4 0.04 
752-2 B4 0.125 0.125 0.125 0.125 
752-2 B7 0.125 0.125 1.25 >1.25 
752-2 B11 0.125 0.125 0.125 0.125 
752-2 C4 0.02 0.02 0.2 >0.2 
752-2 C8 0.5 0.05 0.5 0.5 
749 B2 1.25 0.125 1.25 1.25 
749 B4 0.125 0.125 1.25 0.125 
749 B6 >1.25 1.25 1.25 >1.25 
749 B12 0.125 0.125 1.25 1.25 
749 D3 > 1.25 > > 
750 C6 1.25 1.25 1.25 1.25 
750 C9 1.25 1.25 1.25 1.25 
750 D7 >0.35 0.35 >0.35 0.35 
747 A6 >1.25 > >1.25 >1.25 
747 C2 0.01 > 0.01 > 
747 D8 1.25 0.125 1.25 1.25 
3-147 >2 >2 >2 >2 
5F9 >2 >2 >2 1 
2F5 >2 >2 >2 >2 
2G4 >2 >2 >2 >2 
135.3 >2 >2 >2 0.1 
58/5 >2 >2 >2 >2 
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